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SUMMARY 
 
Effective vaccination relies on the rapid and efficient activation of the human innate immune 
system. Measles virus (MV, Genus Morbillivirus), a member of the paramyxovirus family, is 
known to induce life-long immunity against reinfection. However, the acute infection is 
associated with a dramatic immunosuppression, potentially accompanied by secondary 
infections, which can eventually kill a host. The pathogenesis of established MV vaccine 
strains is less severe and the typical immunosuppression is less pronounced, while life-long 
protection against MV is induced as well, indicating efficient stimulation of the immune 
system. Infection of cells by MV is sensed predominantly by RIG-I recognizing viral 5’-
triphosphate RNAs, and MDA-5 using as yet unknown ligands. The 186 amino acid MV C 
protein, which shuttles between the nucleus and cytoplasm, is identified in this thesis as a 
major viral inhibitor of IFN-β transcription in human cells. Notably, C proteins of wildtype 
MV isolates, known as poor IFN-β inducers, were found to comprise a canonical nuclear 
localization signal (NLS), whereas the respective sequence of all vaccine strains, irrespective 
of their origin, was mutated. Site-directed mutagenesis of the C proteins from a MV wildtype 
isolate and from a vaccine virus confirmed a correlation of nuclear localization and inhibition 
of IFN-β transcription. A functional NLS and efficient nuclear accumulation is therefore 
critical for MV C to retain full potential to downregulate IFN-β induction. The activation of 
the crucial transcription factor IRF3 by phosphorylation, dimerization and nuclear 
translocation was not altered by both vaccine and wildtype MV C. Several protein-protein 
interactions of MV C could be identified during this study and validated by different assays 
including mass spectrometry, co-immunoprecipitation and immunofluorescence. Most 
prominent targets were IPS-1/MAVS and 19S proteasomal components. Knockout of the C 
protein in recombinant viruses caused a severe growth defect in interferon competent cells 
and strong interferon induction. Recombinant MV expressing fluorescently tagged C NLS 
variants confirmed the nuclear localisation of C during infection. In addition a considerable 
fraction of C accumulated in peri-nuclear inclusion bodies during infection, which were 
previously described as viral replication factories or stress granules. The MV P protein was 
shown to be sufficient for the formation and recruitment of C to these cytosolic inclusion 
bodies. To study the interferon induction caused by an infection, recombinant viruses were 
generated, differing only in their C NLS localisation signal. Interferon induction caused by 
rMV without a functional C NLS was stronger and the virus grew slower on interferon 
Interferon induction inhibition by MV C 
 
 
  Page X  
  
competent cells than with a wildtype C NLS. Taken together, a defect in efficient nuclear 
import of C protein is suggested to contribute to the attenuation of MV vaccine strains and 
indicates an important difference between vaccine and wildtype virus strains. Additionally, 
possible molecular mechanisms supported by experimental data are discussed and evaluated. 
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INTRODUCTION 
 
1. Measles Virus 
 
Viruses know us humans inside out. We share thousands of years of co-evolution and co-
habitation. The human immune system evolved to fight invading pathogens, and viral 
infections contributed a considerable part. Retroviral transposons and other genomic 
modifications caused by viruses are importantly contributing to the genome we have now. 
Hosts challenged by viral infection they want to get rid of, evolve and change according to the 
circumstances. However, viruses also evolve and come up with perfidious strategies to 
overcome the hosts defence emerged. And those viruses still existing today are the winners of 
a constant battle between the defence system of the host and the viral countermeasures. Even 
modern medicine could not provide cures for every viral disease; no antibiotic analogue 
against viruses has been identified so far. Millions of years of evolution created viruses as 
organisms on the verge of life and death in before unseen diversity. Some viruses are able to 
infect broad host ranges; they represent typical zoonotic viruses like influenza. They can 
infect animals and humans alike, though certain measures have to be considered when 
crossing the species barrier. Other viruses evolved to a small host range, for example the 
measles virus, which has only one natural host, the human being. 
1.1. A general overview - classification and pathogenesis 
The negative-sense single-stranded helically packed RNA genome of measles virus (MV) 
is non-segmented and approximately 16k nucleotides long. Therefore, MV belongs to the 
order of Mononegavirales and the family of Paramyxoviridae, which is further divided into 
two subfamilies. Measles virus belongs to the subfamily of Paramyxovirinae and the genus 
Morbillivirus along with the Rinderpest virus (RPV) or the canine distemper virus (CDV). 
Other genera of the Paramyxovirinae subfamily include the Avulavirus genus (e.g. Newcastle 
disease virus, NDV), the Henipaviruses (e.g. Hendra virus, HeV), Respiroviruses (e.g. Sendai 
virus, SeV) and Rubulaviruses (e.g. mumps virus, MuV). The second subfamily, 
Pneumovirinae, comprises two genera: Respirovirus (e.g. respiratory syncytial virus, RSV) 
and Metapneumovirus (e.g. human metapneumovirus, hMPV). Altogether all these viruses are 
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responsible for causing a number of different diseases in humans or animals (Fields et al., 
2007). 
The primary host species of MV are humans, but also other primates can be infected, 
although the infection appears to be attenuated (de Swart et al., 2007; van Binnendijk et al., 
1990). Wildtype MV infections of other species than primates and humans have not been 
reported. In vivo model systems for MV infection using cotton rats, macaques and mice still 
remains highly controversial (de Swart, 2009; Niewiesk et al., 1997; Ohno et al., 2007). The 
highly virulent MV caused more than 20 million infections and approximately 158,000 deaths 
worldwide in 2011 (WHO, 2013b). Though effective vaccines exist (e.g. the Schwarz strain of 
the Edmonston linage (ENDERS et al., 1962; Schwarz, 1964)), which lead to life-long 
immunity, MV is still a major cause of childhood morbidity and mortality, especially in 
countries of the Third World. Elimination of MV by the WHO worldwide is currently in 
progress. The first goal set by the WHO to eliminate measles in 2010 could not be reached. 
This was attributed to lowering vaccine coverage in Europe and North America, mainly due to 
vaccine scepticism, as well as the need for higher vaccination coverage in developing 
countries to achieve to goal of herd immunity. Eventually a new strategy was devised. Until 
the end of 2015, global measles deaths shall be reduced by at least 95% compared with 2000 
levels. By the end of 2020 measles elimination shall be achieved in at least five WHO regions 
(WHO, 2013a). A close relative of MV, the Rinderpest virus (RPV) was formally declared 
eradicated in June 2011, with the last case of a wildtype infection being reported in 2001 
(Normile, 2008). 
The virus enters the organism via the respiratory route, infecting lung tissue via aerosol 
inhalation, followed by a primary viremia targeting blood and lymphoid cells (de Swart et al., 
2007; de Vries et al., 2010; Ludlow et al., 2010). First clinical signs of a measles virus 
infection show up 10 days post infection and are fever and Koplik’s spots, followed by a 
characteristic macropapular rash that lasts for 3-5 days. At later stages of the infection, other 
tissues like the skin are also affected, causing the typical rash (Fields et al., 2007; Griffin, 
2010; Yanagi et al., 2006) due to invading T cells (Griffin, 2010; Hirsch et al., 1984). 
Clearance of infectious virus begins with onset of this rash and is completed approximately 20 
days after the infection (Griffin, 2010; Griffin and Oldstone, 2009). However, viral RNA still 
is detectable in peripheral blood mononuclear cells (PBMCs) and respiratory secretions 
several weeks after recovery, indicating ongoing expression of viral antigens (Riddell et al., 
2007). This may be one cause of the induction of a robust, lifelong immunity. In rare cases the 
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virus can persist in the human organism leading to a mortal disease, SSPE (subacute 
sclerosing panencephalitis) (Johnson et al., 1984).  
Associated with an infection with MV is a severe immunosuppression causing a high and 
dangerous susceptibility to other infections (Slifka et al., 2003), responsible for most of the 
fatal cases in developing countries. Several weeks after infection T cells still show a 
decreased in vitro proliferation in response to mitogens (Ward et al., 1991). The infection is 
also characterised by lymphopenia, a depletion of T and B cell numbers in circulation during 
the rash (Arneborn and Biberfeld, 1983; Ryon et al., 2002), and suppression of lymphocyte 
proliferation (Auwaerter et al., 1999; Hirsch et al., 1984). Also dendritic cells were observed 
to be infected in vivo in macaques (de Swart et al., 2007) and inhibition caused by viral gene 
expression on signalling pathways related to the innate immune system was identified (Pfaller 
and Conzelmann, 2008; Schuhmann et al., 2011) . This very effective blockage of the immune 
system of the host on the one hand and the induction of lifelong immunity upon clearance of 
the infection on the other hand is called the “measles paradoxon”. Interestingly, only one 
serotype of MV exists worldwide and the MV encoded antigens are remarkably stable (Fine, 
1993; WHO, 2013b). A survived wildtype infection or a successful vaccination using the 
established vaccine strains fully protects against any wildtype infection known so far.  
1.2. Vaccines and circulating wildtype strains 
Although only one serotype of MV exists, the viruses can be classified according to their 
N gene sequence (sometimes also the H sequence is additionally used). The WHO currently 
officially recognizes 8 clades called A, B, C, D, E, F, G, and H. These clades are further 
divided into 23 genotypes, designated A, B1, B2, B3, C1, C2, D1, D2, D3, D4, D5, D6, D7, 
D8, D9, D10, E, F, G1, G2, G3, H1, and H2 (WHO, 2001). The circulating wildtype strains of 
2012 were predominantly B3, D4, D8, D9, G3 and H1. In America the D and B genotypes 
were dominant, whereas in Africa almost exclusively the B genotype circulated. In Europe, 
Asia and Australia, the main MV genotypes found were D4, D8 and D9, with D9 being more 
prominent in southern Asia (WHO, 2013c) (Fig. 1). 
The current epidemic MV strains evolved probably at the beginning until the midst of the 
20th century (Pomeroy et al., 2008). The ancestor of MV is the now extinct Rinderpest virus 
(RPV), which infected only cattle. The exact time point of the divergence of both viruses is 
debated. Sequence analysis studies suggest the 11th and 12th century (Furuse et al., 2010). It is 
however also stated in the study that the linguistic evidence (Fields et al., 2007), which 
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suggests measles infections as early as the 5th to 7th century is well within the 95% confidence 
interval (Furuse et al., 2010). 
 
Figure 1: Measles wildtype genotype distribution worldwide in 2012.  
Adapted from the measles surveillance data of the WHO (WHO, 2013c). The colour codes of the 
individual genotypes are indicated in the figure. 
Worldwide, wildtype outbreaks occur mainly in developing countries, however the 
number of MV cases in Europe and North America is increasing in the last few years 
(Sleeman et al., 2008). This can be partially attributed to lower vaccine coverage especially in 
Europe, following vaccine scares and fraud MV vaccine publications linking it to autism 
(Murch et al., 2004) as well as the increasing global trafficking (Edelson, 2012). Recent 
outbreaks of measles virus in Germany were reported to be in Berlin in 2011 (Lassen et al., 
2013), and in Berlin and Munich 2013 (unpublished data). 
Vaccination protects effectively against infection by any wildtype virus knwon so far and 
the first vaccione to be licensed was Rubeovax in 1963 (Hilleman et al., 1968). The basis for 
the generation was the isolate of measles virus from human kidney cells of an infected child. 
All vaccine strains available are of the genotype A, curiously, no wildtype strain of genotype 
A was ever sequenced or isolated recently. It was reported  that only 4 vaccine strains were 
generated from different wildtype isolates (Bankamp et al., 2011), namely the Edmonston 
lineage of vaccine strains (ENDERS et al., 1962; Schwarz, 1964), Leningrad-4 (Smorodintsev 
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et al., 1960), CAM-70 (Athman and Philpott, 2004) and Shanghai-191.  The Schwarz strain 
(Schwarz, 1964), which is widely used in Germany for vaccinations, is based on the 
Edmonston isolate, thus belonging to the same linage. It was generated by additional 
passaging of the Edmonston strain in chicken embryo fibroblasts. 
Hallmarks of all vaccine strains are a generally higher induction of the innate immune 
system (Haralambieva et al., 2010; Kessler et al., 2011) and the usage of CD46 (Dörig et al., 
1993; Naniche et al., 1993) as an additional cell entry receptor besides the wildtype receptors 
signalling lymphoid activating molecule (SLAM) (Tatsuo et al., 2000) and nectin-4 
(Muhlebach et al., 2011; Noyce et al., 2011). 
1.3. Structure and molecular biology of measles virus 
The measles virus is a membrane-bound particle of variable size (Fig. 2 A) ranging from 
approximately 350-400nm  (Fields et al., 2007). These particles are pleomorphic and 
occasionally polyploid with a lipid bilayer envelope (Fig. 2 A and C). The (-)-ssRNA ca. 16 
kb genome comprises six genes, flanked by short terminal leader (3’ end) and trailer 
sequences (5’ end). From these genes, a total of six essential structural proteins (N, P, M, F, H 
and L) and two non-structural and non-essential proteins are expressed (V and C) (Fig. 2 B).  
The RNA genome is protected against degradation by the nucleocapsid protein (N), 
which is responsible for packaging it into the ribonucleoprotein complex (RNP). One N 
protein is able to bind to and protect exactly six nucleotides, resulting in the fact that the 
genome length has to be a multiple of six to ensure proper encapsidation (“rule of six”) 
(Calain and Roux, 1993). Associated with the nucleoprotein and the RNA are the 
phosphoprotein (P) and large protein (L). Both L and P form the viral RNA-dependent RNA 
polymerase with L as the catalytic subunit and P as an essential co-factor. The P protein links 
both N and L, thus enabling efficient viral transcription and replication (Liston et al., 1995). 
Only RNPs can serve as templates for the polymerase for both transcription and replication. 
The RNA dependent RNA polymerase has to be present in the virion to ensure infectivity 
(Rima and Duprex, 2009). Transcription and replication of the viral genomic RNA (vRNA) 
occur mainly in perinuclear compartments (Wileman, 2007) resembling intracellular inclusion 
bodies.  
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Figure 2:  Measles virus morphology, replication and transcript ion   
(A) Scheme of the measles virus particle composed of the structural proteins in (B). RNP 
components are depicted in green, other MV proteins in blue. N encapsidates the genomic RNA 
to form the RNP, L and P associate with it. M surrounds the viral RNP lining it to the lipid 
bilayer membrane, depicted in grey here. The two membrane spanning proteins are F, a trimer 
and H a dimer. The F protein consists of two fragments held together by disulfide bonds. The 
non-structural proteins C and V (B) are not part of the virion, and are only expressed in infected 
cells. (C) Electron microscopy picture of a typical measles virus. The surface proteins are visible 
as spikes around the membrane, whereas the RNP with the genomic RNA can be seen inside the 
membranous structure. (D) Overview on transcription from the MV genome, as well as 
replication and translation from the subgenomic RNAs.  
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Leader RNA and the mRNAs are transcribed from the genome in a stepwise manner, mRNAs 
are posttranscriptionally modified by 5’ capping and 3’ polyadenylation. The polymerase 
complex is able to dissociate from the RNP at the gene borders, however transcription always 
starts at the leader sequence. This results in the appearance of a gradient of mRNAs (Barrett 
and Underwood, 1985), although the slope can vary (Cattaneo et al., 1987). The mRNAs 
transcribed by the viral RNA dependent RNA polymerase do not differ from cellular mRNAs 
in that they contain a 5’ cap and a 3’ poly(A) tail. Therefore, they can be translated by the 
cellular ribosomes (Gerlier and Valentin, 2009). The polymerase is also capable of replicating 
the whole genome, resulting in the production of an antigenomic positive sense RNA strand 
(cRNA) which is concurrently encapsidated by N proteins. This RNP is then replicated into 
vRNAs again and immediately complex with N proteins to form genomic RNPs (Kingsbury, 
1974; Rima and Duprex, 2009) (Fig. 2 D). 
The M (matrix) protein co-localises with the RNPs and is required for virus  budding 
(Rima and Duprex, 2009). It is also part of the virion. Responsible for the attachment to target 
cells is the viral transmembrane hemagglutinin protein (H). It forms dimers of dimers 
(tetramers) (Gerlier and Valentin, 2009) and mediates the binding to the cellular entry 
receptors (Santiago et al., 2002). Wildtype MV use the  human signalling lymphocyte 
activation molecule (hSLAM; or CD150) (Tatsuo et al., 2001) and nectin-4 (Muhlebach et al., 
2011; Noyce et al., 2011), whereas attenuated strains also can additionally utilize the CD46 
receptor (Dorig et al., 1993; Naniche et al., 1993) for their entry. Wildtype H, however can be 
artificially adapted to recognize CD46 (Nielsen et al., 2001) reproducing the adaptation 
process during vaccine production. Once the H protein recognizes the receptor, the fusion 
between viral membrane and cellular membrane is accomplished by the fusion protein (F), a 
membrane-spanning trimer (Ader et al., 2013; Brindley et al., 2012). F is a class I fusion 
protein, consisting of two processed peptides F1 and F2 which are derived from the F0 
precursor protein and linked by a disulphide bridge (Smith et al., 2009). Both F and H are 
responsible for the fusion of neighbouring cells, generating the so-called syncytia, giant fused 
cells (BLACK et al., 1956; Gerlier, 2006). This syncytia formation is a hallmark of infection 
in most cell lines, as well as in vivo (Nozawa et al., 1994; Wild et al., 1991). 
Although MV possesses only 6 genes, 8 proteins are translated. The two additional, but 
non-structural proteins (C and V) are encoded in the genome, namely in the P gene (Bellini et 
al., 1985; Cattaneo et al., 1989); they have important functions as virulence factors and 
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antagonists of cellular immune responses (Conzelmann, 2005; Gerlier and Valentin, 2009; 
Goodbourn and Randall, 2009; Pfaller and Conzelmann, 2008; Rima and Duprex, 2009). 
1.4. The P gene products and their functions 
The P gene is unique among the genes of multiple Mononegavirales, due to its ability to 
be able to encode 3 different proteins: P, V and C. 
The exact transcript of the P gene generated by the viral polymerase complex during 
infection is the P mRNA. The first translation product of the P mRNA is the P protein, the 
essential co-factor of the viral polymerase complex. Both the V and the C protein are non-
essential for the viability of the viruses (Radecke and Billeter, 1996; Schneider et al., 1997). 
 
Figure 3: Schematic view on the transcription and translation from the MV P gene.  
The P gene is transcribed from the MV genome during infection by the viral polymerase complex 
L and P, including capping and polyadenylation. The exact transcript of the P gene is the P 
mRNA, whereas the V mRNA has a non-templated G residue inserted at a defined position 
(editing site). The translational product of the first AUG of the P mRNA is the P protein; the 
translation product of the first AUG of the V mRNA is the V protein, thus having the same N-
terminus as the P protein but distinct C-terminal domain due to the frameshift induced by the 
inserted G residue into the mRNA. From both mRNAs the C protein is translated from a second 
AUG start codon downstream of the first by ribosomal leaky scanning. 
The V protein is expressed from the V mRNA which is a result of RNA editing of the 
P mRNA by the viral polymerase complex. A non-templated G is inserted at a defined 
position in the mRNA eventually resulting in the translation of the V protein, which shares the 
N-terminal domain with P but has a distinct C-terminus (Cattaneo et al., 1989). This small 
zinc-finger domain (Liston and Briedis, 1994) turned out to represent a hub module for 
binding and inhibiting the function of a variety of cellular molecules (Andrejeva et al., 2004; 
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Cruz et al., 2006; Palosaari et al., 2003; Pfaller and Conzelmann, 2008; Ramachandran and 
Horvath, 2010; Schuhmann et al., 2011). From both mRNAs of the P gene the C protein is 
expressed via an alternative start codon, recognized by the cellular ribosome via leaky 
scanning (Bellini et al., 1985) (Fig. 3). 
The main function of the P protein is to serve as the co-factor of the viral polymerase 
L (Horikami et al., 1994). It is able to bind to the N protein, linking the polymerase complex 
with the RNP. Additionally it is proposed to position incoming N proteins on the nascent 
RNA (Devaux and Cattaneo, 2004).  
In contrast to the cytoplasmic P and V proteins, C shuttles between the cytoplasm and 
nucleus (Nishie et al., 2007). MV C protein has been reported to down-regulate viral 
transcription and replication (Bankamp et al., 2005; Reutter et al., 2001) and to act as a viral 
release and infectivity factor (Devaux and Cattaneo, 2004), by modulating the polymerase 
activity by binding together with P to the cellular molecule SHCBP1 (Ito et al., 2013). 
The MV P gene products -P, V and C- are long known as viral virulence factors (Escoffier 
et al., 1999; Goodbourn and Randall, 2009; Mrkic et al., 2000; Patterson et al., 2000; Radecke 
and Billeter, 1996; Randall and Goodbourn, 2008; Valsamakis et al., 1998) being able to 
counteract both adaptive and innate immune responses, but only recently more detailed 
knowledge on the multiplicity of their individual and cooperative roles in modulating innate 
immune responses is emerging.  
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2. Defense of a host against viruses and viral counter-measures 
 
During evolution the hosts of viruses evolved strategies to counteract the invading 
pathogen and facilitate clearance of infections. These strategies can be summed up as the 
immune system. The human immune system uses elaborate mechanisms ranging from pattern 
recognitions to specific non-self structure recognition to identify potential threats. The 
response generated is mostly protein based (Chaplin, 2006; Litman et al., 2010), although in 
invertebrates and plants siRNA strategies against viruses are also common (Stram and 
Kuzntzova, 2006).  
The human immune system can be subdivided into the innate immune system and the 
adaptive immune system. While the former is non-adaptive and reacts only to specific 
pathogen associated molecular patterns (PAMP), the latter is a highly diverse and specific 
system to recognise non-self peptides, proteins, structures and modifications. 
2.1. Adaptive immunity 
The diversity and adaptability of the adaptive immune system heavily relies on 
immunoglobulins which are encoded by rearrangable gene segments. These immunoglobulins 
encoded by T and B cells, are able to recognise a multitude of epitopes, not all of them 
foreign (Pancer and Cooper, 2006). Therefore it is crucial for the host to distinguish between 
self and non-self antigens from e.g. pathogens.  To this end, T-cells undergo a selection 
process leaving only those clones alive, which recognize non self antigens. T cells can 
recognize antigens presented by antigen presenting cells (APC). All cells with the exception 
of non-nucleated cells are able to present antigens on major histocompatibility complex 
(MHC) molecules. Two different isoforms of the protein MHC exist: MHC classes I and II. 
While MHC class I proteins are loaded with peptides derived from a special proteasomal 
degradation process, thus presenting intracellular pathogens, the endosomal pathway is 
mainly responsible for providing the peptides for MHC class II molecules. Therefore they 
represent fragments of foreign pathogens from the extracellular space.  Recognition of a 
foreign antigen by T cells leads to activation and proliferation of a subset of B cells in the 
case of MHC-II antigen presenting or killing of the non-self antigen presenting cell by T 
Killer cells for MHC-I antigen presenting cells.  
The B cells in turn are the main antibody producing cells, and release neutralizing 
antibodies into the bloodstream, which then can bind and inactivate pathogens. The B cells 
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can also evolve in memory B cells, providing a long-term memory of the pathogen for 
eventual rapid re-release of antibody upon a reinfection. This mechanism is the base for a 
successful vaccination, eventually leading to life-long immunity against the vaccinated 
pathogen (Charles A Janeway, 2001; Litman et al., 2010). 
2.2. Adaptive immunity during MV infection 
Measles virus activates a T cell response 10-14 days after infection, and the rash is 
caused by infiltrating by CD4+ and CD8+ T cells. Viremia is cleared within a few days after. 
MV can no longer be isolated from PBMCs thereafter. The mechanism how this clearance 
occurs is however not fully understood. Interestingly, MV induces lymphopenia, a decrease in 
numbers of circulating B and T cells (Ryon et al., 2002) as well as a suppression of 
lymphocyte proliferation in vivo. Lymphopenia is probably caused by altered trafficking and 
increased cell death. The status is however returned to normal after the rash disappears 
(Auwaerter et al., 1999). In the case of lymphocyte proliferation it is speculated that a lack of 
IL-2 is responsible for part of the defect (Griffin et al., 1987) and the interaction of MV 
virions with hSLAM may contribute to the phenotype (Schlender et al., 1996). Additionally 
the cell cycle of these cells is arrested in G1 (McChesney et al., 1988; McChesney et al., 
1987) . In  immunocompromised patients MV infection may lead to fatal giant cell pneumonia 
or inclusion body encephalitis, underlining the importance of the adaptive immunity response 
during MV infection (Griffin, 2010). 
2.3. Innate immunity 
The innate immune system is the first line of defence against invading pathogen. It 
responds to stimulation with patterns associated with pathogens (PAMPs) and danger-
associated molecular patters (DAMPs). In contrast to PAMPs, DAMPs are molecules that 
initiate a response, although not being part of invading pathogens. Typically these cytosolic 
and nuclear molecules are released upon tissue damages or cell necrosis. Invading pathogens 
are detected via patterns associated with pathogens (PAMPs), such as LPS (Athman and 
Philpott, 2004; Philpott and Girardin, 2004) from bacteria or dsRNA and triphosphorylated 
RNA (Cui et al., 2008; Hornung et al., 2006; Pichlmair et al., 2006; Pichlmair and Sousa, 
2007) from viruses. It is not as flexible as the adaptive immune system and it does not possess 
any memory of previous infections. The response evoked by PAMP recognition is not subject 
to any variation fitting to the invading pathogen, it is more a general defence initiated with a 
huge variety of mechanisms used, though. Upon PAMP recognition by various cellular and 
extra-cellular pattern recognition receptors (PRRs), the immediate response is the induction of 
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interferon (IFN) and cytokines and the secretion of these cytokines, which in turn signal on 
neighbouring cells to set up an antiviral state (Fig. 4). 
 
Figure 4: Schematic depiction of the intracellular signalling pathway leading to interferon 
beta induction and the interferon signalling pathway.  
(A) Induction of interferon beta. Foreign intracellular RNA is sensed by the RIG-like-helicases 
which in turn are activated and bind to IPS-1. IPS-1 serves as an assembly platform for diverse 
effector molecules, most prominent among them the IKK kinases, TBK1 and the MAP kinases. 
They lead to the activation and nuclear accumulation of the transcription factors NF-κB, IRF3 
and AP1 respectively (Randall and Goodbourn, 2008). Common signalling proteins are depicted 
in blue, the AP1 pathway in brown, the IRF3 pathway in red and the NF-κB pathway in purple. 
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Modifications by phosphorylation are depicted in yellow, ubiquitination in orange. (B) Model of 
enhanceosome assembly and disassembly: The interferon β enhancer is a 57bp element and can 
be separated into different transcription factor binding domains (positive regulatory domains, 
PRDs). In an unstimulated cell, HMGA1a binds to the enhancer DNA element. HMGA1a is 
thought to orchestrate the binding of transcription factors such as Fos/Jun (AP1), dimers of 
phosphorylated IRF3 and IRF7 and NF-κB to the enhancer element of the interferon β promoter 
upon receiving a stimulus. After acetylation of HMGA1a by the recruited p300/CBP the 
enhanceosome disassembles and RNA polymerase II is recruited and transcription starts. (Panne 
et al., 2007; Thanos et al., 1993; Yie et al., 1999) (C) Interferon signalling cascades and 
induction of ISGs. Secreted interferon β binds to the IFNAR receptor on neighbouring cells, 
activating JAK kinases, which phosphorylates STAT1. Active STAT1 dimerises, binds IRF9 and 
activates transcription of interferon stimulated genes (ISGs) in the nucleus. The proteins 
involved are depicted in green, modification by phosphorylation in yellow. 
PRRs can be grouped with respect to their cellular localization. Toll-like receptors 
(TLRs) are located on the extracellular surface or on the inner membrane of endosomes, thus 
responding to extracellular PAMPs. They recognize various ligands, ranging from viral and 
bacterial nucleic acids to specific components of the membrane of pathogens. (Kawai and 
Akira, 2008; Kawai and Akira, 2011; Kumar et al., 2009; Kumar et al., 2011; Randall and 
Goodbourn, 2008).  
Interferon induction by RLRs 
The main intracellular PRRs are RIG-like-helicases (RLRs), among them retinoic acid 
inducible gene I (RIG-I), melanoma-differentiation-associated gene 5 (MDA-5) and 
Laboratory of Genetics and Physiology 2 (LGP2). RIG-I is known to bind to 5’-tri-
phosphorylated RNA (Cui et al., 2008; Hornung et al., 2006; Pichlmair et al., 2006), and the 
search for an MDA-5 ligand is ongoing, though polyI:C and long dsRNA have been identified 
as activators of MDA-5 (Wu et al., 2013). It was also speculated that viral RNA lacking 2‘-O 
methylation is an inducer of MDA-5 (Zust et al., 2011). During MV infection, leader RNA 
and the genomic/antigenomic RNA  can induce activation of RIG-I (Rima and Duprex, 2009). 
Upon binding of its ligand the receptor is activated by dimerization and exposure of its CARD 
domains (Zeng et al., 2010), leading to the activation of a subsequent signalling cascade. The 
exact nature of the MV ligand of MDA-5 is not known, but it is activated during viral 
infection (Ikegame et al., 2010). Importantly, defective interfering particle production by 
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measles virus could lead to a robust interferon induction, as seen for the closely related 
parainfluenza 5 virus (Killip et al., 2011), probably via both RIG-I and MDA-5. 
Both activated RIG-like helicases recruit and activate the mitochondrial membrane-
bound IPS-1/MAVS/Cardif/VISA protein (Kawai et al., 2005; Randall and Goodbourn, 
2008), which then forms clusters at the mitochondrial surface upon activation (Onoguchi et 
al., 2010b; Takamatsu et al., 2013). This adaptor is essential for the three main signalling 
cascades leading eventually to the activation of the cellular transcription factors ATF2/Jun, 
NF-κB and IRF3 (Kumar et al., 2006; Xu et al., 2005). IPS-1 leads to activation of 
FADD/TRAF6 in the NF-κB branch, which subsequently activates the IKK complex. The 
IKK complex phosphorylates IκB, which is then degraded (Alkalay et al., 1995) and the 
transcription factor NF-κB is released and can enter the nucleus to stimulate transcription. 
IPS-1 also activates the TBK1/TANK complex via direct interaction with TRAF3 (Xu et al., 
2005) (Fig. 4 A). 
IRF3 is a transcription factor activated by phosphorylation via the kinases TBK1/IKKi 
at its C-terminal domain (Panne et al., 2007b). It was suggested that expression of the MV N 
protein can in addition to the classical induction cascade enhance IRF3 phosphorylation 
(tenOever et al., 2002). Phosphorylated IRF3 then forms dimers and accumulates in the 
nucleus where it binds to the IFN-β promoter region together with NF-κB and ATF2/c-Jun to 
effectively activate IFN-β transcription (Ohno and Taniguchi, 1983). Regulation of IRF3 
activity is further ensured by association with beta-catenin, which has to be deacetylated by 
histone deacetylases, bridging IRF3 to CBP (Chattopadhyay et al., 2013). If IRF7 is present in 
the cells (e.g. dendritic cells) it can additionally bind in its activated form to the promoter 
region to further stimulate IFNβ expression. The assembly is thought to be orchestrated by 
high mobility group AT-hook 1 proteins HMGA1, although they cannot be part of the final 
IFN-β enhanceosome, due to overlapping binding sites (Panne et al., 2007a; Panne et al., 
2007b; Thanos et al., 1993; Yie et al., 1999). This enhanceosome binds CREB Binding 
Protein (CBP) or p300, which in turn acetylates HMGA1a, eventually causing the disruption 
of the assembly (Yie et al., 1999). CBP/p300 can recruit the RNA polymerase II complex and 
enables efficient transcription by histone remodelling (Vo and Goodman, 2001) (Fig. 4 B).  
To terminate the IRF3 signal, the activated protein binds to Pin1 (Saitoh et al., 2006), 
which causes ubiquitinylation of IRF3 by RBCK1 and degradation via the proteasomal 
pathway (Zhang et al., 2008). The activation of IRF3 is also thought to eventually induce 
apoptosis directly (Chattopadhyay et al., 2010), if not properly terminated. Therefore a fully 
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functional proteasome is critical for this cellular signalling cascade as well, terminating the 
signal, as well as facilitating induction by degrading the inhibitor of p65 and p55. 
Interferon beta is the main cytokine induced by the above explained cascade. In 
addition to that, other proinflammatory cytokines, PRRs itself and other interferon are 
upregulated as well.  The induced interferons can be further divided in three major groups, 
based on their cellular surface receptor. Type I interferons use the IFNAR receptor and 
include IFNα, IFNβ and IFNω. Especially IFNα can be further classified into subgroups 
according to the gene responsible for expression (de Weerd et al., 2007). In contrast to that, 
only one gene is responsible for the expression of IFNβ, consequently only one subgroup 
exists. Type II interferons use the IFNGR and include the single IFNγ. This response is 
differently stimulated than the Type I response. Another group are type III interferons which 
bind the IL10R2 and IFNLR1 and include IFNλ (Fensterl and Sen, 2009). 
Interferon type I induced signalling 
Neighbouring cells have the outlined specific interferon receptors, which subsequently 
induce signalling cascades leading to the expression of interferon stimulated genes and also 
provide feedback to interferon release. These transcribed genes set the cells in an anti-viral 
state and can eventually induce apoptosis in infected cells to clear the organism from the 
pathogen (Randall and Goodbourn, 2008). Secreted interferon beta and alpha activates the 
JAK/STAT-signalling cascade by binding to the type-I interferon receptor (IFNAR), leading 
to the phosphorylation of the transcription factor STAT1. STAT1 dimerizes, binds to IRF9 
and accumulates in the nucleus, where it stimulates the expression of interferon stimulated 
genes (ISGs). Among these are antiviral proteins (e.g. RNAse L, oligoadenylate synthetase 
(OAS) or Mx) and components of the IFN-induction pathways (e.g. the transcription factor 
IRF7), thus creating a positive feedback signal for the enhancement of IFN production (Levy 
et al., 2002; Randall and Goodbourn, 2008). IRF7 can also be activated directly via Toll-like-
receptor signalling in dendritic cells, where it is constitutively expressed (Randall and 
Goodbourn, 2008) (Fig. 4 C). 
2.4. Viral innate immune evasion strategies  
Different viruses have developed different strategies to evade the antiviral innate immune 
response. In the case of measles the main virulence factors antagonizing innate immune 
responses have been identified to be encoded in the P gene: P, V and C. Additionally, the N 
protein of N was also implicated to play a role by blocking nuclear import of activated Stat1 
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(Takayama et al., 2012). A stimulating effect on IFN induction, however, was also reported 
(tenOever et al., 2002). 
The V and P proteins of MV were long identified as potent antagonists of both interferon 
signalling and interferon production. The shared N-terminal domain of P and V for example 
can block STAT1 phosphorylation (Caignard et al., 2009; Devaux et al., 2007). V, in addition, 
binds to STAT2 and JAK1 via the VCTD (Caignard et al., 2007; Ohno et al., 2004; Palosaari et 
al., 2003; Ramachandran et al., 2008; Yokota et al., 2003). Moreover the V protein C-terminal 
domain is capable of binding to IKKα and IRF7, acting as a decoy substrate for 
phosphorylation (Pfaller and Conzelmann, 2008). Additionally it is able to bind and block 
MDA-5 (Childs et al., 2007; Motz et al., 2013), but not RIG-I. Furthermore, this hub-domain 
associates with p65, thus blocking its nuclear import and the proper activation of the Nf-κB 
response (Schuhmann et al., 2011).  The MV P protein, in addition, was shown to induce 
transcription of the TLR inhibitor A20 in macrophage cell lines (Yokota et al., 2008) which 
might enhance negative feedback to proinflammatory responses in these cells.  
A contribution of the C protein to the regulation of IFN induction was suggested recently. 
Specifically, MV mutants deficient for C protein production (Cko) viruses were better inducers 
of IFN-β compared to parental or Vko viruses (McAllister and Samuel, 2009; Nakatsu et al., 
2006). The observed activation of PKR (Toth et al., 2009) , which leads to enhancement of 
IFN induction via activation of ATF-2 and NF-κB (McAllister and Samuel, 2009), suggested 
that in the presence of C the accumulation of viral dsRNA serving as a molecular pattern for 
RLR is down regulated(McAllister et al., 2010). Additionally, it was suggested, that the MV 
C protein either shelters viral RNA or decreasing the overall viral RNA load in the cell 
(Nakatsu et al., 2006; Nakatsu et al., 2008; Sleeman et al., 2008) thus interfering with the 
recognition of the viral RNA by RIG-I or PKR. C protein was also implicated in preventing 
type I IFN-mediated expression of ISG, though less efficiently than V (Fontana et al., 2008; 
Shaffer et al., 2003; Yokota et al., 2011b). 
Among the Morbilliviruses MV is most closely related to Rinderpest virus (RPV) (Furuse 
et al., 2010), which also encodes for a C protein, in a different ORF of the P gene mRNAs. It 
was reported that the RPV C protein blocks interferon β induction presumably in the nucleus, 
although the exact mechanism remains unclear (Boxer et al., 2009). Another close relative of 
MV is the parainfluenza 5 virus. It lacks the expression of a C protein, but the V protein is an 
important virulence factor. Similar to MV V it binds STAT1 and MDA-5 (Childs et al., 2007; 
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Motz et al., 2013), but in addition is able to modulate DDB1 (Li et al., 2006) to induce Stat2 
degradation. 
The Sendai virus C protein is able to restrict production of dsRNA during infection, 
thereby inhibiting the recognition of the virus by the intracellular Rig-like helicases and PKR 
(Takeuchi et al., 2008). The same effect was also reported for yet another Paramyxovirus, the 
human parainfluenza virus 1 (HPIV1) (Boonyaratanakornkit et al., 2011). 
The phosphoprotein (P) of the rhabdovirus rabies virus is able to bind to the TBK1 
complex, thereby inhibiting phosphorylation of IRF3 including its dimerization and nuclear 
translocation (Brzozka et al., 2005; Rieder et al., 2011; Rieder and Conzelmann, 2009). 
Moreover it is also able to inhibit the signalling pathway, which is activated after stimulation 
of the cells with interferon type I (Interferon α/β), by binding to phosphorylated STAT1 and 
STAT2 (Brzozka et al., 2006). Rabies virus does not encode any V or C accessory proteins, 
VSV however has a conserved C ORF with yet unknown function. 
3. Generating recombinant viruses 
 
To study changes of viral proteins in the viral context, recombinant viruses with distinct 
sequences and properties have to be generated. In contrast to DNA or positive strand RNA 
viruses, the viral genome of negative strand RNA viruses per se is not infectious. The 
negative sense orientation of the genomes is responsible for its inability to directly use the 
cellular machinery for transcription and eventually the translation of proteins. The viral 
polymerase complex has to generate subgenomic positive-orientation mRNAs first, and is 
therefore also present in infectious virions. To this end, a rescue of negative strand RNA 
viruses was developed using reverse genetics, relying on the co-transfection of the viral 
cDNA together with helper proteins encoding N, P and L into cells (Conzelmann, 2004; 
Conzelmann et al., 1990; Schnell et al., 1994).  
Once viral antigenomic RNA is generated from a cDNA plasmid using T7 polymerase 
dependent transcription it is loosely encapsidated by the viral N protein which is provided 
either by plasmid transfection or stable cell lines. This loosely packed RNP is then recognized 
by the viral polymerase complex and the transcription of the genome starts. This nascent RNA 
is co-transcriptionally encapsidated by N and in turn used to transcribe viral subgenomic 
mRNAs and to replicate. Upon translation of the viral proteins by the cellular ribosome from 
the subgenomic RNA, the life cycle of the virus starts and infectious particles are released 
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from the cells to spread the infection (Fig 5 A) (Radecke et al., 1995; Schnell et al., 1994; 
Takeda et al., 2000).  
 
Figure 5: Schematic depiction of MV rescue and the plasmids used.  
(A) The processes inside the cell: The viral antigenomic full length RNA (in dark blue) is 
transcribed from cDNA by the T7 polymerase and the 3‘ and 5‘ ends processed by ribozymes. N 
protein (green) loosely encapsidates the viral RNA. The viral polymerase complex (L and P, light 
blue), which are co-expressed as well, form the viral replication polymerase complex and 
replicate the antigenomic RNA to form genomic RNA. From the genomic RNA, the normal viral 
transcription takes place and the viral proteins are expressed by the host machinery. From these 
cells, infectious viral particles are released completing the rescue of recombinant virus. (B) 
Scheme of the plasmid used for viral cDNA transfection. The antigenomic RNA is transcribed 
T7 polymerase dependent and the ends of the RNA cropped by the indicated ribozymes to ensure 
the proper length and termini. (C) Scheme of the method for rescuing measles virus. Plasmids 
encoding viral full-length RNA and MV L are transfected into 293-3-46 cells, which express 
stably MV N, P and the T7 Polymerase. After heat shocking the cells at 42°C they are co-
cultured with Vero-hSLAM cells to provide easily infected cells for emerging rescued virus. A 
successful rescue is detected by syncytia formation of Vero-hSLAM cells and these syncytia are 
picked and the rescue virus multiplied on Vero cells.  
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This basic system works in principle for every negative strand RNA virus. In the case of 
MV, the T7 polymerase and the viral proteins N and P are stably expressed by the 293-3-46 
cell line (Radecke et al., 1995). Only transfection of the viral genome in cDNA and a plasmid 
encoding the MV L protein is necessary. In this study the cDNA was based on the vac2 
plasmid, encoding a Schwarz strain identical viral cDNA (del Valle et al., 2007). This 
sequence was subcloned into the pBluescript vector and flanked with ribozymes (Ghanem et 
al., 2012; Pfaller, 2010) (Fig. 5 B). The ribozymes ensure proper processing of the genomic 
ends dramatically increasing the efficiency of the rescue. Heat shocking the transfected cells 
after 2 days increases the efficiency of the viral rescue, as well, (Parks et al., 1999) by 
inducing cellular heat shock proteins and increasing MV transcription rates. Co-cultivating 
these rescue cells with Vero cells stably expressing the MV high affinity receptor hSLAM 
(Vero-hSLAM, (Ohno et al., 2007)), leads to spread of the virus on these easily infected, 
interferon-negative cells upon successful rescue (Fig. 5 C). Once syncytia formation is visible, 
these plaques can be picked to isolate clones of rescued virus, which are subsequently 
propagated on Vero and Vero-hSLAM cells (Radecke et al., 1995) for stock production. 
4. Aim of this thesis 
 
The aim of this thesis is to characterise the interplay between the innate immune system 
and the measles virus C protein in more detail, especially focusing on revealing differences 
between wildtype and vaccine MV strains. Although a primary target of the C protein is the 
viral replication and transcription machinery, as established by previous publications, the 
impact of C on the host cell signalling pathway cannot be disregarded. Modulation of the host 
cell and especially the innate immune response greatly influences the infectivity and growth 
of the virus in general. Especially in vivo the innate immune system significantly contributes 
to the clearance of pathogens from the host, activating and stimulating the adaptive immune 
response (Le Bon and Tough, 2002). Therefore viruses strife to modulate mechanisms 
involved, targeting cellular signalling pathways and altering their functions to their own 
extend. To this end the impact of C on the host cell innate immune system shall be studied at 
first while overexpressed in cell culture. Additional mechanistic studies are to be done, such 
as screening for protein interaction partners. The insights gained by these experiments are 
used to create recombinant measles virus, which harbours specific alterations in the C protein 
encoding P gene. These viruses are to be used for characterisation of C in the viral context, 
establishing a system, which monitors the cellular response. Moreover, the effects these 
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mutations show in overexpression systems on the hosts signalling cascades shall be confirmed 
during infection.  
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MATERIALS AND METHODS 
1. Materials 
1.1. Chemicals 
Acetone p.a.  Roth 
Acridine orange Roth 
Acrylamide/Bisacrylamide 29:1 Rotiphorese Gel 40  Roth  
Agarose  Invitrogen 
Ampicillin Roth  
APS (Ammonium persulfate) Amresco  
Bactotrypton BD 
Bacto Yeast-extract  BD 
β-Mercaptoethanol Sigma  
Bromphenolblue Sigma  
DMSO (Dimethylsulfoxide)  J.T.Baker  
EDTA (Ethylendiamin-tetraacetat) Sigma  
Ethanol abs. p.a.  Roth  
Ethidiumbromide solution 1 %  Roth  
Formaldehyde 37% solution Sigma 
Glycerol p.a. Roth 
Glycine p.a.  Roth 
Glyoxal Roth 
Isopropanol p.a.  Merck  
HOAc abs. p.a.   Roth 
KOAc (potassium acetate)  Merck 
Milk powder Merck  
Methanol abs. p.a.  Roth  
MgSO4·7H2O  (Magnesiumsulfate-heptahydrate)  Merck  
Na2HPO4·2H2O (Disodiumhydrogenphosphate-dihydrate) Merck  
NaCl (Sodium chloride)  Merck  
NaOH (Sodium hydroxide)  Merck  
NH4Cl (Ammonium chloride)  Merck 
Orange G Sigma / Fluka  
Phenolred Merck 
SDS (Sodium dodecylsulfate)  Merck 
TEMED p.a. (N,N,N’,N’-Tetramethyl-ethylen-1,2-diamine)  Roth  
Tricine PUFFERAN  Roth  
Tris PUFFERAN p.a. Roth  
Triton-X100  Merck / Roth  
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Tween20 Roth  
Complete Protease Inhibitor Cocktail Roche 
Na3VO4 (sodium orthovanadate) Sigma 
NP40 (Nonidet P40) Fluka 
Polyethleneimine (PEI) Sigma Aldrich 
Precision Plus Protein Standarts All Blue Biorad 
Vectashield Hard Set Vector Laboratories 
1.2. Kits 
Dual Luciferase Reporter Assay System  Promega  
Lipofectamine 2000  Invitrogen  
Nucleobond Plasmid DNA Purification AX-100  Macherey&Nagel  
QIAquick Gel Extraction Kit  QIAGEN  
QIAquick PCR Purification Kit  QIAGEN  
Western Lightning Chemiluminescence Reagent Plus  Perkin-Elmer  
Calciumphosphate Transfection Kit Promega 
BCA Assay Kit Pierce 
QIAEx II QIAGEN 
QIAGen RNA purification QIAGEN 
SilverQuest Silver Staining Invitrogen 
1.3. Enzymes and buffers 
Pfu DNA polymerase  Fermentas  
Restriction enzymes New England Biolabs  
T4 DNA ligase  New England Biolabs  
100x BSA  New England Biolabs  
10x Pfu DNA polymerase buffer  Fermentas  
NE buffer 1, 2, 3, 4, EcoRI buffer  New England Biolabs  
10x T4 DNA ligase buffer  New England Biolabs  
Phusion DNA Polymerase Finnzyme 
5xPhusion Buffer HF Finnzyme 
1.4. Antibodies 
1.4.1. Primary 
Name Source Supplier 
α-actin rabbit Sigma-Aldrich 
α-flag rabbit Sigma-Aldrich 
α-HA rat Sigma-Aldrich 
α-MV C 1240 rabbit R. Cattaneo  
α-MV C 1242 rabbit R. Cattaneo  
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α-MV C rabbit Peptideserum: C. Pfaller 
α-MV V/P rabbit Peptideserum: C. Pfaller  
α-RV P (FCA) rabbit Metabion 
α-flag mouse Sigma-Aldrich 
α-IRF3 rabbit Santa Cruz 
α-IRF3 p386 rabbit  
α-IRF3 p396 rabbit  
α-MV N (unconj. or FITC-conj.) mouse Millipore 
1.4.2. Secondary 
Antibody  Supplier 
α-rabbit-PO  Dianova 
α-mouse-PO  Dianova 
α-rabbit Alexa 488  Invitrogen (Molecular Probes) 
α-mouse Alexa 555  Invitrogen (Molecular Probes) 
α-mouse TMR  Invitrogen (Molecular Probes) 
α-rabbit Alexa 633  Invitrogen (Molecular Probes) 
1.5. Oligonucleotides 
1.5.1. For cloning and sequencing: 
No. Name Sequence 
1 MVNfwdSnaBI ATA TAC GTA ATG GCC ACA CTT TTA AGG 
2 MVFfwdSnaBI ATA TAC GTA ATG CCC GAA ACG ACC CCC 
3 MVHfwdSnaBI ATA TAC GTA ATG TCA CCA CAA CGA GAC 
4 MVMfwdSnaBI ATA TAC GTA ATG ACA GAG ACC TAC GAC 
5 MVNrevXhoI ATA CTC GAG CTA GTC TAG AAG ATT  
6 MVCNLS_AAfwd ACA GGA CCG AGC CAC CTG CAG CGG CGA GAA GGC 
AGG CAG TTC GGG T 
7 MVCNLS_AArev ACC CGA ACT GCC TGC CTT CTC GCC GCT GCA GGT 
GGC TCG GTC CTG T 
8 EcoRI-MVCwt-woATG-fwd ATA GAA TTC AAA AAC GGA CTG GAA T 
9 NotI-MVCwt-rev TAT GCG GCC GCT ATC AAG AGC TCG TGG ATC T 
10 MVCsG44R_fwd GGA CAG GAG CGA GCC ACC TGC ACG GAA GAG AAG 
GCA GGC AGT TCG GG 
11 MVCsG44R_rev CCC GAA CTG CCT GCC TTC TCT TCC GTG CAG GTG 
GCT CGC TCC TGT CC 
12 MVCsNotI_rev CAC GCG GCC GCT ATC AGG AGC TCG TGG ATC TCC 
CCT CCT TC 
13 MVCsSnaBI_fwd GTG TAC GTA GCC ACC ATG TCA AAA ACG GAC TGG 
AAT GCA TCC G 
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14 MVCs/wtBamHISnaBIHA GTG GGA TCC TAC GTA GCC ACC ATG TAT CCT TAT 
GAC GTG CCT GAC TAT GCC AGC CTG GGA GGA CCT 
TCA AAA ACG GAC TGG AAT 
15 MV-Cwt-SnaBI-fwd GTG TAC GTA GCC ACC ATG TCA AAA ACG GAC TGG 
AAT GTA TCC G 
16 MVCwtBamHI_fwd GTG GGA TCC GCC ACC ATG TCA AAA ACG GAC TGG 
AAT GTA TCC G 
17 MVLeader-qRT-fwd ACC AAA CAA AGT TGG GTA AG 
18 MVLeader-qRT-rev AAG TGC ACT AGA AGA TGA TC 
19 MVvac2CstoCwtNLS_fwd AGG ACA GGA GCG AGC CAC CTG CAA GGA AGA GAA 
GGC AGG CAG TTC GGG T 
20 MVvac2CstoCwtNLS_rev ACC CGA ACT GCC TGC CTT CTC TTC CTT GCA GGT 
GGC TCG CTC CTG TCC T 
21 TagRFPfwdBamHISnaBI GTG GGA TCC TAC GTA CCG CCA TGG TGT CTA AGG 
GCG AAG AGC TG 
22 TagRFPNotI_rev CAC GCG GCC GCT TAA TTA AGT TTG TGC CCC A 
23 TagRFPfusionNsiI_rev CAC ATG CAT TAA GTT TGT GCC CCA GTT TGC TAG 
GGA 
24 CwtNotIwoTA_rev CAC GCG GCC GCT CAA GAG CTC GTG GAT CTC CCC 
TCC TTC TGC A 
25 CsNotIwoTA_rev CAC GCG GCC GCT CAG GAG CTC GTG GAT CTC CCC 
TCC TTC TGC A 
26 Cs/wtwlinkerwoATG_fwd GTG ATG CAT CCG GCG GCG GCT CAA AAA CGG ACT 
GGA AT 
27 MVC-SV40NLS GAG GGA TCC GCC ACC ATG ACT GCT CCA AAG AAG 
AAG CGT AAG TCA AAA ACG GAC TGG AAT 
28 MV-M(4336)-rev CCT CAA CAA CCC CCA GCA GA 
29 MV-Cwt-XhoI-rev CGC CTC GAG TCA AGA GCT CGT GGA TCT CCC CTC 
30 MV-Cwt/s-Acc65I-fwd GCG GGT ACC GCC ACC ATG TCA AAA ACG GAC TGG 
AAT G 
31 MVCko-rev GGA TGC ATT CTA GTC CGT TTT TCA CGT GGC GTG 
CCT GCT CT 
32 TagRFPfusionAscI-rev GCC GCC CGG CGC GCC ATT AAG TTT GTG CCC CAG 
TTT 
33 MVClinkerwoATG-AscI-fwd GTG GGC GCG CCG GGC GGC TCA AAA ACG GAC TGG 
AAT 
34 MVCHA-fwd-BamHI/SnaBI-
corr 
ATA GGA TCC TAC GTA GCC ACC ATG TAC CCA TAC 
GAT GTT CCA GAT TAC GCT GGC TCA AAA ACG GAC 
TGG AAT 
35 GFP-woATG-AscI-fwd GCG GGC GCG CCG GTG AGC AAG GGC GAG GAG CTG 
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36 GFP-XhoI-rev CGC CTC GAG TTA CTT GTA CAG CTC GTC CAT 
37 p125-EcoRI-fwd GCG GAA TTC GTT TTA GAA ACT ACT AAA A 
38 p125-BamHI-rev CGC GGA TCC AAG GTT GCA GTT AGA AT 
39 MVCs/wt-EcoRI-fwd GCG GAA TTC GCC ACC ATG TCA AAA ACG GAC TGG 
AAT G 
40 MVCs-XhoI-rev GCC TCG AGT CAG GAG CTC GTG GAT CTC CCC TC 
41 NotI-flag-MAP1B-fwd ATA GCG GCC GCG CCA CCA TGG ACT ACA AAG ACG 
ATG ACG ATA AAG GAG CGA CCG TGG TGG TGG AAG 
CCA 
42 NotI-MAP1B-fwd ATA GCG GCC GCG CCA CCA TGG CGA CCG TGG TGG 
TGG AAG CCA  
43 flag-ApaI-MAP1B-rev TAT GGG CCC TTA TCC TTT ATC GTC ATC GTC TTT 
GTA GTC CAG TTC AAT CTT GCA TGC AGG GAA 
44 ApaI-MAP1B-rev TAT GGG CCC TTA CAG TTC AAT CTT GCA TGC AGG 
GAA 
45 IPO8-BamHI-Ha-fwd GCG GGA TCC ACC GCC ATG TAT CCT TAT GAC GTG 
CCT GAC TAT GCC AGC CTG GGA GGA CCT GAC CTC 
AAC CGG ATC ATC CAG GCG CTG 
46 IPO8-NotI-rev TAT GCG GCC GCT CAG TTG TTG CTG GGC ACA GTC 
CC 
47 IPO7-BamHI-Ha-fwd GCG GGA TCC ACC GCC ATG TAT CCT TAT GAC GTG 
CCT GAC TAT GCC AGC CTG GGA GGA CCT GAG ACC 
ATG GCG AGC CCA GGG AAA GAC 
48 IPO7-NotI-rev TAT GCG GCC GCT TAT AGC TGG AAG CCC TCC ATG 
GGG GCC TCA 
49 IPO9-Acc65I-Ha-fwd GCG GGT ACC ACC GCC ATG TAT CCT TAT GAC GTG 
CCT GAC TAT GCC AGC CTG GGA GGA CCT GCG GCG 
GCG GCG GCA GCT GGT GCG GCC 
50 IPO9-NotI-rev TAT GCG GCC GCT TAG ATG CCG ATG GTC TGT AGA 
ACT C 
51 MVCwt/s-flag-SnaBI-fwd GTG TAC GTA GCC ACC ATG GAC TAC AAA GAC GAT 
GAC GAT AAA GGA GCG TCA AAA ACG GAC TGG AAT 
G 
52 MCSseq-fwd GGA GCC ATT CGA AGG CCG GCC G 
53 qPCR-MVNfwd-60 TCA AGA GAA CAC CCG GAA AC 
54 qPCR-MVNrev-60 TTC ATG CAG TCC AAG AGC AG 
55 qPCR-GAPDHfwd-60 AGC CAC ATC GCT CAG ACA C 
56 qPCR-GAPDHrev-60 GCC CAA TAC GAC CAA ATC C 
57 qPCR-IFNbfwd-60 AGG GGA AAA CTC ATG AGC AG 
58 qPCR-IFNbrev-60 TCC TTG GCC TTC AGG TAA TG 
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59 flag-MVN-NotI-fwd ATA GCG GCC GCG CCA CCA TGG ACT ACA AAG ACG 
ATG ACG ATA AAG GAG CCA CAC TTT TAA GGA GCT 
TAG 
60 flag-MVM-NotI-fwd ATA GCG GCC GCG CCA CCA TGG ACT ACA AAG ACG 
ATG ACG ATA AAG GAA CAG AGA CCT ACG ACT TCG 
ACA AGT CG 
61 MVF-fwd-NotI ATA GCG GCC GCG CCA CCA TGT CCA TCA TGG GTC 
TCA AGG TGA AC 
62 MVF-flag-rev-XhoI CGC CTC GAG TCA TCC TTT ATC GTC ATC GTC TTT 
GTA GTC GAG CGA CCT TAC ATA GGA TTT TGA T 
63 flag-MVH-fwd-NotI ATA GCG GCC GCG CCA CCA TGG ACT ACA AAG ACG 
ATG ACG ATA AAG GAT CAC CAC AAC GAG ACC GGA 
TAA ATG CCT TC 
64 BamHI-flag-IRGM-fwd GCG GGA TCC GCC ACC ATG GAC TAC AAA GAC GAT 
GAC GAT AAA GGA GAA GCC ATG AAT GTT GAG AAA 
GCC TC 
65 IRGM-NotI-rev TAT GCG GCC GCT TAG TAT TCA CAT ACC CGC TCC 
TTC T 
66 flagPSMD2-XhoI-fwd-longer GCG GGA TCC GCC ACC ATG GAC TAC AAA GAC GAT 
GAC GAT AAA GGA GAG GAG GGA GGC CGG GAC AAG 
GCG CCG GTG CAG CC 
67 Map1b-first571-apa1-rev AAA CCC CTG AGG TCA CAA AAG TGA ATT AAG GGC 
CCA TA 
68 NotI-PSMD2-rev TAT GCG GCC GCT TAG AGA TCA TAA TTG GGG TTC 
TTC 
69 flag-PSMC3-XhoI-fwd GCG GGA TCC GCC ACC ATG GAC TAC AAA GAC GAT 
GAC GAT AAA GGA AAT CTG CTG CCG AAT ATT GAG 
AGT CCA GTG 
70 PSMC3-NotI-rev TAT GCG GCC GCC TAG GCG TAG TAT TGT AGG TTG 
GC 
71 flag-BamHI-CTNNB-fwd GCG GGA TCC GCC ACC ATG GAC TAC AAA GAC GAT 
GAC GAT AAA GGA GCT ACT CAA GCT GAT TTG ATG 
GA 
72 NotI-CTNNB-rev TAT GCG GCC GCT TAC AGG TCA GTA TCA AAC CAG 
GC 
1.5.2. Primer used for qRT PCRs 
# Name: Sequence: 
1 qRTMVL-fwd ATC AGG GAA ATA TCA GAT GG 
2 qRTMVL-rev AGT TGT GTG CAA GTT TTG AG 
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3 qPCR-MVNfwd TCA AGA GAA CAC CCG GAA AC 
4 qPCR-MVNrev TTC ATG CAG TCC AAG AGC AG 
5 qPCR-GAPDHfwd AGC CAC ATC GCT CAG ACA C 
6 qPCR-GAPDHrev GCC CAA TAC GAC CAA ATC C 
7 qPCR-IFNbfwd AGG GGA AAA CTC ATG AGC AG 
8 qPCR-IFNbrev TCC TTG GCC TTC AGG TAA TG 
 
1.6. Miscellaneous 
Eppendorf-Cups 1.5 mL, 2.0 mL Eppendorf  
Falcon flasks 15 mL, 50 mL BD  
Hyperfilm ECL Amersham 
Multiwell-dishes  24 wells, 12 wells, 6 wells, 96 wells BD  
PVDF Membrane  Millipore  
PCR Cups 200 µL  biozym 
Pipettetips 1000 µL, 200 µL, 10 µL  Peske, HTL  
Gel-Blotting paper Roth 
Cell culture flasks T25, T75  BD  
1.7. Cell lines and media 
D-MEM (Dulbecco’s Modified Eagle Medium)   Invitrogen Gibco 
Trypsin-EDTA   Invitrogen Gibco 
Penicillin-Streptomycin (PenStrep)  Invitrogen Gibco  
L-Glutamine  Invitrogen Gibco 
Fetal Bovine Serum (FBS) Invitrogen Gibco 
Optimem Invitrogen Gibco/ Life Technologies 
RPMI 1640 Invitrogen Gibco 
G418   
 
 Medium for the cell lines:  D-MEM  
     + 10 % FBS  
     + 2 % L-Glutamine  
     + 0.2 % PenStrep.  
     = D-MEM +3 
 
     RPMI 1640 
+19% FCS 
+0.2% PenStrep 
= RPMI+2 
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HEK-293T Human embryonic kidney cells, expressing the T antigen of SV40 
Vero African green monkey cells 
Vero-hSLAM Vero cells stably expressing the human SLAM receptor  
293-3-46 HEK293 cells stably expressing MV N and P & T7 polymerase 
Hep2 human larynx carcinoma cell line 
HeLa human cervix carcinoma cell line 
293T-STAT-/- human embryonic kidney cell line 293T with a knockout of the STAT1 gene 
A549 human lung epithelial cell line 
DG75 wt human B cell line 
 
1.8. Plasmids and bacteria 
E. coli XL1 (blue; Stratagene) was used for plasmid preparations. 
# Name: Description: Cloning: Source: 
1 pCR3 empty vector  empty vector 
2 pBluescript SK II (-) empty vector  empty vector 
3 pCR3-fl-MVC(wt) expressing a flag tagged version of C 
wildtype 
EcoRI-flag-
Cwt-XhoI 
 
4 pCR3-MVC(wt) expression vector for Cwt EcoRI-Cwt-
XhoI 
 
5 pCR3-fl-MVc(schw) expression vector for flag tagged C 
Schwarz 
EcoRI-fl-Cs-
XhoI 
by Christian 
Pfaller 
6 pCR3-MVC(schw) expression vector for Cs EcoRI-Cs-XhoI by Christian 
Pfaller 
7 pBS-HHRz-MVvac2-
HdRz(sc) 
Antigenomic cDNA vector for MV 
vac2 flanked by a Hammerhead 
Ribozyme and a SuperCut Ribozyme 
 from R. Cattaneo/ 
Christian Pfaller 
8 pEMC-MV L Expression vector for MV L, EMCV 
IRES driven 
 by R. Cattaneo 
9 p55c1b-Luc Reporter plasmid for the IRF3 
recognition site, expresses Firefly 
luciferase 
 by T. Fujita 
10 pCMV-RL Renilla luciferase controlled by the 
CMV promoter 
 ordered from 
Promega 
11 fl-IRF3 Expression plasmid for flag tagged 
IRF3 
 by K. Brzozka 
13 p125-Luc Reporter plasmid for the whole IFNb 
promoter, drives expression of Firefly 
Luciferase 
 by T. Fujita 
Interferon induction inhibition by MV C - Materials and Methods 
Materials 
 
 
Page 29  
  
14 pEGFP Expression vector for eGFP  ordered from 
Promega 
15 pTIT-GFP Expression vector for eGFP, T7 
promoter 
 by N. Zapf 
16 pFLAG--IKKa Expression vector for flag-tagged IKKa  by K. Ruckdeschl 
17 pCR3-flag-TBK1 Expression vector for flag-tagged TBK1  by K. Brzozka 
18 RV P Expression vector for rabies virus P 
protein 
 by K. Brzozka 
19 MV V Expression vector for MV V protein  by Christian 
Pfaller 
20 pCR3- fl MV L Expression vector for flag-tagged MV L 
protein 
 by Kerstin 
Schuhmann 
21 pcDNA3.1-fl MV H Expression vector for flag-tagged MV 
H protein 
  MV H ORF, 
SnaBI (vor flag), 
XhoI 
22 pcDNA3.1-fl MV M Expression vector for flag-tagged MV 
M protein 
  MV M ORF, 
SnaBI (vor flag), 
XhoI 
23 pCR3-MV F Expression vector for MV F  by Kerstin 
Schuhmann 
24 pCR3-MV H Expression vector for MV H  by Kerstin 
Schuhmann 
25 fl-IRF35D Expression vector for flag-tagged IRF3 
with 5 D mutations: constitutive active 
 by J. Hiscott 
26 pCR3- MV M Expression vector for MV M  by Kerstin 
Schuhmann 
27 pCR3- MV N Expression vector for MV N  by Kerstin 
Schuhmann 
28 pCR3-MV Cwt44AA Expression vector for MV Cwt, 
Mutation 44AA 
Mutagenesis: 
44AA 
Cwt ORF, EcoRI 
- XhoI 
29 pCR3-MV Cs44AA Expression vector for MV Cs, Mutation 
44AA 
Mutagenesis: 
44AA, S39T 
Cs ORF, EcoRI - 
XhoI 
30 pCR3-fl-MV 
Cwt44AA 
Expression vector for flag-tagged MV 
Cwt, Mutation 44AA 
Mutagenesis: 
44AA 
Cwt ORF, EcoRI 
- XhoI 
31 pCR3-fl-MV Cs44AA Expression vector for flag-tagged MV 
Cs, Mutation 44AA 
Mutagenesis: 
44AA, S39T, 
I103L 
Cs ORF, EcoRI - 
XhoI 
32 pcDNA3.1-fl-MV N Expression vector for flag-tagged MV 
N 
flag-SnaBI-N-
XhoI 
based on 
pCDNA3.1-flag-
IRF7 vector 
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33 pCR3-MV L Expression vector for MV L  by Kerstin 
Schuhmann 
34 pEF-Bos dRIG-I (1-
284) 
Expression vector for the CARD 
domains of RIG-I (constitutive active) 
 by T. Fujita 
35 pBS-HHRz-MVvac2-
ATU-HdRz(sc) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) 
 by Christian 
Pfaller 
36 pBS-HHRz-MVvac2-
ATU-PdV-HdRz(sc) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) and additionally a 
mutation to abolish V expression 
 by Christian 
Pfaller 
37 pCR3-fl-MV P Expression vector for flag-tagged MV P  by Christian 
Pfaller 
38 pBS-HHRz-MVvac2-
ATU-PdC-HdRz(sc) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) and additionally 
mutations to abolish C expression 
Mutagenesis for 
Cko 
based on MV 
vac2-ATU 
39 fl-IPS-1 Expression vector for flag-tagged IPS-1  by Kerstin 
Schuhmann 
40 pCR3-MV fl-V Expression vector for flag-tagged MV 
V 
 by Kerstin 
Schuhmann 
41 pCR3-fl-dRIG-I Expression vector for flag-tagged 
CARD domains of RIG-I 1-284 
 by Kerstin 
Schuhmann 
42 pCR3-fl-RIG-I Expression vector for flag-tagged RIG-I  by Martina Rieder 
43 IRF3-GFP Expression vector for GFP tagged IRF3   
44 pCR3-MV P Expression vector for MV P  by Christian 
Pfaller 
45 pCR3-MV CswtNLS Expression vector for MV C with wt 
NLS sequence 
Mutagenesis: 
G44R 
based on plasmid 
pCR3-Cs 
46 pCR3-fl-MV CswtNLS Expression vector for flag tagged MV C 
with wt NLS sequence 
Mutagenesis: 
G44R 
based on plasmid 
pCR3-fl-Cs 
47 pCR3-Ha-Cs Expression vector for HA-tagged MV 
Cs 
BamHI-Ha-Cs-
NotI 
  
48 pCR3-HA-MV Expression vector for HA-tagged MV BamHI-HA-   
Interferon induction inhibition by MV C - Materials and Methods 
Materials 
 
 
Page 31  
  
CswtNLS Cs with wildtype NLS CswtNLS-NotI 
49 pBS-HHRz-MVvac2-
Cko-GFP-HdRz(Sc) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for GFP and 
additionally mutations in the P gene to 
abolish C expression 
SnaBI-GFP-
NotI 
based on MV 
vac2 Cko-ATU 
50 pCR3-Cwt Expression vector for MV Cwt BamHI-Cwt-
NotI 
  
51 pBS-HHRz-MVvac2-
Cko-CswtNLS-
HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for 
CswtNLS and additionally mutations in 
the P gene to abolish C expression 
SnaBI-
CswtNLS-NotI 
based on MV 
vac2 Cko 
52 TagRFP-profilin TagRFP expression vector, tags profilin  ordered from 
Evrogen 
53 pBS-HHRz-MVvac2-
wtNLS 
Measles virus antigenomic cDNA 
flanked by Ribozymes with a point 
mutation in the P gene altering C G44R 
Mutagenesis: C 
G44R 
based on MV 
vac2 
54 pBS-HHRz-MVvac2-
Cko-Cs-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for Cs and 
additionally mutations in the P gene to 
abolish C expression 
SnaBI-Cs-NotI based on MV 
vac2 Cko-ATU 
55 pBS-HHRz-MVvac2-
Cko-Cwt-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for Cwt and 
additionally mutations in the P gene to 
abolish C expression 
SnaBI-Cwt-NotI based on MV 
vac2 Cko-ATU 
56 pBS-HHRz-MVvac2-
Cko-CwtmNLS-
HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
SnaBI-
CwtmNLS-NotI 
based on MV 
vac2 Cko-ATU 
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duplication of P) encoding for 
CwtmNLS and additionally mutations 
in the P gene to abolish C expression 
57 pCR3-SV40NLS-
CwtmNLS 
Expression vector for CwtmNLS with 
an additional SV40 NLS at the N 
terminus 
BamHI-
SV40NLS-
CwtmNLS-NotI 
58 pCR3-HA-Cwt Expression vector for HA tagged MV 
Cwt 
BamHI-HA-
Cwt-NotI 
 
59 pCR3-HA-CwtmNLS Expression vector for HA tagged MV 
CwtmNLS 
BamHI-HA-
CwtmNLS-NotI 
 
60 pBS-HHRZ-MVvac2-
GFP-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for GFP 
 by Christian 
Pfaller 
61 pCR3-TagRFP Expression vector for TagRFP BamHI-
TagRFP-NotI 
  
62 peGFP-C3 Expression vector for eGFP   by Clontech 
63 pCR3-TagRFP-Cwt Expression vector for a fusion protein 
between TagRFP and Cwt 
BamHI-
TagRFP-AscI-
Cwt-NotI 
64 pCR3-TagRFP-Cs Expression vector for a fusion protein 
between TagRFP and Cs 
BamHI-
TagRFP-AscI-
Cs-NotI 
65 pCR3-TagRFP-
CwtmNLS 
Expression vector for a fusion protein 
between TagRFP and CwtmNLS 
BamHI-
TagRFP-AscI-
CwtmNLS-NotI 
66 pCR3-TagRFP-
CswtNLS 
Expression vector for a fusion protein 
between TagRFP and CswtNLS 
BamHI-
TagRFP-AscI-
CswtNLS-NotI 
67 pBS-HHRz-MVvac2-
Cko-TagRFP-Cwt-
HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for TagRFP-
Cwt and additionally mutations in the P 
gene to abolish C expression 
SnaBI-TagRFP-
AscI-Cwt-NotI 
based on full 
length vector MV 
vac2 Cko-ATU 
68 pBS-HHRz-MVvac2-
Cko-TagRFP-Cs-
HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
SnaBI-TagRFP-
AscI-Cs-NotI 
based on full 
length vector MV 
vac2 Cko-ATU 
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P and the M gene (gene border 
duplication of P) encoding for TagRFP-
Cs and additionally mutations in the P 
gene to abolish C expression 
69 pBS-HHRz-MVvac2-
Cko-TagRFP-
HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for TagRFP 
and additionally mutations in the P gene 
to abolish C expression 
SnaBI-TagRFP-
NotI 
based on full 
length vector MV 
vac2 Cko-ATU 
70 pBS-HHRz-MVvac2-
TagRFP-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for TagRFP 
SnaBI-TagRFP-
NotI 
based on full 
length vector MV 
vac2 ATU 
71 pBS-HHRz-MVvac2-
Cko-TagRFP-
CwtmNLS-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for TagRFP-
CwtmNLS and additionally mutations 
in the P gene to abolish C expression 
SnaBI-TagRFP-
AscI-
CwtmNLS-NotI 
based on full 
length vector MV 
vac2 Cko-ATU 
72 pBS-HHRz-MVvac2-
Cko-TagRFP-
CswtNLS-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for TagRFP-
CswtNLS and additionally mutations in 
the P gene to abolish C expression 
SnaBI-TagRFP-
AscI-CswtNLS-
NotI 
based on full 
length vector MV 
vac2 Cko-ATU 
73 PPM1b-GFP Expression vector for a fusion between 
protein phosphatase, Mg2+/Mn2+ 
dependent, 1B (PPM1B), transcript 
variant 2 and GFP 
 ordered from 
Origene 
74 pcDNA3-FLAG-
DDB1 
Expression vector for flag-tagged DNA 
damage binding protein 1 (DDB1) 
 ordered from 
addgene 
75 pCR3-HA-IPO8 Expression vector for HA-tagged 
importin 8 (IPO8) 
BamHI-HA-
IPO8-NotI 
IPO8 mit BamHI-
NotI in pCR3 
76 pBS-HHRz-MVvac2-
VCko-ATU-
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
 cloned by Kerstin 
Schuhmann 
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HdRZ(SC) additional transcription unit between the 
P and the M gene (gene border 
duplication of P) and additionally 
mutations in the P gene to abolish V & 
C expression 
77 pBS-HHRz-MVvac2-
Cko-fl-Cs-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for flag-
tagged Cs and additionally mutations in 
the P gene to abolish C expression 
SnaBI-flag-Cs-
NotI 
based on full 
length vector 
MVvac2 Cko 
78 pBS-HHRz-MVvac2-
Cko-fl-Cwt-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) encoding for flag-
tagged Cwt and additionally mutations 
in the P gene to abolish C expression 
SnaBI-flag-
Cwt-NotI 
based on full 
length vector 
MVvac2 Cko 
79 pCR3-fl-MAP1B Expression vector for flag-tagged 
Microtubule associated protein 1 B 
NotI-flag-
MAP1B-ApaI 
  
80 pCR3-fl-MAP1B-fl Expression vector for flag-tagged 
Microtubule associated protein 1 B 
NotI-flag-
MAP1B-flag-
ApaI 
  
81 pCR3-MAP1B-fl Expression vector for flag-tagged 
Microtubule associated protein 1 B 
NotI-MAP1B-
flag-ApaI 
  
82 pCR3-MAP1B Expression vector for Microtubule 
associated protein 1 B 
NotI-MAP1B-
ApaI 
  
83 flag-Stat1 Expression vector for flag-tagged Stat1  cloned by 
Vanessa 
Hoffmann 
84 pCR3-MV F-fl Expression vector for flag-tagged MV F 
(C-terminal) 
NotI-MV F-
flag-XhoI 
  
85 pCR3-fl-MV H Expression vector for flag-tagged MV 
H 
NotI-flag-MV 
H-XhoI 
  
86 pBS-HHRz-MVvac2-
VCko-Cwt-HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) coding for Cwt and 
SnaBI-Cwt-NotI based on full 
length vector MV 
vac2 VCko-ATU 
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additionally mutations in the P gene to 
abolish V & C expression 
87 pBS-HHRz-MVvac2-
VCko-CwtmNLS-
HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) coding for CwtmNLS 
and additionally mutations in the P gene 
to abolish V & C expression 
SnaBI-
CwtmNLS-NotI 
based on full 
length vector MV 
vac2 VCko-ATU 
88 pBS-HHRz-MVvac2-
VCko-CswtNLS-
HdRZ(SC) 
Measles virus antigenomic cDNA 
flanked by Ribozymes with an 
additional transcription unit between the 
P and the M gene (gene border 
duplication of P) coding for CswtNLS 
and additionally mutations in the P gene 
to abolish V & C expression 
SnaBI-
CswtNLS-NotI 
based on full 
length vector MV 
vac2 VCko-ATU 
89 pCR3-fl-MV N Expression vector for flag-tagged MV 
N (N-terminal) 
NotI -flag-MV 
N-XhoI 
  
90 pCR3-fl-MV M Expression vector for flag-tagged MV 
M 
NotI-flag-MV 
M-XhoI 
  
91 pCR3-fl-IRGM Expression vector for flag-tagged 
IRGM 
BamHI-flag-
IRGM-NotI 
  
92 HA-CBP Expression vector for HA tagged Creb 
binding protein (CBP) 
 ordered from 
addgene 
93 HA-p300 Expression vector for HA tagged p300  ordered from 
addgene 
 
If not stated otherwise, these plasmids were generated during this phd thesis. 
1.9. Viruses 
Name Description: 
rMV vac2 Recombinant MV with the exact vac2 sequence 
rMV vac2-Cko Recombinant MV with the exact vac2 sequence, except for mutations 
in the P gene, abolishing the expression of the C protein. The C ATG 
was knocked out as well as two stop codons introduced downstream. 
No amino acid change in P and V is induced. 
rMV vac2-GFP Recombinant MV with the vac2 sequence and the additional 
transcription unit between the P and the M gene, duplicating the P gene 
borders. In this case the transcription unit encodes the GFP protein. 
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rMV vac2CwtNLS Recombinant MV with the exact vac2 sequence, except for a point 
mutation in the P gene, which changes the G44 residue in C to an 
arginine. In the P and V N-terminus a lysine is changed to an arginine. 
rMV vac2- TagRFP Recombinant MV with the vac2 sequence and the additional 
transcription unit between the P and the M gene, duplicating the P gene 
borders. In this case the transcription unit encodes the TagRFP protein. 
rMV vac2Cko- TagRFP-Cwt Recombinant MV with the vac2 sequence and the additional 
transcription unit between the P and the M gene, duplicating the P gene 
borders. Expression of the C protein is knocked out as described 
previously. In this case the transcription unit encodes the TagRFP-MV 
Cwt fusion protein. 
rMV vac2Cko-TagRFP-Cs Recombinant MV with the vac2 sequence and the additional 
transcription unit between the P and the M gene, duplicating the P gene 
borders. Expression of the C protein is knocked out as described 
previously. In this case the transcription unit encodes the TagRFP-MV 
Cs fusion protein. 
rMV vac2Cko-TagRFP-CwtmNLS Recombinant MV with the vac2 sequence and the additional 
transcription unit between the P and the M gene, duplicating the P gene 
borders. Expression of the C protein is knocked out as described 
previously. In this case the transcription unit encodes the TagRFP-MV 
CwtmNLS fusion protein. 
rMV vac2Cko-TagRFP-CswtNLS Recombinant MV with the vac2 sequence and the additional 
transcription unit between the P and the M gene, duplicating the P gene 
borders. Expression of the C protein is knocked out as described 
previously. In this case the transcription unit encodes the TagRFP-MV 
CswtNLS fusion protein. 
 
 
1.10. Buffers and solutions 
If not stated otherwise, the solvent is desalted water. 
1x PBS (pH 7.4)  
1 M NaCl, 27 mM KCl, 12 mM KH2PO4, 65 mN Na2HPO4·2H2O. 
70 % EtOH  
H2Odd, 70 % (v/v) Ethanol abs.  
20 % SDS  
H2Odd, 20 % (w/v) SDS.  
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Transformation:  
LB-Medium  
85 mM NaCl, 0.5 % (w/v) Bacto Yeast-extract, 1 % (w/v) Bactotrypton, 1 mM 
MgSO4, pH 7.5. 
LB++  
LB-Medium, 20 mM MgSO4, 10 mM KCl.  
 
DNA purification (Mini):  
Flexi I  
100 mM Tris (pH 7.5), 10 mM EDTA, 200 µg/mL RNase.  
Flexi II  
200 mM NaOH, 1 % (v/v) SDS.  
Flexi III  
3 M KOAc, 2 M HOAc (pH 5.75).  
 
Agarose-Gels:  
1 % agarose gels 
1 % (w/v) agarose in 1x TAE.  
10x TAE  
400 mM Tris (pH 7.8), 50 mM NaOAc·3H2O, 10 mM EDTA.  
Running buffer 
1x TAE, 40 µg/L ethidium bromide. 
Loading buffer (Orange G) 
5x TAE, 0.125 % Orange G, 15 % Ficoll 400.  
1kb marker 
380 µl 10x TE, 100 µl Blue Juice, 20 µl NEB 1kb DNA ladder 
Blue Juice 
50 % 10xTAE, 15% Ficoll 400, 0.125% Bromphenol blue, 0125% Xylenecyanol, 
0125% Orange G 
 
Jagow-Proteingels:  
10x Anode buffer 
2 M Tris (pH 8.9).  
10x Cathode buffer 
Interferon induction inhibition by MV C - Materials and Methods 
Materials 
 
 
Page 38  
  
1 M Tris (pH 8.25), 1 M Tricin, 1 % (v/v) SDS.  
Gel buffer 
3 M Tris (pH 8.45), 0.3 % (v/v) SDS.  
Proteingel-lysisbuffer  
Tris (pH 6.8), 10 % glycerol (v/v), 6 M urea 2 % SDS (v/v), 0.01 % (w/v) bromphenol 
blue, 0.01 % (w/v) phenol red, 5 % (v/v) β-mercapto ethanol. 
10 % APS 
H2Odd, 10 % (w/v) Ammonium persulfate.  
 
Native Gels: 
2x Native sample buffer 
125 mM Tris-Cl, pH 6.8, 30% glycerol, Bromphenolblue 
Lysis buffer 
50mM Tris-Cl, pH 8.0, 1% NP-40, 150 mM NaCl, 5 mM orthovanadate, 100 µg/ml 
leupeptin, 1mM PMSF 
Gel Buffer 
1,5 M Tris, pH 8,8 
Lower Chamber Buffer 
25 mM Tris-Cl, pH 8.4, 192 mM Glycin 
Upper Chamber Buffer  
25 mM Tris-Cl, pH 8.4, 192 mM Glycin, 1% DOC  
 
Western-Blots:  
10x Semidry-Buffer  
480 mM Tris (pH 8.6), 390 mM glycine, 0.05 % SDS.  
1x Semidry-Buffer 
10 % 10x Semidry-Buffer, 18 % methanol abs.  
PBS-Tween 
1x PBS, 0.05 % (v/v) Tween20.  
 
Co-IP: 
PBS-EDTA 
 1x PBS, 5 mM EDTA 
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Co-IP Buffer 
 50mM Tris (pH 7.5), 150 mM NaCl, 2mM EDTA, 1mM Na3VO4, NP40 0.5%. 
Co-IP Buffer Wash Buffer II 
 50mM Tris (pH 7.5), 150 mM NaCl, 2mM EDTA 
 
Transfection: 
PEI 
 Sterile solution of PEI in H2O (1 mg/mL). 
 
Silver staining: 
Fixative solution 
40% ethanol, 10% acidic acid 
All other solutions provided by the Silverquest Kit (Invitrogen) 
 
Northern Blotting 
50x Phosphate Buffer 
250 mM Na2HPO4 x 2 H2O, 250 mM HaH2PO4 x H2O 
RNA agarose gel 
2g Agarose, 4mL 50x phosphate buffer, 26.7 mL Formaldehyde 37%, 167.3 mL H2O 
Glyoxal solution 
8.8 M Glyoxal 
10x SSC 
1.5 M NaCl, 150 mM Na-citrate x 2 H2O, pH = 7.0 
Zeta hybridizing buffer 
250 mM Na2HPO4 x 2 H2O, 250 mM HaH2PO4 x H2O, 1mM EDTA, 7% SDS, pH = 
7.2 
Zeta 5% wash buffer 
8% 50x phosphate buffer, 1mM EDTA, 5% SDS 
Zeta 1% wash buffer 
8% 50x phosphate buffer, 1mM EDTA, 1% SDS 
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2. Methods 
2.1. Working with DNA 
2.1.1. Mini preparation 
1 mL LB-medium including antibiotic was inoculated with a single bacteria colony from 
LB-agar plates and shaken over night at 37°C. The grown bacteria were pelleted for 60s 
at room temperature and 14,000 rpm and the pellet was resuspended in 200 µL FLEXI I 
buffer. 200 µL of FLEXI II buffer were added and the mixture was incubated at room 
temperature for 5 minutes to lyse the cells. Upon the addition of 200 µL of FLEXI III 
buffer to the mixture it was stored on ice for 5 minutes. The protein precipitate was 
removed by centrifugation (7 min, rt, 14,000 rpm). The supernatant was added onto 400 
µl isopropanol abs. and centrifuged again (7 min, rt, 14,000 rpm). After removal of the 
supernatant the DNA pellet was dried at room temperature and finally dissolved in 50 µL 
H2Odd.  
Restricition control digestions were carried out to identify clones for sequencing and re-
transformation. 
2.1.2. Midi preparation  
(Nucleobond Plasmid DNA Purification Kit, Macherey&Nagel) 
50mL of an overnight culture of transformed bacteria in LB (+antibiotic) were pelleted at 
3,500rpm, 4°C for 20 minutes. The supernatant was discarded and the pellet resuspended 
in 8 mL of buffer RES. 8 mL of buffer LYS (lysis buffer) were added to the suspension 
and the mixture was incubated at room temperature. 8 mL of buffer NEU (neutralizing 
buffer) were added after complete lysis of the bacteria, mixed, resulting in precipitation 
of proteins, lipids and genomic DNA. One AX 100 (including filter) column was 
equilibrated with 12 mL buffer EQU (equilibration buffer) and the suspension was 
loaded. The filter was washed afterwards with 5mL Buffer EQU and after the buffer 
passed the column removed and 8mL Buffer WASH added to wash the column. Plasmid 
DNA bound to the column was eluated with 5 mL of buffer ELU (elution buffer). The 
eluate was mixed with 3.5 mL isopropanol abs. and centrifuged for 20 minutes at 14,000 
rpm and 4°C. The supernatant was removed and the DNA pellet washed with 2 mL of 
ice-cold 70% ethanol and centrifuged for 10 minutes at 14,000 rpm and 4°C. The purified 
pellet was dried at room temperature and resuspended in 400µl sterile desalted Water 
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(H2Odd). DNA concentration was determined photometrically (Nanodrop) and the 
preparation was finally stored at -20°C. 
2.1.3. Agarose gel electrophoresis 
A heated 1% agarose solution in TEA buffer was used to cast gels of the required sizes. 
12 µL of the preparation were mixed with 3 µL Orange G and loaded into the pockets. 
Separation was carried out at 120 V and 400mA for 45 minutes in 1x running buffer. The 
nucleic acids were detected via exciting the ethidium bromide with UV-radiation. 
2.1.4. PCR 
Cloning PCR 
The reaction was prepared according to the following scheme: 
Enzyme/Buffer amount 
Template 1µl (1pg – 10ng) 
Primer 1 (10µM) 5µl 
Primer 2 (10µM) 5µl 
5xBuffer HF 20µl 
DMSO 3µl 
dNTPs 0.8µl 
Phusion Polymerase 1µl 
H2Odd 64.2µl 
 
A PCR Cycler machine was used to carry out the reaction using the following 
program: 
# Temperature Duration 
1 98°C 30s 
2 98°C 10s 
3 50°C (dependent on primer) 30s 
4 72°C 15s per kbp -> 30x back to step 2 
5 72°C 10 min 
6 4°C pause 
 
To analyse the resulting PCR product by gel electrophoresis, 5 µL of the PCR product 
was mixed with 1 µL Orange G loading buffer and loaded on an 1% agarose gel. The 
Electrophoresis was performed at 120 V for 45 min. 
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Mutagenesis PCR 
This PCR reaction can be used to introduce site-directed mutations into vectors. 
Methylated vectors are used as a template and the whole vector is amplified during the 
PCR resulting in non-methylated mutated vectors. The methylated template is 
afterwards digested by DpnI. 
The PCR reaction was prepared according to the following scheme: 
Enzyme/Buffer amount 
Template 1µl (1pg – 10ng) 
Primer 1 (10µM) 2.5µl 
Primer 2 (10µM) 2.5µl 
10xBuffer 10µl 
dNTPs 1µl 
Pfu Polymerase 1µl 
H2Odd 82µl 
A PCR Cycler machine was used to carry out the reaction using the following 
program: 
# Temperature Duration 
1 95°C 30s 
2 95°C 10s 
3 50°C (dependent on primer) 30s 
4 72°C 120s per kbp -> 18x back to step 2 
5 72°C 10 min 
6 4°C pause 
 
To remove the methylated template DNA, DpnI (2.5 U) was added to the reaction 
mixture and incubated at 37°C for 2h. 
2.1.5. PCR purification 
(QIAquick PCR Purification Kit)  
500 µL of buffer PBI were added to the PCR reaction, mixed and loaded on a QIAquick 
column, followed by centrifugation for 1 min at room temperature and 14,000 rpm. The 
flow-through was discarded, 750 µL PE washing buffer were loaded on the column and 
centrifuged at room temperature and 14,000 rpm. After removal of the flow-through, the 
column was centrifuged again to remove remaining residual PE buffer. Bound nucleic 
acids were eluted with 30 µL H2Odd by centrifugation for 1 min at 14,000 rpm. 
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2.1.6. Preparative restriction 
Blunt-ended PCR products or circular plasmids were digested with suitable restriction 
enzymes to create specific overhangs for ligation. The PCR product DNA preparations 
were incubated with the restriction enzymes with restriction sites close to the 3' and 5' 
ends. The vector for the PCR fragment is digested in the same way to create a linear 
vector-fragment, which can be religated to a new plasmid with the insert from the PCR. 
Plasmid DNA or PCR products were incubated with restriction enzymes as 
recommended by the supplier (New England Biolabs). 
2.1.7. Gel purification of DNA fragments 
(QIAquick Gel Purification Kit, QIAEx II Kit)  
Restriction reactions for cloning were separated by electrophoresis as described above. 
Bands of the predicted size were cut out from the gel. The gel fragment was mixed with 
thrice its volume buffer QG and incubated at 50°C for 10 min. After dissolving of the 
gel, the resulting solution was loaded on a QIAquick column and centrifuged at 14,000 
rpm for 1 minute at room temperature. The column was washed with 750 µL buffer PE 
and centrifuged again (same conditions as before). After removal of the flow-through, the 
column was centrifuged again to remove residual PE buffer. Bound nucleic acids were 
eluted with 30 µL H2Odd by centrifugation for 1 min at 14,000 rpm. 
For plasmids or inserts longer than 10000nt (e.g. viral cDNA backbones), the QIAExII 
Kit was used according to the manufacturers protocol.  
2.1.8. Ligation 
Linearised vectors and processed PCR products were ligated using T4 DNA ligase in a 
reaction as follows: 
Enzyme/Buffer amount 
Vector 0.5µl 
Insert 10µl 
T4 DNA Ligase 1µl 
10xBuffer  T4 Buffer 2µl 
H2Odd 6.5µl 
As a negative control the vector was ligated without the insert. The preparation was 
incubated for 2 hours at room temperature.  
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2.1.9. Transformation 
50 µL of a chemically competent E. coli XL-1 suspension were thawed on ice and 1 µL 
of plasmid DNA was added. The bacteria were incubated for 20 minutes on ice, followed 
by a heat-shock for 2 minutes at 42°C and cooling on ice for 2 minutes. After addition of 
200 µL LB++ medium, the resulting suspension was shaken at 37°C for 30-90 minutes. 
For midi preparations 75µl of the bacteria suspension were added to 50 mL of LB 
medium + antibiotic (Ampicillin or Kanamycin, depending on the used plasmids) and 
shaken for 16 hours at 37°C (180 rpm).  For cloning, the whole suspension was plated on 
LB-agar (+antibiotic) plates and incubated o/n at 37°C. 
2.1.10. Control restriction 
Control restriction reactions were carried out as follows: 
DNA (Mini Preparation) 1 µL 
Restriction enzyme 1/2 0.1 µL 
100xBSA (if required) 0.1 µL 
Buffer 1 µL 
H2O dd ad 10 µL 
The buffers and additional BSA were used as recommended by the supplier of the 
restriction enzymes (New England Biolabs). The mixture was incubated for 2 h at 37°C. 
2.1.11. Sequencing 
For plasmids or PCR inserts 30-100ng/µl DNA in 20µl water were sent to GATC. Either 
the provided standard primers were used or custom ordered primers (metabion, 
Martinsried) were diluted to 10ng/µl and sent as 20µl aliquots separate from the 
plasmid/PCR DNA to GATC.  
Sequencing was carried out by GATC (Konstanz). 
2.2. Working with proteins 
2.2.1. Polyacrylamide gel electrophoresis 
 
For western blots a 10%,12% or 15% denaturing separating gel and a 4% stacking gel 
were used, prepared in the following way: 
 H2Odd Gel buffer Glycerol Acrylamide APS TEMED 
separating-gel 
(15%) 
8.4 mL 12.0 mL 2.0 mL 13.5 mL 175 µL 17 µL 
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separating-gel 
(12%) 
11.1 mL 12.0 mL 2.0 mL 10.8 mL 175 µL 17 µL 
separating-gel 
(10%) 
12.9 mL 12.0 mL 2.0 mL 9.0 mL 175 µL  17 µL  
stacking-gel 
(4%) 
9.0 mL 3.5 mL - 1.4 mL 116 µL  18 µL  
The polymerization time was about 2h and the acrylamide was provided as a premixed 
solution. 
Gelelectrophoresis: 
The cells were treated 24 h p.Tr. with an equal amount of proteingel-lysisbuffer (for 
100µL cells-suspension 100µL buffer) then boiled at 95°C for 5 minutes. As a protein 
marker Precision Plus Protein Standard (BIORAD) was used. Each pocket of the gel was 
loaded with 5µL of the marker or 50µL-80µl of the cell lysates. The separation was 
carried out at 37V for ca. 16 h. 
2.2.2. Native gels 
Native Gels (7.5%) were cast according to the following procedure without a stacking 
gel: 
Separating Gel:  
water 11.3 mL 
acrylamide 3.5 mL 
Tris (1.5M) 5 mL 
TEMED 20 µl 
APS 200 µl 
The gels were prerun 30 minutes at 40mA at 4°C. After loading of the samples the gels 
ran for approximately 1h at 25mA at 4°C. Blotting and immunodetection were carried 
out as described before. 
2.2.3. Gradient gels 
Gradient Gels (4-20%) were cast according to the following procedure using a gradient 
mixer. The two solutions were prepared separately: 
 H2Odd Gel buffer Glycerol Acrylamide APS TEMED 
separating-gel 
(20%) 
1.2 mL 4.0 mL 0.67 mL 6  mL 58.3 µL 5.6 µL 
separating-gel 
(4%) 
6 mL 4.0 mL 0.67 mL 1.2 mL 58.3 µL 5.6 µL 
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A stacking gel was added afterwards according to the usual 4% stacking gel. 
2.2.4. Western blotting 
After removal of the stacking gel, the separating gel washed for 15 minutes in 1x Semi 
Dry buffer. Three in 1x Semi Dry buffer soaked Gel-Blotting-Papers were placed on the 
blotting device and an also in 1xSemi Dry soaked, previously in methanol activated, 
PVDF membrane (Millipore) laid on top of it. Then the gel and another 3 layers of 
soaked blotting papers topped the membrane and the blotting chamber was closed. All 
work was carried out bubble free. The Blotting itself was carried out for 2h at 400mA. 
When the transfer was finished, the PVDF membrane was washed with 2.5% milk 
powder in PBS to block unspecific binding sites 1-2 h at r.t.. 
2.2.5. Immunodetection 
The blot membrane was washed three times with 20 mL PBS-TWEEN for 10 minutes 
each time. The primary antibodies were used in required dilution (see Materials) in PBS-
TWEEN and incubated with the membrane over night at 4°C. Subsequently the 
membrane was washed again three times with 20 ml PBS-TWEEN for 10 minutes each 
time. The secondary antibody was incubated with the membrane for 2h at room 
temperature diluted in PBS-TWEEN. Afterwards the membrane was washed again three 
times with 20 mL of PBS-TWEEN. 
The Western Lightning Chemiluminescence Reagent Plus (Perkin-Elmer) was mixed 
immediately before applying it to the membrane (the amount as required for the size of 
the membrane, about 500 µL per membrane). The Fusion (Vilber-Lourmat) device 
including the Fusion Cap Software was used to capture images of the blots. 
2.2.6. Silver Staining 
(SilverQuest™ Silver Staining Kit, Life Technologies) 
After fixation of the polyacrylamide gel in the fixative solution for 1h, it was washed 
with 30% ethanol in water for 10 minutes. Afterwards the sensitizing solution was added 
onto the gel and incubated while shaking for 10 minutes. Following another two washing 
steps - first with 30% ethanol, then with water - the gel was incubated for 15 minutes 
with the staining solution. The staining solution was decanted and the gel quickly washed 
for 10-30 s with water and then incubated with the developing solution. The reaction was 
Interferon induction inhibition by MV C - Materials and Methods 
Methods 
 
 
Page 47  
  
stopped with the stopping solution after clear bands started to appear (usually around 8-
10 minutes after addition of the developer). The gel was then washed with water again 
and imaged using the Fusion device and the white background light. 
 
2.3. Working with cells 
2.3.1. Cell culture 
Cells were cultured in Dulbecco’s modified Eagle Medium (DMEM) supplemented with 
10% Fetal Calf Serum (FCS), 0.4% Penicillin/Streptomycin and 1% (-)-L-Glutamate and 
incubated at 37°C and 5% CO2. = DMEM+3 
Or: 
RPMI1640 supplied with 10% Fetal Calf Serum (FCS), 0.4% Penicillin/Streptomycin 
and incubated at 37°C and 5% CO2. = RPMI +2 
Stably transfected cell lines were selected using antibiotics as indicated in the list below. 
Cell Lines: 
HEK-293T Human embryonic kidney cells, expressing the T 
antigen of SV40 
DMEM+3 
Vero African green monkey cells DMEM+3 
Vero-hSLAM Vero cells stably expressing the human SLAM receptor  DMEM+3 +1:1000 
G418 every 2 passages 
293-3-46 HEK293 cells stably expressing MV N and P & T7 
polymerase 
DMEM+3 +1:1000 
G418 every 2 passages 
Hep2 human larynx carcinoma cell line DMEM+3 
HeLa human cervix carcinoma cell line DMEM+3 
293T-STAT-/- human embryonic kidney cell line 293T with a 
knockout of the STAT1 gene 
DMEM+3 
A549 human lung epithelial cell line DMEM+3 
DG75 wt human B cell line RPMI+2 
 
2.3.2. Transfection methods 
Lipofectamin 
This protocol is for 24-well plates and can be scaled up for other plates/dishes: 
Interferon induction inhibition by MV C - Materials and Methods 
Methods 
 
 
Page 48  
  
The plasmids for transfection were mixed in reaction tubes and the total DNA amount 
was adjusted with stuffer DNA to be equal in each tube. 
The required amount of transfection reagent (2.5x the mass of DNA in µg) was diluted 
in D-MEM (50 µL/transfected well) and incubated for 5 min at r.t.. Plasmids were 
diluted additionally with 50 µL D-MEM. The solutions were combined, mixed 
carefully and incubated for 20 minutes at r.t.. The transfection mixtures were added 
drop wise on seeded cells in 24-well plates and mixed carefully. The cells were again 
incubated at 37°C in an incubator. To determine transfection efficiency, pEGFP was 
transfected into one well under the same conditions and eGFP expression was 
determined using UV microscopy 24h p.Tr.. 
PEI 
This protocol was used for 6cm-dishes and can be adjusted for different dishes/plates: 
Plasmids for transfection were mixed in reaction tubes and total DNA amount was 
adjusted with stuffer DNA to be equal in each tube. 
PEI was used as a transfection agent (2.5x the mass of DNA in µg), diluted in 200 µL 
D-MEM and incubated for 5 minutes at room temperature. The DNA was diluted in 
200 µL D-MEM. The combined solutions were carefully mixed and further incubated 
for 20 minutes at room temperature. The seeded cells were treated with the mix, and 
carefully mixed.  The cells were again incubated at 37°C in an incubator. To determine 
transfection efficiency, pEGFP was transfected into one well under the same 
conditions and eGFP expression was determined using UV microscopy 24h p.Tr.. 
Calciumphosphate 
This protocol was used for 6-well-plates and can be adjusted for different 
dishes/plates: 
Plasmids for transfection were mixed in reaction tubes and total DNA amount was 
adjusted with stuffer DNA to be equal in each tube. 
The Calciumphosphate Kit was warmed to room temperature before using. The DNA 
sample was mixed with 25µl of the CaCl2 solution and filled with nuclease-free water 
to 200µl. The mixture was added dropwise to vortexing 200µl of Hepes-Saline and 
finally incubated at room temperature for 30 minutes. The seeded cells were treated 
with the preparation, and carefully mixed.  The cells were again incubated at 37°C in 
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an incubator. 6h p.Tr. the growth medium was changed. To determine transfection 
efficiency, pEGFP was transfected into one well under the same conditions and eGFP 
expression was determined using UV microscopy 24h p.Tr.. 
2.3.3. Luciferase assay  
(Promega Dual Luciferase Reporter Gene Kit) 
24h p.Tr. 293T cells were lysed with 200µl/24-well 1xPassive Lysis Buffer (PLB) at 
room temperature. Of these lysates 20µl were transferred to 96-well non-transparent 
plates and the automatic measurement carried out using the Berthold LB-960 
Luminometer and the MikroWin 2000 software. The activity of the firefly luciferase was 
measured by injecting 40µl firefly substrate into one well and detection of light for 5 
seconds afterwards. The quantification of the renilla luciferase was performed in a 
similar manner, using 40µl of Stop&Glo Buffer, which was additionally injected into the 
well. The analysis of the data was carried out using standard spread sheet programs. 
2.3.4. Immunofluorescence 
24h p.Tr. Vero/HeLa/A549/Hep2 cells in 24-well plates grown on glass plates (for 
immunofluorescence) were stimulated with 100µl of Sendai virus defective interfering 
particles (SeV DI). After 7h the medium was removed and the cells washed with 1xPBS 
(Phosphate Buffered Saline). If the cells were not stimulated they were washed 24 p.Tr.. 
After washing the cells were fixed onto the glass plates with 3% PFA for 20 minutes at 
room temperature, then washed with 1xPBs again before NH4Cl-solution in PBS was 
added for another 10 minutes at room temperature. After removal of the ammonium 
chloride solution the cells were washed again with 1xPBS, then incubated with 0.5% 
Triton X-100 in PBS for 10 minutes at room temperature. The free protein binding sites 
were blocked with 2.5% milk powder in PBS for 15 minutes, after the cells were washed 
3 times with 1xPBS. After another washing with 1xPBS 80µl of the primary antibody 
dilution in PBS was put onto the glass plates and incubated for 1h at 37°C. Three 
washing steps with 1xPBS followed and the secondary antibody dilution (with ToPro3 
for nuclei staining) was added to the cells and incubated at 37°C for additional 60 
minutes. The cells were washed with 1xPBS 3 times afterwards and finally 1 time with 
water. To mount the glass slides on object plates a drop of Vectashield Hard Set(Vector 
Laboratories) solution was used and the plates were fixed with nail varnish. 
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For acquiring confocal images a Zeiss LSM 510 was used. The images were afterwards 
edited with Zeiss LSMBrowser and a standard image processing / vector graphic 
programs (ImageJ). 
2.3.5. Co-Immunoprecipitation 
24h p.Tr. of 293T cells grown in 60mm dishes were harvested from the surface using 
1mL PBS. The cells were pelleted at 2800rpm, 4°C for 5 minutes and the supernatant 
removed. The cells were lysed in 300µl Co-IP Buffer. The mixture was incubated at 4°C 
for 2h and then centrifuged at 14,000 rpm, 4°C for 2 minutes to remove the cell debris. 
To check the input, 30µL of the cleared lysate were removed and mixed with protein gel 
loading buffer. The remaining supernatant was added onto 100µl Flag-Beads (α-flag 
antibody coupled to agarose beads) and incubated o/n at 4°C. To wash the IP, the beads 
were pelleted (14,000 rpm, 4°C, 2 minutes), the supernatant removed and 500µl Co-IP 
Buffer added. The washing step was repeat three times, the last time instead of Co-IP 
Buffer 250µl Protein Gel lysis Buffer were added onto the beads. The protein content of 
the IP and the input cells were analysed using polyacrylamide gels. 
2.3.6. IRF3 dimerisation assay 
293T cells were harvested 24h p.Tr. and 18h p. Stimulation with Sendai Virus DI (25µl) 
in 1 mL PBS and pelleted at 2000 rpm for 10 minutes at 4°C. The pellet was lysed in 
100µl Native Lysis Buffer and centrifuged again at 14000 rpm for 10 minutes at 4°C to 
remove cell debris. The supernatant was stored at -80°C and analysed on native gels. 
2.3.7. Mass Spectrometry 
The pull-down of the proteins was carried out according to the protocol of co-
immunoprecipitations, with the following differences: 
Cells from 3 100mm dishes were harvested and after lysis for 2h at 4°C using Co-IP 
buffer the lysates were cleared by centrifugation and put on 400µL flag-beads. The 
washing step was repeated 6 times, the buffer for the last 3 washing steps lacked both 
protease inhibitors as well as the Nonidet P40 detergent.  
Elution was carried out using a flag peptide (Sigma) diluted in the washing buffer to a 
concentration of 300ng/µL. The beads were incubated with the mixture for 30 min at 4°C 
and the supernatant removed after centrifugation as elution.  
The elutions were then subjected to PAGE and subsequently a silver staining. 
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The elutions were then either subjected to gel electrophoresis and the gel slices used for 
analysis or the whole elutes. The samples were sent to the Adolf-Butenand Institut of the 
LMU Munich to Prof. Axel Imhofs Lab. The experiments itself were carried out by Dr. 
Lars Israel in the lab. 
2.3.8. Quantitative Realtime PCR 
The cDNA of purified total cellular RNA was analyzed by real-time PCR with the 
Quantitect SYBR Green PCR Kit (Qiagen) on a LightCycler 2.0 & LightCycler 480 
(Roche). Values for relative quantification of single probes were calculated from a 
standard curve of serial dilutions of one of the samples. The other samples were diluted 
1:10 for further analysis. The obtained results in arbitrary units were recalculated setting 
the mean value for the induction control to 100. 
2.3.9. Microarray analysis 
(Affymetrix GeneChip Human Gene 1.0 ST Arrays) 
cDNA from total cellular RNA was amplified using Ambion T7 transcription kits. The 
preparation of the amplified cDNA as well as the fluorescent labeling was carried out in 
the microarray facility of Professor Patrick Cramer’s lab under the supervision of Kerstin 
Maier. Following these steps, the probes were hybridized to the microarrays and the 
fluorescence read out.  
Analysis of the resulting data was done using R and Microsoft Excel. 
2.4. Working with RNA 
2.4.1. RNA purification 
(QIAgen RNAeasy Kit) 
293T/A549 cells grown in 24-wells were harvested in 350 µl RLT buffer and the 
complete RNA was extracted using Qiagen RNAeasy Kit according to the 
manufacturer’s protocol. The protocol can be scaled up for usage in 6-wells as well. The 
protocol was carried out at RT using only RNAse-free water. 
Cells lysed in RLT were supplemented with the same volume of 70% ethanol in RNAse-
free water and mixed by pipetting up and down. A new column was loaded with the 
mixture and centrifuged at 10,000 rpm for 15s to bind the RNA. The column was then 
washed with 350µl buffer RW1 (10,000 rpm , 15s). Remaining DNA was digested on 
column using QIAGEN RNAse-free DNase I for 15 min at RT. Another 350µl of RW1 
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was used to wash the column before the final washing step with 500µl buffer RE (2min, 
10,000 rpm). The collection tube was removed and replaced with a new one and residual 
buffers removed by centrifugation for 1 minute at full speed. The RNA was eventually 
eluted using 30µL RNAse-free water. 
2.4.2. Reverse transcription 
(Roche Transcriptor Transcriptase) 
Whole cell isolated RNA was reverse transcribed at 55°C for 30 min using Roche 
Transcriptor Transcriptase Kit after ligation of oligodT Primer (Invitrogen) at 65°C for 
10 min. 
2.4.3. RNA Agarose gels 
4-5µg of whole cellular RNA in a total volume of 7.2 µl were added to 1.8µl glyoxal and 
3µl 5x phosphate buffer. The mix was incubated for 45 min at 56°C and before loading it 
onto the gel 3µl blue juice was added. 
The gel was cast according to the following scheme: 
 
The agarose was dissolved in water and phosphate buffer by stirring and heating, while 
the volume was kept constant. The formaldehyde was added when the cleared solution 
cooled down to be lukewarm. 
A 240 x 200 mm gel was cast from the mixture and the probes loaded. Electrophoresis 
was performed in 1x phosphate buffer at 25V overnight. Afterwards the RNA was 
stained using acridin orange and 1xphosphate buffer for washing. Prominent bands 
(Ribosomal RNA for whole cell extracts) were visualized using UV light to check the 
integrity of the RNA on the gel. 
 
Ingredient: Amount: 
Agarose 2 g 
ddH2O (ultrapure) 167.3 mL 
50x phosphate buffer 4 mL 
37% formaldehyde 26.7 mL 
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2.4.4. Northern Blotting 
(Vacu-Blot System, Biometra) 
The RNA was transferred on Nylon membranes (Stratagene, GE Healthcare) using the 
Vacu-Blot system for 2h at 100 mBar. After the membrane is air-dried the RNA is 
crosslinked on the membrane using 0.125 J UV light. 
2.4.5. Radioactive labelling of probes 
(Ready Prime II Kit, GE Healthcare) 
The probes were generated from DNA PCR fragments (25ng), radioactively labelled with 
32P-alpha-CTP using the ready prime II Kit (GE Healthcare) according to the manual, 
followed by purification with the QIAquick Nucleotide removal Kit (QIAgen) and a 
denaturing step at 95°C. 
2.4.6. Detection of RNA on Northern Blots 
The nylon membranes were incubated with zeta hybridizing buffer for 10 minutes at 
68°C in an orbital shaker. The preincubation buffer was subsequently replaced with 8 mL 
zeta hybridising buffer including the labelled probe, and incubated overnight at 68°C. 
The membranes were afterwards washed once with zeta wash buffer 5%  and twice with 
zeta wash buffer 1% for 20 minutes at 68°C each. After air drying the membrane a 
phosphoscreen was exposed to the labelled blot from 3 days up to 14 days depending on 
the amount of radioactivity on the blot. Signals on the screen were the read by the Storm 
scanner (Molecular dynamics, GE Healthcare). 
2.5. Working in silico 
2.5.1. Alignments 
(Clustal Omega, EMBL;  Jalview, Barton Lab, University of Dundee) 
The alignments of the primary structure of proteins and nucleic acids were done using 
ClustalOmega (Sievers et al., 2011). The alignments were afterwards displayed using 
JALView (Clamp et al., 2004; Waterhouse et al., 2009). 
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2.5.2. Conservation scoring 
(ConSurf, Bio-sof LLC) 
The conservation scoring was done using ConSurf (Ashkenazy et al., 2010) using its 
standard parameters. The conservation score was added as a B-value to the ab initio 
calculated structure to depict the conservation as a colour change. 
2.5.3. Secondary structure prediction 
(Quick 2D) 
For secondary structure predictions different programs were used to compare the results. 
The collection was done using Quick2D which uses the prediction algorithms by 
PSIPRED (Jones, 1999), JNET (Barton, 1999), Prof (Ouali and King, 2000; Rost, 2001), 
Coils (Lupas et al., 1991),  HMMTOP (Tusnady and Simon, 1998), Phobius (Kall et al., 
2004) and IUPRED (Dosztanyi et al., 2005). 
2.5.4. Tertiary ab-initio structure prediction 
(I-Tasser, Zhang Lab, University of Michigan, Pymol ) 
The ab-initio tertiary structure calculation was done using the freely available I-TASSER 
(Roy et al., 2010; Zhang, 2008). Images of the structures were taken using pymol. 
2.5.5. Phylogenetic analysis 
(Clustal Omega, EMBL;  Jalview, Barton Lab, University of Dundee) 
Phylogenetic trees were generated from alignments using Clustal Omega. The trees were 
subsequently edited and displayed using JalView. 
2.5.6. Mass spectrometry analysis 
(Scaffold, Proteome Software, MASCOT) 
The masspectrometry, MASCOT identification of peptides and library search was done 
in the lab of Professor Axel Imhof by Dr. Lars Israel. Analysis and comparison of the 
resulting datasets was done using Scaffold 4.0 and Microsoft Excel. 
2.5.7. Protein networks analysis 
(Cytoscape) 
Networks of proteins were created using Cytoscape. The data for the interaction maps in 
those networks was based of the protein-protein interaction databases Biogrid and 
InnateDB. 
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2.6. Working with viruses 
2.6.1. Measles virus rescue 
293-3-46 cells grown in 6-wells were transfected with calcium phosphate (Promega). The 
cells were washed twice with DMEM+3 6h p.Tr. and incubated o/n at 37°C and 5% CO2. 
24h p.Tr. the cells were heat shocked at 42°C for 3h. 48h hours after the heat shock the 
cells were detached from the surface and added onto Vero-hSLAM cells including the 
medium. In the following days the cells were examined for syncytia formation, the 
syncytia then were picked from the cell culture plates and added to Vero cells in T25 
flasks. Fully infected flasks were frozen at -20°C o/n and then thawed on ice. The 
suspension was centrifuged at 2,800 rpm and 4°C for 5 min to remove cell debris, the 
supernatant was frozen in 1ml aliquots at -80°C and titrated. 
2.6.2. Measles virus stock production 
Pelleted Vero cells from 3 confluent T75 flasks were infected with an MOI of 0.005 from 
a rescue and incubated at 37°C for 1h. After addition of DMEM+3 medium the cell 
suspension was divided into 6 T75 flasks and incubated at 32°C and 5% CO2. Once the 
desired growth is reached (after 80h for vaccine virus) the media was completely 
removed and the cells scratched in 2mL Optimem per flask. The combined Optimem and 
cells from 6 flasks was then frozen to -20°C and thawed on ice for 7-8 h. The cell debris 
were removed by centrifugation at 4°C, 1,600 rpm for 10 minutes and frozen to -80°C in 
1mL aliquots. 
2.6.3. Measles virus titration 
Vero-hSLAM or Vero cells growing in 96-well plates were infected with each 100µl of 
up to 7 times 1:10 diluted viral stocks solutions. After 48h incubation at 37°C and 5% 
CO2, the medium was removed, the cells washed with 1xPBS and fixed with cold 80% 
acetone for 20 minutes at 4°C. After the acetone was removed the cells were dried and 
afterwards incubated with 50µl of a 1:2000 dilution of α-MV N-FITC antibody in PBS 
over night at 4°C. The antibody dilution was removed, the cells washed with 1xPBS and 
the nucleoprotein of measles virus visualized using a fluorescence microscope. The foci 
were counted and the infectious titre (foci forming units) was calculated according to the 
used dilutions.  
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2.6.4. Growth curves 
For growth curves, 5x105 cells per timepoint (6h, 24h, 48h, 72h) were infected with virus 
in as little volume as possible (around 1 mL). After incubating the mixture for 1h at 37°C 
each timepoint was seeded in one 6 well including 2 mL of medium. 5h post seeding the 
cells were washed twice with DMEM+3 and the first timepoint frozen to -20°C including 
the medium. The other timepoints were frozen to -20°C subsequently. For analysis, the 6-
well plates were thawed on ice for 2h, and then the cell lysate and the medium transferred 
to eppendorf vials. The cell debris was removed by centrifugation (1800 rpm, 4°C, 10 
min) and the supernatant titrated. 
2.6.5. Purification of measles virus 
To purify the measles virus, 12 mL of freshly made, already cleared stocks were 
carefully overlayed on top of 30% sucrose solutions in Beckman Coulter centrifugation 
tubes. 6 preperations were used for one centrifuge run at 27,000 rpm at 4°C for 2h.  After 
centrifugation the supernatant was completely removed and the pelleted virus 
resuspended in 500µL Optimem. The fractions were then combined, then aliquots made 
and frozen to -80°C for subsequent titration and usage. 
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RESULTS 
 
1. Interferon inhibition of MV C depends on its intracellular 
localisation 
 
To compare the capacities of the P, V, and C proteins from wildtype MV and vaccine 
strains, P gene cDNA was cloned into expression vectors from mRNAs of Vero-hSLAM cells 
(Ono et al., 2001) infected with a clinical MV isolate of the D5 genotype 
(MVi/Berlin.DEU/04.08), provided by A. Mankertz (RKI Berlin). The sequences for the 
vaccine strain proteins were subcloned from the full length cDNA of the MV vac2 strain (del 
Valle et al., 2007), the C protein sequence is the same as the Schwarz vaccine strain C 
sequence (Devaux et al., 2008; Schwarz, 1964). All of these clones were sequence verified 
and subcloned for expression studies in pCR3 vectors.  
 
Figure 6: Scheme of the P, V and C expression vector open reading frames.  
The open reading frames of MV P, V and C are depicted in light blue, green and dark blue 
respectively. The N-terminal domain shared by P and V is depicted in light blue for both ORFs. 
The first and the last six nucleotides of the ORFs are indicated above the schemes. Additionally, 
the mutations introduced in P and V to suppress C expression are highlighted above the 
respective ORFs and the responsible nucleotides are underlined. The ATG of C was mutated to 
ACG, and two stop codons were introduced downstream of the mutated ATG to suppress any 
revertants and prevent translation from alternative start codons. These mutations do not change 
the P and V amino acid sequence. For V expression from a plasmid, the editing site was mutated 
mimicking the RNA editing by the viral polymerase, the additional G residue inserted for the 
frameshift are indicated.  
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Individual vectors expressing only MV P and V proteins were constructed by 
introduction of silent mutations disrupting the C translation initiation codon and introducing 
two nearby stop codons, in order to suppress revertants, which is important especially for the 
generation of recombinant viruses later on. V expression was directed by inserting the 
additional G residue in the editing site of the P mRNA. This G residue is inserted into the P 
mRNA during infection by the viral polymerase complex. The cloning strategy was 
previously described for the respective MV Schwarz constructs (Pfaller and Conzelmann, 
2008).  
1.1. Measles virus C protein is able to inhibit interferon induction 
To determine the ability of each of these proteins to individually interfere with the 
interferon induction system, dual luciferase reporter gene assays were performed. Expression 
of firefly luciferase (FL) controlled by the full-length IFN-β promoter (p125-Luc plasmid) 
was transfected in 293T cells, together with plasmids encoding the MV P gene products P, V 
and C and CMV promoter controlled Renilla luciferase for normalisation. These cells then 
were stimulated  with a preparation of Sendai virus (SeV) defective interfering particles (DI-
H4), which were kindly provided by Dominique Garcin (Strahle et al., 2007). Stimulation in 
mock-transfected cells resulted in the induction of firefly luciferase expression, which could 
be quantitatively measured. Rabies virus P protein (RV P), which counteracts activation of 
IRF3 by TBK-1 (Brzozka et al., 2005; Rieder et al., 2011) was used as a positive control in 
these assays and also showed the strongest inhibitory effect observed.  
While expression of P of the MV wt isolate (Pwt) had only a marginal effect on the 
activation of the IFN-β promoter, expression of V and C proteins (Vwt
 
and Cwt; respectively) 
substantially and dose-dependently diminished induction (Fig. 7 A). Since DI-H4 infection is 
able to activates both MDA-5 and RIG-I (Yount et al., 2008), and MV V is known to prevent 
MDA-5 activation (Andrejeva et al., 2004; Motz et al., 2013) and NF-κB activity (Schuhmann 
et al., 2011), an inhibitory effect of Vwt was not unexpected. Notably, however, Cwt protein 
revealed a similar strong inhibitory effect, suggesting that this protein can individually 
interfere with RLR-mediated IFN-β induction. To assay whether stimulation of the interferon 
system by factors downstream of the initial recognition of foreign PAMPs by RLR still could 
be blocked by Cwt, the kinase TBK-1 was overexpressed. Notably both Vwt and Cwt were 
able to inhibit expression of the reporter gene in a dose-dependent manner (Fig. 7 B). The 
presence of the proteins was confirmed by western blotting.
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Figure 7: Inhibition of IFN-β promoter and IRF3 binding element promoter activity by 
wildtype MV P gene products.  
(A) and (B) inhibition of IFN-β promoter activity by P gene products from the wildtype MV 
isolate MVi/Berlin.DEU/04.08. Dual luciferase assays from 293T cells transfected with different 
amounts (300ng, 600ng) of plasmids encoding either Pwt, Vwt, or Cwt protein, or rabies virus 
phosphoprotein (RV P) as a positive control, and 6 h later infected with Sendai virus (SeV) DI-
H4 (A) or overexpression of fl-TBK1 (200ng) (B). Lysates were harvested 18 h post infection or 
24h post transfection for luciferase assays and Western blot with specific antisera (lower panel). 
(C) and (D) Inhibition of IRF3 binding element promoter activity by P gene products from the 
wildtype MV isolate MVi/Berlin.DEU/04.08. Stimulation and transfection occurred with fl-
dRIG-I (C) and fl-TBK1 (D) overexpression analogous to A and B. Firefly luciferase (FL) was 
normalized with renilla luciferase (RL) co-expressed from transfected pRL-CMV and values 
from mock-infected cells were set to 1. Standard deviations of triplicates are displayed.  
The major pathway required for to the induction of interferon beta involves the activation of 
the transcription factor IRF3. A reporter construct harbouring 6 repeats of the IRF3 DNA 
binding site controlling expression of firefly luciferase (p55c1b-Luc) was used to determine 
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the interference with IRF3-dependent promoter stimulation, as the full length interferon beta 
also harbours binding sites for other transcription factors. 293T cells were stimulated by co-
expression of dRIG-I, which is a constitutive active, truncated version of RIG-I consisting 
only of its CARD domains. Alternatively fl-TBK1 overexpression was used as the stimulus 
(Fig. 7 C, D). The results obtained were similar to the assays with the full-length interferon 
beta promoter reporter construct. In both cases Vwt and Cwt were able to inhibit reporter gene 
expression in a dose dependent manner, whereas the Pwt protein failed to do so. RV P was 
used again as a positive control in both assays. Interestingly, while the Cwt protein was 
superior in inhibition of the full length interferon promoter stimulated by SeV DIs, in the case 
of the IRF3 binding site reporter, the Vwt protein shows the stronger effect after stimulation 
by plasmid transfection. 
To exclude the possibility that one of these MV proteins induces a general shutdown 
of cellular transcription, a constitutive expressing Renilla luciferase plasmid was co-
transfected. All luciferase reporter assays were normalized to the amount of renilla luciferase 
present in the lysates. 
Taken together, these results identify the C protein of wildtype MV as an additional 
inhibitor of the IFN-β induction pathway encoded by measles virus.  
1.2. MV C proteins of vaccine strains show a decreased inhibition 
To reveal whether the C protein of the widely used MV Schwarz vaccine strain (CS) 
has retained the ability to inhibit IFN-β induction, Cwt and Cs
 
encoding plasmids were 
transfected in parallel into 293T cells in addition to the reporter plasmids. Indeed, expression 
of Cs reduced IFN-β promoter activity after stimulation with DI-H4 or fl-TBK-1 (Fig. 8 A 
and B). Notably, however, inhibition by Cs
 
was considerably less pronounced compared to 
Cwt. While after infection with DI-H4 only marginal differences were detectable (Fig. 8 A), 
the dissimilarity became more apparent after more downstream stimulation by over-
expression of fl-TBK-1 (Fig. 8 B). As confirmed by Western blot experiments of the lysates 
used in the reporter gene assays, the weaker performance of Cs was not due to generally lower 
expression levels.  
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Figure 8: Inhibition of IFN-β promoter activity by different C proteins in 293T and 293T 
Stat -/- cells.  
(A) and (B) Inhibition of IFN-β promoter activity by different C proteins in 293T cells. Cwt from the 
wildtype MV isolate MVi/Berlin.DEU/04.08, Cs from the vaccine strain Schwarz. Dual luciferase 
assays from 293T cells transfected with increasing amounts of plasmids (125ng, 250ng, 500ng and 
750ng) encoding either Cwt or Cs protein, rabies virus phosphoprotein (RV P, 500ng and 750ng) as a 
positive control or MV flag-H as a negative control (500ng and 750ng). (C) and (D) Inhibition of IFN-
β promoter activity by different C proteins in 293T STAT1 -/- cells. Stimulation and transfection 
occurred analogous to A and B with 300ng and 600ng transfected for all viral protein encoding 
plasmids into a STAT1 knockout 293T cell line. Firefly luciferase (FL) values were normalized with 
Renilla luciferase (RL) values co-expressed from transfected pRL-CMV and values from mock-
infected cells were set to 1, the other data calculated relatively. Standard deviations of triplicates are 
displayed. The cells were stimulated 6 h later by infection with Sendai virus (SeV) DI-H4 (A) or 
overexpression of fl-TBK1 (200ng) (B). Lysates were harvested 18 h post infection or 24h post 
transfection for luciferase assays and Western blot with specific antisera (lower panels).  
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MV C protein was also reported to interfere with JAK/STAT signalling (Nakatsu et 
al., 2008; Shaffer et al., 2003), which could differentially affect the induction of proteins 
involved in the IFN induction pathways. Experiments were therefore also performed in 293T 
cells lacking the STAT1 gene, which is necessary for feedback loops induced by interferon 
from the supernatant. These cells were again stimulated using SeV DI H4 or overexpression 
of fl-TBK1 and transcription from the interferon beta promoter was measured by expression 
of firefly luciferase. In these assays however, the superior inhibition by Cwt became even 
more evident (Fig. 8 C and D), with similar levels of Cwt and Cs expressed and confirmed by 
western blotting of the lysates.  
Again the positive control for these luciferase reporter gene assays was RV P, the 
negative control was MV fl-H, which showed no reduction of IFN-β promoter controlled 
luciferase induction in all experiments. 
In summary, the C proteins of the wildtype MV isolate MVi/Berlin.DEU/04.08 and 
the Schwarz vaccine strain differ in their ability to prevent interferon induction. 
1.3. In silico characterisation of MV C 
The C protein is a 186 amino acid short protein, which has a molecular weight of 
around 21 kDa. The expression by leaky scanning from the P and the V mRNA during 
infection is quite efficient, and high amounts of the C protein can be detected in lysates of 
infected cells. The C protein of MV wildtype strains was reported to possess both a nuclear 
localization signal (NLS) and a nuclear export signal (NES) (Nishie et al., 2007). The NLS is 
located in the N-terminal part of the protein from amino acid 41-48 comprising a classical 
basic cluster motif. The NES is located in the middle part of C from amino acid 76-85, 
representing a classical leucin-rich NES (Figure 9 A). The nuclear export is CRM1 dependent 
(Nishie et al., 2007). 
Alignment of the primary amino acid sequence of C proteins taken from wildtype 
strains and vaccines strains revealed a prominent difference between vaccine and wildtype 
strains, namely a mutation in the nuclear localization sequence of the C protein. Another 
mutation is conserved among the 4 different vaccine strains, which were generated from 4 
different isolates (Bankamp et al., 2011): L25P. This mutation however, is also present in one 
of the wildtype strains in the alignment, MVi/Wincrage. Interestingly, very few mutations 
were introduced into MV C during generation of the vaccine strains by passaging compared to 
wildtype isolates (Figure 9 B). 
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Figure 9: Alignment analysis of the MV Cwt primary amino acid sequence.  
(A) Scheme of the MV C open reading frame, the reported (Nishie et al., 2007) nuclear 
localisation signal and the nuclear export signal are highlighted as yellow boxes. (B) Alignment 
of the sequences of C proteins from MV wt isolates and vaccine strains of different origin. 
Genotype and GenBank accession numbers are indicated. Deviations from a consensus sequence 
are shown in black. A canonical nuclear localization signal (NLS; boxed) is only present in the 
proteins of wildtype isolates. Vaccine strains possess a common R44G exchange. (C) Alignment 
of the C proteins of different paramyxoviruses as indicated before the sequences. The degree of 
conservation is indicated below the alignment as well as a consensus sequence when possible. 
(D) Phylogenetic tree analysis of the paramyxovirus C proteins aligned in C.  
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All Morbilliviruses encode a C protein as do some other members of the 
paramyxoviridae family, e.g. Nipah Virus, Hendra virus or human parainfluenza virus 1 and 
3. Comparing the primary sequences of C proteins from a selection of paramyxoviruses no 
apparent conserved region can be identified. Notably, the exact NLS sequence is not 
conserved (Figure 9 C). Especially the N- and C- termini of the proteins differ considerably 
and Sendai virus encodes for four different C proteins, the longest C protein is depicted in the 
figure. Moreover, measles virus C also has a distinct C-terminal sequence, consisting of a 
cluster of serines.  
Phylogenetic analysis of the C proteins showed a clear clustering of the 
morbilliviruses, whereas all the other paramyxoviruses were more distantly related. The 
closest relative of MV C is RPV C. Interestingly CDV C clusters with PDV C, being more 
distinct from MV C than PdPRV C. C proteins of Henipaviruses are even closer related to 
MV C than those of Sendai or parainfluenza viruses (Figure 9 D). Taken together however, 
the phylogenetic tree of the C proteins clearly resembles the tree of the N proteins, which is 
used for the classification of the viruses to certain families and subfamilies. This indicates that 
C and N proteins evolved to a same degree to form the different virus species.  
To analyse the secondary structure of MV C in more detail, the Quick2D assembly 
(Bioinformatics toolkit of the GeneCenter, LMU Munich) of bioinformatics programs was 
used to predict helices or beta sheets (Fig 10 A). In addition, unstructured regions were 
annotated. The four different secondary structure prediction algorithms used (PSIPRED 
(Jones, 1999), JNET (Barton, 1999), Prof (Ouali and King, 2000; Rost, 2001)) yielded almost 
similar results. In accordance with results of IUPRED (Dosztanyi et al., 2005), the N-terminal 
region is supposed to be unstructured. The remainder of the protein can be divided into 
approximately 4 different alpha helices, intercepted by non-structured regions. There are some 
hints in the prediction programs that beta sheets may also exist, however they were not 
predicted with all algorithms and are very short. No coiled-coil structures (PCOILS (Lupas et 
al., 1991)) could be predicted. The analysis of the primary sequence for transmembrane 
structures by PHOBIUS (Kall et al., 2004) and HMMTOP (Tusnady and Simon, 1998) was 
also negative, indicating that the C protein possesses no membrane anchors, as it was 
expected.  
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Figure 10: Secondary structure prediction and conservation scoring of MV Cwt.  
(A) Secondary structure prediction of MV Cwt. Above the predictions the NLS is indicated in the 
schematic representation of the C ORF, beneath it is the amino acid sequence of MV Cwt. 
Different algorithms were used as indicated in the figure to predict secondary structure features 
including alpha and beta sheets, coiled-coil structures, transmembrane regions (PHOBIUS, 
MMMTOP) and disordered regions (IUPRED). The colour red and the letter M indicate an alpha 
sheet, the colour blue and the letter E a beta sheet. Disordered regions are indicated in yellow 
using the letter D. There were no coiled-coils regions detected. (B) Conservation scoring of the 
amino acids according to Consurf. The conservation score is indicated on the y-axis, while the x-
axis represents the amino acid position. Black lines were used to highlight the separation of 
conserved regions and the numbers indicate their respective amino acid positions. The 
parameters for Consurf and the secondary structure predictions are in the appendix. 
For further insight into conserved regions, which might correspond to functional 
domains, the algorithm of Consurf (Ashkenazy et al., 2010) was used. Consurf accumulates 
similar protein sequences by BLAST (Altschul et al., 1990) searching. Afterwards these 
sequences are aligned and the dimension-less conservation score calculated, which represents 
the degree of conservation of each amino acids. In the case of MV C the conserved regions 
nicely fit to the predicted secondary structure elements, confirming both prediction programs. 
Interestingly, the nuclear localisation signal is located at the N-terminal unstructured domain, 
which represents the longest non-conserved region of the protein. This again confirms the 
data from previous alignments, that the exact sequence of the NLS is not conserved within the 
searched cluster of Morbilliviruses. The predicted disordered parts linking the four major 
helices also seem to be little conserved (Fig. 10 B). 
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Figure 11: Ab initio tertiary structure predictions for MV Cwt.  
The predictions were done using I-Tasser, the model represented here has the highest confidence score 
(C-score=-2.60). The estimated accuracy of the model is: 0.41±0.14 (TM-score)  11.1±4.6Å (RMSD) . 
(A) A ribbon model rendered in pymol to highlight the NLS and NES in yellow. Only the backbone of 
the peptide chain is displayed and the alpha helices are depicted as broader bands, while unstructured 
regions are represented as a line.  (B) Conservation scores colours according to Consurf for the model 
in (A)  blue = high conservation, red = low conservation score. 
 
Structural prediction of the tertiary structure of MV Cwt were done using the ab intio 
calculation algorithm I-Tasser (Roy et al., 2010), as no structural models of closely related 
proteins are available. In overall agreement with the prediction of the secondary structure, 
MV C forms a 4 helix bundle with an unstructured N-terminal domain. The unstructured 
regions include the NLS, while the NES is located within helix 1 (Fig. 11 A). Conservation 
colouring (by Consurf conservation scores) revealed that the helices were mostly conserved 
except for the more C-terminal part of helix 1 (Fig. 11 B), largely confirming the combination 
of the previous secondary structure predictions with the ConSurf results. 
Taken together these results indicated that a major difference between vaccine strains 
and wildtype strains is a functional nuclear localisation signal. Being located in a predicted 
unstructured part of the protein, the overall structure of a 4 helix bundle is supposedly not 
influenced by mutations in this region. 
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1.4. Nuclear localization of MV C correlates with interferon inhibition 
To study the significance of the nuclear localisation signal of C several mutants were 
generated (Fig. 12).  
 
Figure 12: A functional NLS is a prerequisite for nuclear accumulation of MV C.  
The intracellular localization of the MV Cwt and Cs proteins and of the indicated mutants was 
analyzed by confocal laser scan microscopy in HeLa cells 24 h p.t. transfected with the indicated 
plasmids. C proteins were stained with the C-specific peptide/rabbit antiserum C1242 and 
visualized with anti-rabbit-Alexa488 secondary antibody (green). Nuclei were stained with 
ToPro3 iodine (white). The sequences of the NLS are displayed next to the scheme of the 
respective mutants. 
The functional MV Cwt NLS was destroyed by site-specific mutation of the basic cluster 
motif (44RK to 44AA) exchanging arginine and lysine to alanine. Additionally, the defective 
NLS of MV Cs was repaired to the wildtype NLS situation by exchanging the G44 residue to 
an R. Finally a heterologous NLS (SV40 large T antigen NLS) was added to the N-terminus 
of a MV Cwt mutation with destroyed NLS (44AA). The subcellular localisation of these 
mutants was assayed by immunofluorescence and detection of the overexpressed C protein 
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was done by using specific antibodies. As expected from the predictions, MV Cwt was 
located exclusively in the nucleus (Fig. 12 B). MV Cs, although possessing a NES signal, was 
distributed over cytoplasm and nucleus. It still can shuttle to the nucleus, being small enough 
to fit through the nuclear pores (Fig. 12 C). Mutations in the nuclear localisation signal of Cwt 
(MV CwtmNLS) abrogate its dominant nuclear accumulation, yielding a localisation 
phenotype similar to MV Cs (Fig. 12 D). Repairing the basic cluster of the NLS sequence of 
MV Cs back to the wildtype situation promotes the accumulation of MV CswtNLS in the 
nucleus (Fig. 12 E). This mutant exhibits the same localisation as MV Cwt. Upon fusing the 
SV40 large T antigen NLS to the N terminus of CwtmNLS, the localisation of this protein to 
the nucleus is restored (Fig. 12 F). For all these localisations it has to be considered, that the C 
protein possesses both an NLS (mutated or not mutated) as well as an unchanged NES. This 
means that it still shuttles to some degree, whereas the confocal images portrait the 
localisation of C at an exact timepoint picturing C in its preferential location. Therefore in the 
case of Cwt the balance between nuclear and cytoplasmic protein is definitely on the side of 
the nucleus, however it does not mean that the same C molecule is not present at some 
timepoint in the cytoplasm, as well. 
The functional consequences of these mutations and different intracellular 
localisations were assayed using luciferase reporter gene assays (Fig. 13). The P protein of 
rabies virus was used again as the positive control, whereas the MV fl-H protein served as the 
negative control. For normalization purposes the CMV promoter controlled Renilla luciferase 
encoding plasmid was always co-transfected. The expression levels were equal as checked by 
Western blot analysis (below the luciferase assays). 
The p125-luciferase plasmid (Fig. 13 A-B) was co-transfected with plasmids encoding 
for the different C mutants as well as the stimulus fl-TBK1.  MV Cwt was able to inhibit 
induction of the interferon beta promoter more efficiently than MV Cs, as seen in previous 
experiments. The wildtype C NLS mutant (CwtmNLS), however, clearly showed a loss of 
function compared to Cwt, whereas the repaired NLS Cs (CswtNLS) gained function. The 
inhibitory effect of CwtmNLS was comparable to Cs and the effect of CswtNLS is 
comparable to Cwt. This indicates that the decreased efficiency of Cs is only due to its 
cytoplasmic localisation. The protein still can decrease induction of interferon beta, upon its 
relocation to the nucleus by repairing the NLS.  
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Figure 13: Nuclear localization of MV C is required for efficient inhibition of IFN-β 
promoter activity.  
(A, B) Dual luciferase assays were used to determine activation of the IFN-β promoter. Plasmids 
encoding the indicated protein constructs (300 and 600 ng of C, 200 ng fl-TBK-1, 600 ng RV P 
or fl-MV H) were transfected into 293T cells and induction of p125-luc-directed FL activity was 
determined 24 h p.t.. All assays were normalized with co-expressed RL, mock values set to 1 and 
relative induction is shown. Standard deviations of triplicates are displayed. (A) The inhibitory 
activity of Cwt
 
is completely lost by after disruption of the NLS and Cs gains full activity after 
repair of the NLS R44G mutation. (B) An ectopic heterologous SV40 large T antigen NLS can 
substitute for the authentic internal C protein NLS in SV40NLS-CwtmNLS. (C) Quantitative RT-
PCR from 293T cells stimulated by expression of ΔRIG-I (100ng) in the presence of the indicted 
viral protein constructs (400ng). IFN-β mRNA normalized with GAPDH mRNA. Columns show 
average values from two experiments, error bars represent standard deviation. Lysates were 
harvested 24h post transfection for luciferase assays and the protein content analysed by western 
blotting and immunodetection with specific antisera (lower panels).  
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Adding an exogenous NLS (SV40 large T antigen NLS) to the N-terminus of 
CwtmNLS also restored the function of CwtmNLS (Fig. 13 B), reflecting the Cwt situation. 
This indicates that the exact sequence of the NLS is not important but only the spatial 
distribution of C inside the cell. 
Quantitative realtime PCR of interferon beta messenger RNA showed the same results 
as the luciferase assays (Fig. 13 C). Cwt and CswtNLS were more efficiently inhibiting the 
transcription of interferon beta messenger RNA than Cs and CwtmNLS. This time a plasmid 
coding for a constitutive active mutant of RIG-I, comprising only the CARD domains was 
used as a transfectable stimulus. The normalisation was done using GAPDH mRNA levels, 
again indicating that MV C does not induce a general shutdown of transcription as the 
GAPDH mRNA values of mock and the C transfected cells were similar. 
In summary the NLS sequence drives the preferential accumulation of C in the nucleus 
and the mutation in the vaccine C abrogates the function of the NLS, resulting in a different 
intracellular distribution of the protein. The inhibition of IFN-β induction clearly correlates 
with the accumulation of C in the nucleus and occurs at a transcriptional level downstream of 
TBK1. 
 
1.5. MV C does not interfere with activation of IRF3 
For effective induction of IFN-β, a crucial transcription factor, IRF3, has to be fully 
activated. The classical activation steps include its phosphorylation at C-terminal serine 
residues; especially phosphorylation at serine 386 and 396 was shown to be obligatory. The 
phosphorylated transcription factor then dimerizes and is imported actively into the nucleus. 
Within the nucleus activated IRF3 binds to the DNA at its recognition sites and is responsible 
for the recruitment of cofactors required for efficient transcription initiation such as e.g. p300 
and CBP (Panne et al., 2007a; Yoneyama et al., 1998). 
An IRF3 binding site reporter plasmid (p55c1b-Luciferase) was co-transfected with 
plasmids coding for Cwt and Cs. Induction was done using overexpression of the transcription 
factor IRF3 and the luciferase activity was measured afterwards. Only the Cwt protein was 
able to inhibit reporter gene induction in a dose dependent manner, whereas Cs mostly failed 
to do so. This indicates an inhibition downstream of IRF3 and upstream of interferon beta 
translation (Fig. 13 D). 
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Figure 14: MV C inhibits IRF3 stimulated interferon induction (A) but does not interfere 
with IRF3 activation by phosphorylation (B), dimerization (C) or nuclear accumulation (D).  
(A) Dual luciferase assays were used to determine activation of the IRF3 response element 
(p55c1b) promoter. Plasmids encoding the indicated protein constructs (250 to 750 ng of C, 200 
ng fl-IRF3) were transfected into 293T cells and induction of p55c1b-luc-directed FL activity 
was determined 24 h p.t.. All assays were normalized with co-expressed RL, mock values set to 1 
and relative induction is shown. Standard deviations of triplicates are displayed. (B) 293T cells 
expressing MV C, RV P as a positive control, fl-MV H as a negative control, and flag-tagged 
IRF3 (fl-IRF3) from transfected plasmids as indicated, were stimulated by SeV DI H4 to activate 
IRF3. Induction of p125-luc-directed FL activity was determined 12 h p.t.. All assays were 
normalized with co-expressed RL, mock values set to 1 and relative induction is shown. Standard 
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deviations of triplicates are displayed (top panel). Phosphorylation of IRF3 S386 and S396 was 
analyzed by Western blotting following SDS-PAGE of whole cell lysates harvested 12 h post 
transfection using specific antibodies. The expression level of the overexpressed proteins MV C, 
RV P, fl-IRF3 and MV fl-H was additionally monitored in the same western blot experiment, as 
well as the cellular control protein actin (lower panel).  (B) Native PAGE of whole lysates 
collected from 293T cells 24 h post transfection. IRF3 dimerization was stimulated by 
overexpression of fl-TBK-1. IRF3 was stained with anti-IRF3 antibodies. The sizes of the IRF3 
dimer and the monomer are indicated next to the blot. (C) HeLa cells were mock-infected or 
infected with SeV DI-H4. At 18 h p.i. endogenous IRF3 was visualized by staining with anti-
IRF3 antibody and Alexa 488 (green) and fl-Cwt expressed from transfected plasmids by anti-
flag and Alexa-555 (red). The nuclei were stained with ToPRO3 (white). The figure shows a 
representative example of multiple experiments. 
To assay the phosphorylation status of overexpressed flag-IRF3, cells stimulated with 
SeV defective interfering particles H4 were lysed after 12h. A luciferase reporter gene assay 
of the same lysates showed, that even the initial low level induction of interferon beta by SeV 
DI H4 is blocked by MV Cwt, whereas RV P is less effective in blocking these initial steps 
(Fig. 14 A). RV P, however, is able to completely prevent phosphorylation of IRF3 at position 
386 and 396 as indicated by phosphorylation-specific antibody western blots (Fig. 14 B). MV 
Cwt instead does not block visibly any phosphorylation of IRF3 compared to the mock 
stimulated cells or the negative control (MV fl-H). All inhibitory proteins were confirmed as 
expressed in this assay by Western blot analysis and subsequent detection of the proteins by 
specific antibodies.  
To assess the dimerization of IRF3, native gel electrophoresis experiments were 
conducted. RV P co-expression induced a complete loss of IRF3 dimerization after 
stimulation with fl-TBK1 overexpression. Both MV Cwt and Cs could obviously not inhibit 
this dimerization step compared to the empty vector control (Fig.  14 C). 
The nuclear import is thought to be a final step in activation of IRF3. In non-
stimulated cells IRF3 was distributed in the cytoplasm and co-expression of MV Cwt does not 
alter this localisation. Upon stimulation - with SeV Dis - IRF3 accumulated visibly in the 
nucleus. Co-expression of MV Cwt again did not alter this behaviour, resulting in both Cwt 
and IRF3 residing inside the nucleus of activated cells (Fig. 14 D). 
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Taken together, these results indicate that the mechanism of Cwt does not involve 
inhibition of phosphorylation, dimerization or nuclear import of IRF3.  
 
2. Identification of cellular interaction partners of MV C 
 
Most mechanisms employed by viral proteins to disturb cellular signalling pathways 
use protein-protein interaction as an interface to manipulate the host. In the case of MV for 
example, V binds strongly to the cellular helicase MDA-5, thereby inhibiting its ATPase 
activity and subsequent signalling (Andrejeva et al., 2004). It is therefore likely, that the C 
protein also interacts with cellular proteins to modify their functions.  
Binding assays were mainly done using co-immunoprecipitation experiments in 293T 
cells, where both putative binding partners were overexpressed. One of the tagged interaction 
partners was then bound to a matrix either coated with HA or with flag antibodies. The lysates 
of these pulldowns were then subjected to Western blot analysis followed by 
immunodetection to show whether the precipitation worked. Possible co-purified protein 
interaction partners were detected by Western blotting as well. Whole cell lysates were also 
analysed in a similar fashion to show the presence of the proteins in the input of the pulldown. 
Alternatively these pulldowns were analysed by mass spectrometry instead of Western 
blotting to identify endogenous proteins bound to the tagged protein.  
Another method employed to identify binding partners of C was overexpression of 
putative binding partners together with C in Hep2 cells. These cells were stained with 
fluorescent antibodies and then subjected to confocal microscopy analysis. A co-localisation 
of two proteins would then indicate an interaction. 
2.1. Interaction partners in the interferon pathway 
The first obvious choices for interaction partners to screen for were proteins involved 
in major steps in the interferon induction cascade. Among these were the PAMP recognizing 
helicase RIG-I, the scaffolding protein IPS-1, the kinase TBK1 and the transcription factor 
IRF3. Additionally, the co-factors needed for efficient transcription of interferon beta mRNA 
in the nucleus, CBP and p300, were tested. As described above, a nuclear binding partner for 
Cwt was suggested since the inhibitory strength of MV C correlated with its nuclear 
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accumulation. Furthermore the inhibition was still visible, although weaker, downstream of 
stimulation by overexpression of TBK1 or IRF3.  
 
Figure 15: Co-immunoprecipitation of MV Cwt with various proteins in the interferon 
pathway.  
The pulldowns of flag-tagged overexpressed proteins in 293T cells together with C were done 
using a flag-antibody coated matrix. The whole cell lysates before the immunoprecipitation 
experiments were analysed by Western blots as well as the IP and the Co-IP as indicated in the 
figure. The percentage indicates the relative amounts of WCL and the IP loaded on the gel. (A) 
Flag-tagged RIG-I, IPS-1, TBK1 and IRF3 were analysed for binding to MV Cwt. Plasmids 
coding these proteins were transfected as indicated below the blots. As a negative control for 
background binding, MV Cwt was overexpressed alone. For detection of the flag-tagged proteins 
the flag antibody was used (upper panels of the Western blots), for detection of MV Cwt, the anti 
MV C serum was used (lower Western blot panels). (B) Flag-tagged MV Cwt and IKKα (as a 
positive control) were analysed for binding to HA-tagged CBP or p300. Plasmids coding these 
proteins were transfected as indicated below the blots. As a negative control for background 
binding, the HA constructs were overexpressed alone. For detection of the flag-tagged proteins 
the flag antibody was used (middle panels of the western blots), for detection of MV Cwt, the 
anti MV C serum was used (lower western blot panels) and for detection of the HA-tagged 
proteins anti-HA antibodies were used (upper western blot panels).  
Surprisingly, MV Cwt showed a strong interaction with flag-tagged IPS-1 in co-
immunoprecipitation experiments (Fig. 15 A). None of the other proteins of the pathway 
mentioned above were able to co-purify Cwt, although they were all precipitated almost 
equally efficient or even stronger (fl-IRF3). The transcriptional co-activators -CBP and p300- 
also show no association with flag-Cwt at all (Fig. 15 B). The positive control flag-IKKα 
Interferon induction inhibition by MV C - Results 
Identification of cellular interaction partners of MV C 
 
 
Page 75  
  
(Yamamoto et al., 2003), however, was able to co-purify both p300 and CBP, proving that the 
assay worked in principle. 
Taken together, MV C is only able to interact with IPS-1, considering the so far 
assayed possible interaction partners in the interferon induction pathway. All nuclear 
interaction targets evaluated in these assays did not interact with C. 
2.2. Known binding partners of MV C 
Two binding partners of MV C were described previously. Weak binding to 
phosphorylated STAT1 after interferon gamma stimulation was described (Yokota et al., 
2011b) and Immunity-related GTPase family M protein (IRGM) (Gregoire et al., 2011). Both 
proteins were therefore analysed for a co-purification in co-immunoprecipitation experiments 
to verify the binding partners proposed in the literature. The following experiments were done 
using Cwt protein as the binding partner, although different variants of vaccine C proteins 
were used in the literature.   
Using co-immunoprecipitation experiments, the interaction of Cwt with 
phosphorylated Stat1 could not be confirmed (Fig. 16 A). Not even weak binding was visible 
in the flag matrix pulldown experiments using overexpressed flag-tagged STAT1. 
Phosphorylation of flag-STAT1 was induced by stimulation of the living cells with 
recombinant type I interferon for 45 minutes.  
To study interaction with mitochondrial proteins IRGM and IPS-1 in comparison, the 
flag-tagged proteins were co-expressed with HA-tagged Cwt in 293T cells. The pulldown was 
carried out using a HA-antibody coated matrix. Fl-IRGM was able to co-purify HA-Cwt, thus 
reproducing the reported interaction (Fig. 16 B). The interaction seems to be comparable to 
the interaction of HA-Cwt with fl-IPS-1, identified in Figure 15. This experiment additionally 
confirms the binding of HA-Cwt to fl-IPS-1 using a pulldown with another antibody and 
matrix. 
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Figure 16: Co-immunoprecipitation experiments of MV Cwt with known binding partners 
(pSTAT1 and IRGM). 
 The pulldowns were done using a flag-antibody coated matrix (A) or a HA-antibody coated 
matrix (B) and lysates from 293T cells transfected with plasmids encoding the protein as 
indicated below the blots. The whole cell lysates before the immunoprecipitation experiments 
were analysed by Western blots along with the IP and the Co-IP as indicated in the figure. The 
percentage indicates the relative amounts of WCL and the IP loaded on the gel. (A) Pulldown of 
flag-STAT1 to co-purify Cwt. All cells were stimulated 45min prior to the harvest with 1000 
Units/ml interferon Type I to induce STAT1 phosphorylation. (B) Comparison of the binding of 
HA-Cwt to either flag-IRGM or flag-IPS-1.  
2.3. Screening for cellular interaction partners of MV C 
Another method to identify co-purified proteins with MV C in the pulldown lysates 
besides Western blotting and immunodetection is mass spectrometry. The advantage of this 
technique is, that all proteins present in the pulldown can be detected at once, providing an 
unbiased screening approach, taking cellular endogenous protein content and expression 
levels into account. This technique was employed to analyse the endogenous proteins of 293T 
cells that were pulled down as interaction partners of MV Cwt.  
2.3.1. Mass spectrometry driven analysis of Cwt pulldown eluates 
Flag tagged Cwt or CwtmNLS was overexpressed in 293T cells and the whole cell 
lysates incubated with beads coated with flag antibodies. After thoroughly washing away 
unbound proteins, the bound flag-tagged proteins and their interaction partners were 
specifically eluted from the beads using flag peptides. 
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Figure 17: Silver stained gels of purified proteins.  
For these experiments a flag-antibody coated agarose bead matrix was used to pull down flag-
tagged C variants. Elution was done using 300ng/ml flag peptide and the eluted flag-C is 
highlighted in the figure with a blue box. For both pulldowns the flag-tagged proteins were 
overexpressed in 293T cells. Two elutions are depicted. A In the first experiment pCAGGS-fl-
Cwt was used for the transfection, the mock control were empty vector transfected cells. B In the 
second experiment pCAGGS constructs of Cwt, fl-Cwt, fl-CwtmNLS were transfected, the mock 
control was overexpressed untagged Cwt. 
To verify that the pulldown itself worked, these elutes were subjected to gel 
electrophoresis followed by silver staining of the proteins on the gel (Figure 17). Two 
experiments were done using flag-Cwt (Fig. 17 A, B) and flag-CwtmNLS (Fig. 17 B) as a 
bait. The first experiment used empty vector transfected cells as a mock control, while in the 
second experiment Cwt without a tag was overexpressed. In both trials the pulldown itself 
worked fine, at the correct size (ca. 23 kDa for flag-tagged C constructs) a band appeared only 
in the fractions which should contain flag-tagged C (Fig. 17 blue box).  No untagged C 
protein was purified (Fig. 17 B, first lane), suggesting that C does not bind unspecifically to 
the matrix. Unfortunately the flag matrix itself seems to bind strongly to a few cellular 
proteins around 40 and 64 kDa also visible in the silver stained gel. In both cases, the second 
elution step worked less well, yielding less pulled down protein, but also less background. 
Comparing the two pulldowns in Fig. 17 B, it can be said that the elution of MV flag-
CwtmNLS from the beads seemed to be more efficient. However, this can also be due to a 
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higher level of MV fl-CwtmNLS in the input lysates, which were not subjected to silver stain 
analysis. 
In both experiments, no prominent additional binding partners visible on the gel except 
for a few faint protein bands between 50 and 75 kDa and larger than 150 kDa.  These bands, 
however, indicated that some proteins were specifically co-purified with the flag tagged C 
proteins compared to the mock controls. There were no obvious differences between Cwt and 
CwtmNLS visible on the silver stained gel. 
The protein content of the eluates in Fig. 17 was then analysed by mass spectrometry 
followed by peptide identification. These peptides then were attributed to proteins using 
different protein libraries for the viral protein and for the cellular human proteins (NCBI 
library). In the first experiment, the lysates were subjected to a short gel electrophoresis  and 
three slices made of the gel, that were subsequently subjected to three different mass 
spectrometry analysis runs. The runs were later combined to one experiment using the 
Scaffold software.  For the second experiment the lysates were directly analysed in the 
instrument without a preceding gel separation. 
In all elutes, in which flag tagged measles virus C was overexpressed, the protein 
could be identified (Fig. 18 A). This confirms the bands seen on the silver stained gel were 
indeed the precipitated flag-tagged C. The quantitative value for the first experiment was 
higher due to the three runs combined which results in an increased sensitivity of the assay. 
This quantitative value represents normalized unweighted spectrum counts, which is a relative 
number for general abundance of the detected protein in the eluate. 
In the second run, the pulldown of fl-Cwt was less efficient than that of fl-CwtmNLS 
again confirming the observations made on the silver-gels.  
To identify the cellular proteins in the eluates, the peptides identified by the mass 
spectrometry were blasted against the NCBI protein database. The resulting proteins that were 
identified with a probability of at least 80% to be present in the eluates are depicted in Fig. 18 
B. The list comprises only proteins which could not be detected in the mock or Cwt controls 
and present in both experiments. The full dataset is displayed in the appendix. Again it can be 
seen that the quantitative values in the first experiment are higher, due to the combination of 
three runs. The table is sorted by the quantitative value of the first mass spectrometry 
experiment. The most abundant protein in all elutes except the fl-CwtmNLS pulldown was the 
microtubule associated protein 1B (MAP1B). MAP proteins are involved in development of 
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the neuronal system, as well as microtubule assembly (Halpain and Dehmelt, 2006). MAP1B 
is cleaved in the cell to form a heavy chain and a light chain (LC1). The heavy chain can also 
bind light chain expressed from another gene, namely LC3B, which is an important protein 
during autophagy (Barth et al., 2010). Fragments of both the heavy chain and the light chain 
of MAP1B were found in the eluate. Notably, the protein was only co-purified with fl-Cwt, 
not with fl-CwtmNLS. 
Interestingly, a cluster of proteins belonging to the 19S subunit of the proteasome was 
found specifically binding to fl-Cwt and also to fl-CwtmNLS, although less spectra were 
found in this pulldown, indicating a weaker binding. These include PSMD1, PSMD2, 
PSMD3, PSMC1, PSMC2, PSMC3, PSMC5 and PSMD13. PSMD2 was the most abundant 
interaction partner in both experiments. Insulin receptor substrate 4 (IRS4), which was also 
detected only in the fl-Cwt elutes, can act as a scaffolding protein for tyrosine kinases and 
associates with cytoplasmic signalling proteins containing a SH2 domain. It is phosphorylated 
by the insulin receptor. The phosphoglycerate dehydrogenase (PHGDH) is involved in early 
steps of L-serine synthesis in animal cells.  SLC25A3 (Solute Carrier Family 25) and 
SLC1A5 (Solute Carrier Family 1 (Neutral Amino Acid Transporter), Member 5) are both 
soluble molecule carriers. The former one carries phosphates over the mitochondrial 
membrane, whereas the latter is able to carry neutral amino acids. SLC1A5 was also 
described as a receptor for the RD114 retrovirus. Both transporters were only co-purified with 
fl-Cwt. 
Ring-finger containing protein 219 (RNF219) is a probable E3 ubiquitin ligase, due to 
its RING-finder domain; no studies describing its function are so far available. The only 
annotation is that it acts as an ubiquitin ligase for MyD88, an important adaptor in Toll-like-
receptor signalling (Wang et al., 2005). RNF219 was only found in fl-Cwt containing elutes. 
Apoptosis-Inducing Factor, Mitochondrion-Associated, 1 (AIFM1) is a protein which 
is essential for nuclear breakdown during apoptosis. Additionally it can cause mitochondria to 
release cytochrome c and caspase-9 (Cregan et al., 2004). AIFM1 was found to be associated 
to both fl-Cwt and fl-CwtmNLS in the pulldown experiments. 
Coordinator Of  PRMT5, Differentiation Stimulator (COPRS) is a histone-binding 
protein and required for H4 'Arg-3' methylation mediated by PRMT5 modulating transcription 
(Lacroix et al., 2008). In the interferon signalling cascades PRMT5 was previously identified 
as JAK2 binding protein 1 (Pollack et al., 1999). 
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Figure 18:  Identification of protein binding partners of MV Cwt by mass spectrometry.  
The values for the protein detection in the tables are quantitative values for normalized 
unweighted spectrum counts. (A) The content of the MV Cwt proteins (flag-Cwt, fl-CwtmNLS) 
in both mass spectrometry experiments (1. and 2.) is indicated in the figure. The counts for the 
flag-peptide also used for elution were removed. (B) Proteins detected specifically in both 
experiments are co-purified with either flag-Cwt or flag-CwtmNLS. Proteins also pulled down in 
the mock control were removed as well as proteins present in only one of the mass spectrometry 
experiments. The official gene symbols were used to annotate the proteins. Additionally the 
quantitative values for co-purified of DDB1 and IPO8 is depicted from the first mass 
spectrometry experiment, both proteins were not detected in the second experiment. (C) 
Abundance of the proteins in human mass spectrometry pulldown experiments. The database 
used for the calculations was the PepTracker database.  
Two additional proteins are displayed, which were only identified in the first mass 
spectrometry experiment: DNA-damage-binding protein 1 (DDB1) and importin 8 (IPO8). 
DDB1 was chosen for further analysis due to its reported interference with the interferon 
induction pathway, as well as its binding to the PIV5 V protein (Precious et al., 2005).IPO8 
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was chosen as a putative importin candidate, which could responsible for the nuclear import 
of Cwt. 
Unfortunately, none of the previously reported uinteraction partners of C, IPS-1, 
IRGM and STAT1 could be identified in the mass spectrometry pulldowns. Also the only 
recently described MV C and P interactor SHCBP1 was not present in the preparations (Ito et 
al., 2013). 
The general abundance in mass spectrometry analysis of these putative binding 
partners of C was analysed using the PepTracker website, which assembles mass spectrometry 
data. A higher abundance of the proteins means a higher likelihood of an unspecific 
association with the protein to any other protein (‘sticky proteins’). These proteins are not 
necessarily unspecific binding partners. They, however, have to be treated carefully in further 
analysis. Only two proteins of the list have a higher abundance than 50%: SLC25A3 and 
PHGH. The abundance of all other detected proteins was lower than 30% or they were not 
even detected before in the experiments listed in the database (Fig. 18 C). 
 
To analyse the putative interaction partners of Cwt in more detail, protein-protein 
interaction network analysis were conducted. The interactions were gathered from the 
BIOGRID database. The individual interaction details were merged using Cytoscape, the 
interaction partners of Cwt coloured in blue (proteasomal components) and yellow (all other 
interaction partners). The resulting protein-protein interaction network is displayed in Fig. 19 
A and surprisingly highly interconnected with an average number of neighbours of 4.The 
clustering coefficient of the resulting network was 0.2 and the network heterogeneity was 
3.13. For further more detailed visualization, all proteins which interact with only one of the 
putative Cwt interaction partners were eliminated (Fig. 19, B). The proteins identified from 
the proteasome are all part of a subunit of the 26S proteasome particle, the 19S regulatory 
subunit. No proteins from the core subunits were found in the mass spectrometry experiments. 
In both networks, this 19S subunit forms a cluster, centred on the putative interaction partners 
coloured in blue, whereas the other proteins cluster around it and upon removing the 
secondary interaction partners (Fig. 19 B) no proteasomal components which belong to the 
core are still present. This indicates that the C protein might bind individually to the 19S 
subunit only, without the core subunits present, suggesting that it is and interaction 
independent of the process of proteasomal degradation. The protein network in Fig. 19 C 
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varies the size of the nodes according to the connectivity of the proteins, the ubiquitin chains 
(UBC) were deleted from this view, due to its high interconnectivity. The bigger the nodes 
are, the more edges connect these nodes to one another, the more interaction partners on of 
those proteins has. A total of eight proteins are highly connected in this network, besides the 
putative Cwt interaction partners. F-box only protein 25 (FBXO25) a part of the SCF 
complex, the Cullin Ring finger ubiquitin E3 ligase CUL3, Ubiquitin D (UBD) an ubiquitin-
like protein, the proto oncogene MYC, the Histone deacetylases HDAC5 and SIRT7, the 
small molecular modifier SUMO2 and the cyclin dependent kinase 2 (CDK2). Interestingly 
with regard to the interferon system, STAT1 is also found as a secondary interaction partner 
linking PSMC3 and PHGDH. 
 
Figure 19: Protein-protein interaction networks of MVCwt binding partners. 
The binding partners of MV Cwt identified by mass spectrometry are depicted in yellow, the 
proteasome components detected are depicted in blue. All other proteins are coloured in light 
red. The networks were generated using Cytoscape and spring-embedded layouts. The interaction 
data was taken from the BIOGRID database. The blue lines represent interactions, the circles 
proteins, annotated with their gene symbol. (A) Complete BIOGRID interactions of the proteins 
specifically interacting with Cwt. (B) Proteins which do at least interact with 2 proteins that were 
present in the pull-downs. (C) Spring-embedded network layout of the data in (B) with the node 
size scaling with its connectivity. 
Interferon induction inhibition by MV C - Results 
Identification of cellular interaction partners of MV C 
 
 
Page 83  
  
In summary, a few endogenous proteins specifically co-purified with Cwt or CwtmNLS 
and could be identified using mass spectrometry. Cwt seems to preferentially associate with 
the 19S proteasomal subunits as well as a small number of other proteins as indicated by two 
independent assays. Already known binding partners like IPS-1, phosphorylated STAT1 and 
IRGM could not be detected in the pulldown eluates. 
2.3.2. Validation of putative interaction partners 
The putative interaction partners identified in the mass spectrometry screens were 
analysed for binding to Cwt in a different assay: Co-immunoprecipitation followed by 
immunodetection of the proteins on Western blots (Fig. 20).  
Four candidates were chosen to be tested in the initial verfication assays: IPO8 (Fig. 20 A)  as 
a potential importin for Cwt, DDB1 (Fig. 20 B) due to its implication in interferon inhibition 
by PIV5 V , MAP1B (Fig. 20 C) as the protein with the highest abundance that was detected 
in the mass spectrometry experiments and PSMC3, as a component of the 19S subunit of the 
proteasome (Fig. 20 D), which was already mentioned as an interactor of Cin a yeast-two-
hybrid screening previously (Ito et al., 2013). The interaction between Cwt and DDB1, 
however could be verfied as very weak, as judged from the difference between the exposure 
of the Co-IP blot and the input blot. In addition, association between the proteasomal 
component PSMC3 and Cwt could be proven in this assay as well, being moderate strong and 
comparable to the Cwt – IPS-1 binding as seen in parallel assays (data not shown). The 
interaction between Cwt and importin 8 could not be verfied using this method. The same 
holds unfortunately true for the interaction between Cwt and MAP1B, which was the most 
abundant interaction partner in the mass spectrometry pulldowns (Fig. 20). 
Taken together, two (DDB1 and PSMC3) of four proteins identified as interaction 
partners of Cwt by mass spectrometry analysis, could be immediately verified using co-
immunoprecipitation experiments with flag-tagged C or HA tagged Cwt and the respective 
putative interaction partners. 
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Figure 20: Co-immunoprecipitation experiments of MV Cwt with putative interaction 
partners identified by mass spectrometry: IPO8(A), DDB1(B), MAP1B(C) and PSMC3(D).  
The pulldowns were done using HA-antibody (A) or flag-antibody (B,C,D) coated matrix and 
lysates from 293T cells. The whole cell lysates before the immunoprecipitation experiments were 
analysed by Western blots as well as the IP and the Co-IP blots as indicated in the figure. The 
percentage indicates the relative amounts of WCL and the IP loaded on the gel. (A) Co-
purification of MV flag-Cwt with importin-8 (IPO8). anti-HA antibodies were used to detect 
HA-tagged IPO8 (upper panels). anti-flag antibodies were used to detect the flag-tagged Cwt 
protein (lower panels) (B) Co-purification of MV Cwt with flag-DDB1. anti-flag antibodies were 
used to detect the flag-tagged DDB1 protein (upper panels) and the C-antibody was used to 
detect the Cwt protein (lower panels). (C) Co-purification of MV Cwt with flag-MAP1B. anti-
flag antibodies were used to detect the flag-tagged MAP1B protein (upper panels) and the C-
antibody was used to detect the Cwt protein (lower panels). (D) Co-purification of MV Cwt with 
flag-PSMC3. anti-flag antibodies were used to detect the flag-tagged PSMC3 protein (upper 
panels) and the C-antibody was used to detect the Cwt protein (lower panels). 
Yet another assay to support the interaction between two proteins in living cells is co-
localisation in immunofluorescence. To this end, the Cwt was tagged with TagRFP, depicted 
as red fluorescence in the figure, to be able to detect it easier, without having to rely on 
antibodies. TagRFP overexpressed in Hep2 cells is a cytoplasmic protein (Fig. 21 A). If the 
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Cwt protein is fused N-terminally to TagRFP, the prominent nuclear localisation of the 
resulting fusion protein is comparable to the localisation of the Cwt protein without the 
fluorescent tag (Fig. 21 B). The flag tagged proteins were stained using a flag antibody and an 
Alexa-488 conjugated secondary antibody, appearing as green in the figure.  The nuclei were 
stained with ToPro3 and coloured in blue. Co-localisation of the two overexpressed proteins 
would result in a yellow colour appearing in the merge images at the respective sites of co-
localisation.  
 
Figure 21: Immunofluorescent images to detect co-localisation between C and various 
proposed binding partners.  
All proteins indicated were overexpressed in Hep2 cells and stained using their tags (flag, green 
fluorescence) or were fluorescently tagged (TagRFP-Cwt, red fluorescence).  The flag tagged 
proteins were stained using anti-flag antibodies and anti-mouse Alexa 488 as a secondary 
antibody. The nuclei were stained using ToPro3. (A) Overexpression of Tag-RFP alone and (B) 
overexpression of TagRFP-Cwt. The following proteins were overexpressed with or without 
TagRFP co-expression as indicated in the figure: IPS-1 (A), DDB1 (B), IRGM (C), MAP1B (D) 
or PSMC3 (G). A co-localisation is indicated by a yellow colour in the merge images.  
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Overexpressed flag-IPS-1 was detected in Hep-2 cells clearly as a typical 
mitochondrial distribution in the cytoplasm. In some cases also the aggregations formed by 
activated IPS-1 were visible in the staining, hinting that the overexpressed IPS-1 still has the 
endogenous localisation and function. TagRFP-Cwt showed no clear co-localisation with flag-
IPS-1 (Fig. 21 C). Upon overexpression, flag-DDB1 was found to be evenly distributed in the 
cytoplasm of the cells. As it is the case with IPS-1, no clear co-localisation with TagRFP-Cwt 
was visible after co-expression of both proteins in the same cells (Fig. 21 D). Flag-IRGM 
localised to the cytoplasm of the transfected cells as well as partially to the nucleus. However, 
when TagRFP-Cwt and fl-IRGM were co-expressed in the same cell both altered their 
intracellular localisation. They co-localised in a peri-nuclear space, the TagRFP-Cwt protein 
was recruited from the nucleus to the cytoplasm, whereas fl-IRGM accumulated at the exact 
same spot. Overexpressed fl-MAP1b was distributed in the cytoplasm like DDB1, only the 
outer nuclear rim seemed to be stained more intensively. Upon co-expression of Tag-RFP-
Cwt and fl-MAP1b, both proteins retained their localisation and did co-localise only in a few 
small cytoplasmic dots. The 19S proteasomal component PSMC3 was detected upon 
overexpression only in the cytoplasm of the cells, although the 19S subunit was reported to 
reside in the nucleus of cells (von, 2006). Co-expression of TagRFP-Cwt and flag-PSMC3 led 
to a recruitment of TagRFP-Cwt out of the nucleus into the cytoplasm to co-localise partially 
with PSMC3. 
 
In summary the interaction of Cwt with IRGM and PSMC3 could be shown as a co-
localisation and change in localisation of the individual proteins in confocal images of living 
cells expressing both proteins. For MAP1B a co-localisation can be found in a few specific 
cytoplasmic dots, but the overall localisation of C and MAP1b differed. IPS-1 and DDB1 did 
not co-localize in the experiments shown here. 
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3. Analysis of MV C in the viral context 
 
MV C has an important role during the course of infection, most probably by 
regulation of replication and transcription (Devaux and Cattaneo, 2004; Ito et al., 2013; Toth 
et al., 2009). However, it has to be concluded now, that in addition to the modulation of viral 
polymerase activity, C is also able to bind to cellular proteins and to modulate host cell 
behaviour and response. Several approaches were used to elucidate the role of the C protein in 
MV infected cells focusing on the alteration of cellular pathways during infection as well as 
viral protein-protein relations. 
To this end, MV virus cDNA were cloned and recombinant virus rescued from this 
cDNA (Fig. 22). The basis for all engineered cDNAs was the full-length genomic cDNA of a 
vaccine measles virus with a sequence identical to the Schwarz vaccine strain: vac2 (del Valle 
et al., 2007). C expression from the virus can be abrogated by introducing mutations into the P 
gene to mutate the C translation start codon, as well as introducing two stop codons 
downstream. The introduction of more than one single nucleotide change is necessary to 
avoid a reverting of the virus back to C expression, due to evolutionary pressure. The 
mutations were the same as introduced into the plasmids to abrogate C expression; details are 
depicted in Fig. 1R. To express mutants of C from the viral genome, the C coding sequence 
has to be isolated from the P gene otherwise the alterations made or tags added in the P gene 
would affect all three encoded proteins: C, V and P. Therefore an additional transcription unit 
(ATU) was inserted in the backbone of the vac2 strain cDNA by duplicating the P gene 
borders (pMV vac2-ATU) (Fig. 22 C). The MV gene border transcription start signal 
(CTTAGG) is placed after the P gene polyA signal, to ensure polyadenylation of the P gene 
encoded mRNAs and a proper transcription start for the ATU. The very same poyladenylation 
signal was then introduced after a multiple cloning site. Consequently rMV vac2-ATU 
expresses a small non-coding RNA from the ATU. The multiple cloning site can be used to 
introduce new open reading frames by standard cloning techniques. This vector can be 
combined with mutation in the P gene abrogating C expression. In addition to a knockout of C 
in the original P gene, the C protein and its mutants can now be inserted in the ATU and are 
expressed from the additional transcription unit after virus rescue. In the following 
fluorescence studies, ORFs of TagRFP tagged C constructs as depicted in the figure were 
inserted into the MV vac2-ATU (Fig. 22 C). It was also possible to revert the Cs defect NLS 
to the wildtype NLS by inserting a point mutation into the P gene, which induces a G44 to R 
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transition in C but only a conservative R50K mutation in the P and V N-terminus, which is 
also present in the wildtype isolate D5 (Fig. 22 D). This virus is called rMV vac2CwtNLS. 
 
Figure 22: Scheme representing the genomes of recombinant MVs generated during this 
thesis.  
The genome is depicted in 3‘-5‘orientation (leader-trailer) and the open reading frames within 
the genome highlighted as boxes. The respective encoded protein names are indicated in these 
boxes. (A) MV vac2: rMV retaining the unchanged vac2 sequence. (B) MV vac2Cko: rMV with 
the vac2 sequence and silent mutations in the P gene to abrogate C expression (deletion of the 
start codon and introducing two stop codons). These mutations are detailed in Fig.6. (C) The 
additional transcription unit (ATU) is generated by a duplication of the P gene border between 
the P and the M gene. The important nucleotides are highlighted in the figure. For cloning 
purposes a multiple cloning site was inserted into the ATU. MV vac2 – ATU: rMV vac2 with an 
additional transcription unit between the P and the M gene. The gene borders of the P gene are 
duplicated and a non-protein coding multiple cloning sites for cloning purposes inserted. MV 
vac2 – Cko – ATU: rMV vac2- ATU with additional mutations in the P gene similar to rMV 
vac2-Cko to abolish C expression. MV vac2-Cko-TagRFP-Cwt/s/wtmNLS/swtNLS: rMV on the 
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basis of rMV-Cko-ATU with an open reading frame inserted in the additional transcription unit. 
Here it encodes for the different TagRFP tagged C proteins. (D) MV vac2CwtNLS: rMV having 
the sequence of the MV Schwarz strain, except for one conservative mutation (R50K) in the P 
gene, introducing a G44R exchange into C to restore the wildtype nuclear localisation signal. P 
and V are also affected by a R50K in their common N-terminal domain.  
The rescue was done by transfecting full length cDNA and MV L-encoding plasmids 
into 293-3-46 cells, co-culturing them with Vero-hSLAM cells until syncytia formation from 
individually rescue events was visible as described in the introduction. These syncytia were 
picked and isolated and grown on Vero cells. The titration of all the viruses were done on 
Vero cells (see introduction Fig. I3). The rescue of recombinant virus from all the cDNA 
constructs depicted in Fig. 22 was successful. 
3.1. Host transcription regulation induced by rMV vac2 infection 
To get an overview how the host cell reacts on an RNA level to an infection by MV, 
microarray experiments were conducted using rMV vac2 infected B-cells. The viruses used 
for these experiments were purified by pelletation to remove any cytokines from the 
supernatant of the stock-producing cells, which could alter the behaviour of infected cells. A 
B-cell line (DG75) was chosen to represent a cell type which is naturally infected in its host 
by wildtype measles virus as well as the vaccine strains. The changes in the total mRNA 
content compared to mock infected cells were subsequently analysed (Fig. 23). They are 
represented as fold changes of the viral infected cells compared to the mock infected cell 
population harvested at the same timepoint. Two distinct timepoints were analysed: 24h and 
48h post infection with rMV vac2 using an MOI of 1. The total cellular RNA content then 
was hybridized on Affymetrix Human GeneChip 1.0 arrays and these arrays then analysed for 
binding of cellular RNAs in the microarray facility of the Cramer group (Genecenter, 
Munich).  
The RNAs detected were 81 fold upregulated or 6 fold downregulated at most 
compared to mock infected cells after 48h of infection. The differentially regulated cellular 
RNAs (regulation > 2, p < 0.5) could be clustered into three basic clusters according to their 
regulation in infected cells over time: Genes which were downregulated (Fig. 23 A), genes 
which were upregulated (Fig. 23 B) and genes which were strongly upregulated temporarily 
after 24h, but then declined after 48h  (Fig. 23 C).  
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Figure 23: RNAs regulated by infection with MV vac2 at different timepoints in human B-
cells.  
DG75 cells were infected with MV vac2 at an MOI of 1 and the total RNA harvested after 24h 
and 48h subjected to microarray analysis. (A, B, C) Clusters of regulated RNAs according to the 
scheme above the lists. The official gene symbol and the affymetrix ID of the probes on the 
microarray are display in the first two columns of the table. The last two columns indicate the 
fold changes of the RNA detected in comparison to mock infected cells after 24h or 48h. 
Negative values mean a downregulation, positive values an upregulation. The colour coding was 
done according to the blue-white-red scheme, blue meaning downregulation, red meaning 
upregulation. The RNAs displayed showed at least 2 fold regulation and have a p value smaller 
than 0.5. Only parts of the regulated genes are displayed here, representing the highest changes 
compared to mock. The complete list of significantly regulated RNAs clustered and unclustered 
is in the appendix. This experiment represents duplicates. (D) Detection of the L mRNA of 
measles virus in the samples and relative quantification by qRT-PCR. At 24h the amount of L 
mRNA was to 1, the value for 48h p.i calculated relatively. The values represent the mean of the 
duplicates. The mock infected control was negative for L mRNAs and is therefore not displayed 
here. 
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The infection was monitored by quantitative realtime PCR using primers specific for 
the MV L mRNA (Fig. 23 D) and the 24h value was set to 1, as L mRNA could not be 
detected in mock infected cells. After 48h, the intracellular content of MV L mRNA doubled, 
indicating that viral multiplication indeed took place. 
To characterize these clusters in further detail, pathway analysis was performed using 
the web based DAVID bioinformatics server. The first cluster could not be annotated 
automatically (Fig. 24 A). However, it is obvious that most of these are small nucleolar RNAs 
(SNORDs). Some of these SNORDs play an important role in the 2’-O-methylation pathway, 
especially the mainly downregulated SNORDs: 78, 26 and 50B. 4-Hydroxyphenylpyruvate 
Dioxygenase-Like (HPDL), the second most downregulated RNA is largely uncharacterized 
in literature. RAB3A mRNA encodes a Ras-related protein involved in exocytosis probably 
by regulating a late step in synaptic vesicle fusion (Zahraoui et al., 1989). 
The upregulated genes (Fig. 23 B) can easily be characterized as interferon and 
infection stimulated genes (Fig. 24 B), their products representing chemotactic signals for 
immune cells. Most of these genes encode proteins that are classical interferon stimulated 
genes (ISGs): e.g. IFIT1, IFIT2 or chemokines (CCL5, CXCL11 & 10). These are part of the 
typical inflammatory and anti-viral response of a cell and are used to attract the adaptive 
immune system or as an alert signal to neighbouring cells.  IFIT1 binds triphosphorylated 
RNA and inhibits expression of 2’ O-methylation defective RNAs along with IFIT2. They 
both exhibit direct antiviral activity (Zhou et al., 2013). Secreted CCL5 attracts blood 
monocytes, memory T helper cells and eosinophils, whereas CXCL11 and 10 are 
chemotactics for T cells mainly. Notably, the upregulation of the interferon beta mRNA is 
significant only after 48h to a value of 6-fold, which is fairly low, compared to a 81-fold 
induction of IFIT2.  
Interestingly, the third cluster of genes (Fig. 23 C) contains genes responsible for 
amino acid metabolism and biosynthesis (Fig. 24 C). Unfortunately there is no annotation for 
FAM106A (Family With Sequence Similarity 106, Member A), and its function remains 
unknown. Phosphoserine Phosphatase (PSPH) plays an important role in the biosynthesis of 
serine, catalysing the last step of L-serine formation. Solute Carrier Family 7 (Anionic Amino 
Acid Transporter Light Chain, Xc-System), Member 11 (SLC7A11) is an amino acid carrier 
specific for glutamate and cystein.  Cation Transport Regulator Homolog 1 (CHAC1) is a 
negative regulator of the notch signalling pathway.  The Cystathionase (CTH) protein 
catalyses the conversion of cystathione into cysteine and therefore is also involved in amino 
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acid metabolism. For ROCK1P1 (Rho-Associated, Coiled-Coil Containing Protein Kinase 1 
Pseudogene 1) no detailed annotation or description could be found. 
 
Figure 24: Functional annotation and clustering of the RNAs found to be regulated more 
than 2-fold in microarray experiments.  
Three different clusters were made according to the regulation of the RNAs over time (24h and 
48h post infection) and the list of genes submitted for functional annotation and clustering using 
the DAVID websuite. The full profiles are in the appendix. The pathways are indicated next to 
the different clusters (A, B and C as in Fig. 23), Count displays the number of genes matching to 
the pathway which represents the percentage fraction in the next column. Both the p-value and 
benjamini are indicators of the significance of the overrepresentation of the pathway in the subset 
of genes submitted for analysis. 
In summary, MV infection of B cells induced the expected innate immunity responses 
apparently, lacking however a robust induction of interferon beta. Notably, the transcription 
of genes coding for small nucleolar RNAs was severely downregulated. 
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3.2. MV Cko viruses are heavily attenuated 
The first step approaching the function of the C protein in a viral context is the knock-
out of the C ORF from the P and V mRNA. This was done in a similar fashion to the 
generation of the plasmids coding only for the P and the V protein (see Figure 6). The P gene 
was mutated within the full-length viral cDNA vector. This mutated cDNA vector was then 
used for rescuing rMV vac2Cko. MV lacking the expression of the C protein are heavily 
attenuated albeit viable and were reported to induce more interferon than their parenteral 
viruses (Devaux and Cattaneo, 2004; Devaux et al., 2008; Nakatsu et al., 2008).  
A comparative growth curve in Vero cells of rMV vac2 and rMV vac2Cko revealed 
that the Cko virus indeed grows to titres approximately 1-1.5 logs lower than the parental 
strain (Fig. 25 A). Interestingly the cytotoxic phenotype observed after 72h in Vero cells was 
notably more pronounced in cells infected with MV vac2Cko, although the infectious viral 
titres were lower at that timepoint. At the last timepoint, rMV vac2Cko seems to catch up to 
rMV vac2. Comparing interferon competent (A549) and interferon incompetent (Vero) cell 
lines (Fig. 25 A and B), it can be concluded that rMV vac2Cko is greater attenuated 
(approximately 2 logs) in a cell line which still has a functional innate immune system. In 
addition to that, A549 cells survived the infection with the rMVs, whereas the Vero cells were 
completely dead 96h post infection. Syncytia formation was observed only to a low degree in 
A549 cells, whereas the Vero cells showed a high syncytia formation ratio. The overall titres 
of infectious rMV particles in Vero cells were at all timepoints generally higher compared to 
A549 cells (around 1 log), again underlining the difference between those two cell lines. 
Notably, a decrease of infectious virus titres in cells is earlier visible in A549 cells (after 48h) 
than in Vero cells (after 72h), although the Vero cells die earlier. 
A lack of expression of the C protein during infection was also confirmed on the 
western blot of lysates of Vero cells infected with rMV vac2, rMV vac2Cko and mock. 48h 
after infection P and V as well as N are normally expressed and can be detected in the lysates 
of both virus infected Vero cells. However, only rMV vac2Cko failed to produce the C protein, 
confirming that the knockdown was successful. Importantly, only the C protein is affected and 
not the other two proteins encoded by the P gene, P and V (Fig. 25 C). 
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Figure 25: Characterisation of C knockout MV vac2.  
Growth curves of MV vac2 and MV vac2Cko in interferon negative Vero cells (A) and interferon 
competent A549 (B) cells. Viral titres were measured at the indicated timepoints. (C) Western 
blot analysis showing the lack of MV C expression by rMV vac2Cko. Vero cells were infected 
with the indicated viruses and the cells harvested 48h p.i.. Specific antibodies were used to detect 
the viral proteins. (D) qRT-PCR of infected A549 cells 72h post infection with an MOI of 0.01 
comparing rMV vac2 and rMV vac2Cko. Three RNAs were quantified: the cellular IFN-β and 
GAPDH mRNAs and the viral N mRNA. 4 different normalisations were done, using the ratios 
indicated on the y-axis of the charts, effectively showing the higher induction of interferon β in 
Cko viruses. The mean values of three replicates are shown, with the mock value set to 1 if 
possible or the value for rMV vac2 set to 100 (%) and the remaining values calculated 
accordingly. 
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To further characterize the differences of rMV vac2 and rMVCko focusing on the 
innate immune system, quantitative realtime RT-PCR was performed to compare the 
induction of interferon caused by the two rMVs during infection. Overall, rMV vac2 infection 
with the same MOI induced more interferon β mRNA after 72h. However, rMV vac2Cko also 
shows a reduced transcription of N mRNA, indicating a slower growth, which has to be taken 
into account. Normalisation of the interferon β mRNA levels with the MV N mRNA levels 
revealed, that the induction of IFN-β mRNA per viral N mRNA is 4.5 times higher for rMV 
vac2Cko. MV vac2 seemed to cause a growth arrest in A549 cells as more cellular RNA could 
be purified from rMV vac2Cko and mock infected cells than rMV vac2 infected cells. 
Normalisation using GAPDH mRNA was therefore also carried out, still showing that rMV 
vac2Cko induces relatively more interferon β mRNA than rMV vac2 (Fig. 25 D), albeit the 
effect is less pronounced. These qRT-PCR experiments are in accordance to results published 
by other groups (McAllister et al., 2010; Toth et al., 2009). 
Aberrant RNA production induced by the lack of a C protein could lead to various 
effects, ranging from increased read-throughs of different genes or the generation of dsRNA. 
To analyse the viral RNAs produced by the rMV vac2 and rMV vac2Cko in comparison, 
Northern blots were done. 4µg of the total RNA of infected Vero cells was separated on 
agarose gels according to their size. Within the total cellular RNA the MV mRNAs and 
transcriptional products were detected on nylon membranes by hybridisation of MV specific 
radioactively labelled oligonucleotides.  
Four different probes were used to detect MV specific RNAs (N, P, H and F 
sequences) and one cell-specific probe (actin) to visualize the amount of cellular RNA present 
in the preperations (Fig. 26 A). The calculated sizes of the expected mRNAs and readthrough 
RNA products are listed in the right panel, next to the northern blot (Fig. 26 A). These 
calculations do not include the polyA sequence, which elongates the mRNAs by 
approximately 200 A nucleotides. Identification of the mRNAs and other RNAs was done 
according to their length and strength of the signal. If not stated otherwise, the bands 
described for the viral RNAs were visible in both the lanes for rMV vac2 and rMV vac2Cko 
infected cells, and specifically not in the mock control lane. 
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Figure 26: Northern blot and detection of viral RNAs from rMV vac2 and rMV vac2Cko 
infected cells.  
(A) Radioactively labelled probes for different mRNAs (MV N, P, H, F and the cellular mRNA 
actin) were used to detect viral RNA in total RNA extracts from infected and mock infected Vero 
cells as indicated above the respective blots. The infections were done with an MOI of 0.5 and 
the cells harvested 36h post infection. The viral mRNAs are indicated with small yellow arrows. 
In the left panel the sizes of the marker are displayed in kilobases. The blue lines represent a 
continuation of the marker on the original gel to indicate the sizes of the detected mRNAs. In the 
right panel the calculated sizes of the expected RNAs are indicated in bases. E.g. F-H indicates 
the readthrough of the MV F and H mRNA. These calculated sizes do not include the polyA tail, 
which additionally elongates these RNAs by ca. 200 bases.  (B) Quantification of the indicated 
bands from the northern blot in A. The bands for the mRNAs (yellow arrows) were quantified 
using ImageJ and normalized to the actin control. The values for vac2 mRNA is always set to 
100% and the mRNA amount for rMV vac2Cko calculated accordingly.  
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On the N probe blot, the N mRNA could be detected as the most prominent band with 
a size of approximately 1.7kb. A second band at 3.5 kb corresponds to the size of N-P 
readthrough mRNA, a third at ca. 5kb to the N-P-M readthrough mRNAs. The longer the 
readthrough is the fainter the bands are and the less abundant the RNAs are. In the case of the 
MV P specific probe, the P mRNA was most prominently detected. As for the N blot, both N-
P and N-P-M readthrough transcripts were visible as well at the exact same height. 
Additionally, at 3.2 kB the P-M readthrough transcript could be detected. The MV H specific 
probe worked less well, however the H mRNA was still detected. A faint band of an H-F 
readthrough transcript can be seen at 4.5 kB. In the case of the F specific probe, a multitude of 
bands was detected, the most abundant transcript being the F mRNA at 2.5 kB. A potential F-
H readthrough RNA of 4.5kB was also visible; no F-L transcript could be detected. The other 
bands at 1.5, 2 and 4 kB however could not be attributed to an RNA species expected. 
Especially the bands appearing at a lower height than the F mRNA indicate truncated or 
degraded F transcripts in the preparation. A general degradation of the RNA however, was not 
visible in the other blots. These additional bands, seen in the F blot are specific for the 
infected cells, as they do not appear in the mock infected cellular RNA. 
The actin mRNA blot revealed that in the mock control cells the most cellular RNA 
was present, whereas in the case of the rMV vac2 infection the cells already have decreased 
actin mRNA content. This correlates with the expected beginning of cell death after 36h of 
infection. To a lesser extend the effects of infection caused cell death were also seen in the 
rMV vac2Cko infected RNA preparation.  
Unfortunately, in neither of these blots the genomic or antigenomic RNA was visible, 
which would appear at a size of approximately 16kB.  
Quantification of the bands using ImageJ (Fig. 26 B) further confirmed the visual 
impression that rMV vac2Cko compared to rMV vac2 produces less mRNAs. The amount of 
mRNAs (N, P, F and H) normalized to the actin control is generally around 80% lower in 
cells infected with rMV vac2Cko. Interestingly, the differences of the mRNA content of the 
more 3’ genes (N, P) between rMV vac2 and rMV vac2Cko seems to be greater than that of 
the more 5’ genes (F, H). This could possibly indicate a change in the mRNA transcription 
gradient. 
Judging from the overall mRNA levels in the preparation, the result of the growth 
curves could be confirmed. rMV vac2Cko grows slower and consequently produces less 
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mRNAs than the rMV vac2. However, no alterations like a different mRNA readthrough 
transcript composition were visible other than a lower general abundance of viral RNAs. The 
ratio between genome and mRNA production could not be calculated, as the genome could 
not be detected. 
3.3. The localisation of C during infection 
The localisation of MV C during infection was reported to be either in the nucleus or 
in the cytoplasm (Bellini et al., 1985; Nishie et al., 2007).  
To assess the localisation of the C protein during the actual infection, several confocal 
approaches were used. 48h after infecting Vero cells with rMV vac2, the C and N protein 
were stained using fluorescent antibodies (Fig. 27 A). Clearly, the C protein (depicted in 
green) co-localized with the N protein (depicted in red) during these late stages of infection 
(48h p.i.). An obvious nuclear accumulation is not visible (nuclei in white). This was expected 
in the case of the C protein of the vaccine strain of measles virus. However, compared to the 
observed localisation of C during overexpression a notable change are the inclusion bodies or 
stress granules formed by C and N. Clearly visible however, is the syncytia formation caused 
by MV infection (bottom images). The nuclei of the fused cells are still intact and cluster in 
the middle of these giant cells. Infection of Vero cells with wildtype virus failed, and cells 
that could be infected with wildtype virus proved to be difficult, if not impossible, to stain 
with antibodies. 
Timepoints earlier than 48h p.i. could not be imaged. Later timepoints have to be done 
using lower MOIs in order to avoiding a complete destruction of the cell monolayer. 
Therefore, plasmids encoding TagRFP-tagged Cwt protein were transfected into cells and 
afterwards infected with GFP expressing rMV vac2 (rMV vac2-GFP) (Fig. 27 B). The GFP 
expression was used to monitor the infection while localisation changes in TagRFP-Cwt were 
visible without having to rely on antibody staining. In non-infected, plasmid expressing cells, 
TagRFP-Cwt localises exclusively to the nucleus. In infected cells, two different situations 
could be seen: In some GFP and TagRFP positive cells, TagRFP-Cwt still resided in the 
nucleus, whereas in some cases TagRFP-Cwt was recruited to the cytoplasm where it formed 
inclusion bodies. These inclusion bodies are also visible in the GFP staining, as GFP seems to 
be recruited to these sites as well. They represent probably the same inclusion bodies seen 
with N antibodies previously. Notably, a recruitment of C to the cytoplasm only occurred in 
cells, where the GFP inclusion bodies were already visible.  
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Figure 27: Intracellular localisation of C and mutants in the viral context. 
(A) Immunofluorescent staining of MV C and N in Vero cells infected with MV vac2 48 p.i.. C 
protein was stained with anti-1442 C antibodies and anti-rabbit Alexa-488 secondary antibodies 
(green). MV N was stained using anti-MV N (mouse) and anti-mouse Tetramethylrhodamine as a 
secondary antibodies (red). The nuclei were stained with ToPro3 (white). The respective proteins 
detected are indicated above the images. Merge represents the overlay of all three channels, a 
yellow colour indicating colocalisation. (B) Hep2 cells transfected with a plasmid encoding 
TagRFP-tagged Cwt and infected with rMV vac2-GFP. 24 p.i. the cells were fixed and the 
images taken. The nuclei were counterstained using ToPro3 (blue). Green indicates the 
fluorescence of GFP, whereas red indicates the presence of TagRFP-Cwt. (C) Intracellular 
localisation of TagRFP-C variants expressed from the recombinant measles viruses indicated 
next to the images. HeLa cells were infected with the indicated viruses using an MOI of 1 and 
confocal images takes 24h p.i.. A red fluorescence indicates the presence of the TagRFP-tagged 
proteins. HAL annotated images depict the cells using normal phase contrast light microscopy. 
Merge represents the overlay of the two images. 
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To visualise the intracellular localisation of C expressed by the virus, recombinant 
viruses were generated as described before (Fig. 22 C). These rMVs harbour TagRFP-tagged 
C variants in the additional transcription unit, while expression of the original C from the P 
gene is knocked out (see above). All of these constructs could be rescued and showed bright 
red fluorescence, indicating the localisation of C during infection. For control purposes, rMV 
encoding only TagRFP in the additional transcription unit was used to infect HeLa cells. 24h 
after infection TagRFP fluorescence was visible in the whole cytoplasm and the nucleus, 
showing no distinct localisations (Fig. 28 C). Fluorescence of rMV vac2Cko-TagRFP-Cwt, 
however, could be detected in both the nucleus and cytoplasmic inclusion bodies, whereas the 
TagRFP-Cs expressed by rMV vac2Cko-TagRFP-Cs was only found in the inclusion bodies in 
the cytoplasm.  TagRFP-CwtmNLS encoded by rMV vac2Cko-TagRFP-CwtmNLS was also 
located exclusively to the cytoplasmic inclusion bodies and completely removed from the cell 
nucleus. TagRFP-CswtNLS instead was present in the nucleus as well as in the cytoplasmic 
inclusion bodies, in a similar fashion to TagRFP-Cwt. Interestingly, the nuclear C protein 
fraction seemed to additionally accumulate in the nucleoli of infected cells. 
These localisation studies indicate that the different C proteins behave, even when 
expressed from a recombinant virus, in accordance with the data observed for protein 
overexpression. One major difference however, was the occurrence of cytoplasmic inclusion 
bodies in all viruses, which do not show up during overexpression of the C proteins alone. 
 
The re-localisation of MV Cwt which is observed upon infection suggests that a viral 
protein or RNA is responsible for that. Alternatively any cellular protein induced during 
infection could be responsible for the alteration in MV C localisation. It is known from 
previous studies that co-expression of MV N and P results in the formation of cytoplasmic 
inclusion bodies containing both P and N, similar to those observed during infection.  
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Figure 28: Immunofluorescent images of MV N, C and P co-expression.  
Hep2 cells were co-transfected with plasmids encoding the MV proteins indicated in the table 
left of the images. The vac2 N protein was detected using anti-N-FITC antibodies (green). The C 
proteins (wildtype D5 (A) or schwarz (B)) were tagged with TagRFP at the N-terminus (red). 
The flag-tagged vac2 P protein was detected using flag antibodies and anti-mouse Alexa 633 as 
secondary antibodies (blue). The respective proteins detected are indicated above the images. 
Merge represents the overlay of all three channels, a yellow or purple colour indicating co-
localisation. (C) Co-immunoprecipitation experiments of MV Cwt and Cs with MV flag-P. 
The pulldown experiments were done using a flag-antibody coated matrix and lysates from 293T 
cells and were transfected with plasmids encoding for the proteins indicated above the Western 
blots. The whole cell lysates before the immunoprecipitation experiments were analysed by 
western blots as well as the IP and the Co-IP blots as indicated in the figure. The percentage 
indicates the relative amounts of WCL and the IP loaded on the gel. The blue arrows highlight 
the faint band for HA-MV C in the co-immunoprecipitation Western blot, the stronger band 
above is unspecifically detected by the antibody. HA-antibodies and flag-antibodies were used 
for the detection of the tagged proteins as indicated next to the blots. 
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To test, whether co-transfection of MV N or P also induces a localisation change for 
Cwt, immunofluorescence experiments were conducted. Indeed, a triple overexpression of 
MV C, N and P showed a clear co localisation of those three proteins in dots, which look like 
cytoplasmic inclusion bodies in the cells (Fig. 28). This is the case for both Cwt (Fig. 28 A) 
and Cs (Fig. 28 B). Overexpression of N and P results in the expected co-localisation and 
inclusion body formation. Interestingly, both P and N showed a cytoplasmic distributed 
localisation upon individual overexpression, while Cwt retained its nuclear localisation and 
Cs the cytoplasmic-nuclear distribution. Co-expression of MV C and N did not result in any 
localisation change of both proteins. Surprisingly, however, MV P and C co-expression 
clearly showed the inclusion body formation with C and P co localising in the cytoplasmic 
aggregations. Thus, P alone is sufficient to recruit Cwt or Cs completely to the cytoplasm and 
together they are able to induce dots or cytoplasmic aggregates during infection even in the 
absence of MV N. These dots resembled the inclusion body formation observed during 
infection, but were much smaller. 
Consequently the binding of Cwt to MV P was checked by co-immunoprecipitation. 
And indeed C was able to bind to P in these experiments; however the interaction seemed to 
be very weak, suggesting an indirect binding (Fig. 28 C, blue arrows). 
In summary, expression of MV P is sufficient to recruit C to the cytoplasm where they 
both form granules, regardless whether C is derived from the vaccine strain or the wildtype 
strain. MV P and Cs/wt can interact, as seen in co-immunoprepitations, although very weak. 
3.4. Characterisation of C and its NLS in the viral context 
The rMV vac2Cko virus has many defects regarding replication to be useful as an 
immediate tool to study the details of the influence of the C protein on the host cells. These 
defects could lead to unwanted variables regarding the interferon induction, like aberrant 
production of stimulating RNAs. Therefore, it is necessary to try different mutants of C (e.g. 
NLS mutants) to assess the effects of the differently regulated C localisation in a viral context 
during infection.  
To this end, two recombinant viruses were used: rMV vac2, the authentic recombinant 
vaccine strain and rMV vac2CwtNLS a recombinant virus which has only one point mutation 
compared to rMV vac2 in the P gene (Fig. 22 D). This point mutation causes the expression of 
a C with a restored wildtype NLS similar to CswtNLS mentioned above (G44R).  
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Comparing rMV vac2 with rMV vac2CwtNLS no differences in growth were 
observed in interferon gene negative Vero cells. In the interferon competent A549 cells these 
viruses also grew almost similar, diverging however at later timepoints for up to 0.5 logs. 
Interestingly, the rMV vac2 seems to grow slower than rMV vac2CwtNLS (Fig. 29 A). The 
experiments were done in parallel using the same virus stocks for infection, to ensure 
comparability.  
 
Figure 29: Comparison of rMV vac2CwtNLS and rMV vac2.   
(A) Growth curves of rMV vac2CwtNLS in comparison to rMV vac2. Two different cell lines 
were used for growth comparisons: interferon negative Vero cells (top panel) and interferon 
competent A549 cells (bottom panel). Viral titres were measured after the indicated timepoints. 
(B) qRT-PCR of rMV vac2, rMV vac2CwtNLS and mock infected A549 cells 12h post infection 
with an MOI of 10 comparing rMV vac2 and rMV vac2Cko. Three RNAs were quantified: the 
cellular IFN-β and GAPDH mRNAs and the viral N mRNA. 4 different normalisations were 
done, using the ratios indicated on the y-axis of the charts. The mean values of two replicates are 
shown, with the mock value set to 1 if possible or the value for rMV vac2 set to 100 (%) and the 
remaining values calculated accordingly.  
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Quantitative realtime PCR experiments were performed to compare the IFN-β mRNA 
induced upon infection of A549 cells with rMV vac2 or rMV vac2CwtNLS. The cells were 
infected with an MOI of 10 and harvested after 12h. The mRNA levels of interferon β, 
GAPDH as a normalisation control and measles virus N as the infection control were 
quantified. The amount of interferon β mRNA normalised to GAPDH mRNA induced by 
rMV vac2 was higher than in the case of rMV vac2CwtNLS (Fig. 29, B). The infection 
however was equal or even slightly higher in the case of rMV vac2CwtNLS as indicated by 
the MV N mRNA content normalised to GAPDH mRNA. A higher MV N mRNA content is 
thought to correspond to a higher PAMP generation by intracellular measles virus replication 
as well as a higher growth rate. Therefore a normalisation was done for interferon β mRNAs 
on GAPDH mRNAs and the MV N mRNA. In this analysis the difference between both 
strains is even more obvious; the induction caused by rMV vac2 was up to 50% higher. 
Taken together, these experiments indicate behaviour of these two different viruses 
(rMV vac2 and rMV vac2CwtNLS) according to what was observed in the protein 
overexpression assays. rMV vac2CwtNLS seems to grow better in interferon competent cells, 
while the induction of interferon β mRNA was lower after 12h of infection.  
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DISCUSSION 
 
1. The impact of MV infection on host transcription 
 
Analysis of the whole RNA content of cells after infection with rMV vac2 and a 
harvest after 24h and 48h revealed that several cellular genes are regulated in different ways. 
This regulation can be either a response of the cell to eliminate the invading pathogen, or an 
active regulation induced by the virus. Both possibilities however, cannot be fully separated in 
the data presented here.  
As commonly observed in infections, the upregulation of ISGs, namely cytokines and 
IFITs is a response of the cell to the infection. Due to the infection with an MOI of 1, not all 
cells are infected after 24h or even 48h of infection. Therefore, the little interferon and 
cytokines released by the infected cells, could elicit a huge response in the non-.infected cells. 
In the infected cells however, the whole extend of the response would be limited by the 
presence of V and P. The cytokine response as well as the interferon response was expected. 
Interestingly, small nucleolar RNAs seemed to be measles virus infection specifically 
downregulated, up to 6 fold after 48h. Notably, C seems to accumulate in nucleoli during 
infection, prompting the suggesting, that it can possibly modulate or degrade snoRNAs there. 
The lot of these snRNAs found to be downregulated are involved in the 2 O’ methylation 
guidance (Maden and Hughes, 1997). 2’-O methylation of the mRNA cap is an important 
marker to discriminate cellular RNAs from viral RNAs, which supposedly lack these 
modifications. This methylation could be an important mechanism discriminating self and 
non-self mRNAs, and mRNAs lacking this methylation were proposed to be MDA-5 inducers 
(Zust et al., 2011). For measles virus it was reported that the cap structure of the RNA is 
identical to the cellular mRNAs, though 2’-O methylation was not tested (Yoshikawa et al., 
1986). A putative 2’-O methyltransferase domain however, was identified within the viral 
polymerase L (Ferron et al., 2002). In contrast to the prediction, a closely related virus, RSV 
was reported to produce mRNAs that lack 2’-O methylation (Barik, 1993). Regarding the 
microarrays, a downregulation of 2’-O methylating guidance enzymes could either result in a 
general lower abundance of correctly modified RNAs or a lower specificity of the methylation 
machinery in general. The former possibility would supposedly induce the innate immune 
system, especially MDA-5. In the case of a MV infection, the involvement of the snoRNA 
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guidance in 2’-O methylation seems highly unlikely. The replication and viral RNA 
production occurs in the cytoplasm of infected cells, whereas the 2’-O methylation machinery 
is located in the nucleoli. Therefore, the role of the downregulation of snoRNAs during MV 
infection remains speculative. Unfortunately only one other study regarding microarrays and 
measles infection is available up to date (Bolt et al., 2002). In this paper, human PBMCs were 
infected with wildtype and Edmonston MV, and the response of the cell differed in respect to 
the innate immunity response. The vaccine MV was able to upregulate the host genes stronger 
than the wildtype variant. Specifically, innate immunity related proteins, chaperones, 
transcription factors and other proteins of the endoplasmic reticulum stress response were 
found to be upregulated. This supports the data obtained in the results presented here, with the 
exception of the snoRNAs, which were supposedly not detected by the microarray they used.  
 
2. MV C is a nuclear inhibitor of innate immunity – alone and 
during infection 
 
The C protein of measles virus was initially characterised as a modulator of viral 
replication and transcription. In addition to these functions, C influences cellular signalling 
cascades as well. Recombinant viruses lacking C expression were reported to induce more 
interferon than their parenteral strains (Devaux and Cattaneo, 2004; Nakatsu et al., 2006; 
Nakatsu et al., 2008) in vitro. In addition to that, it was reported that C is able to prevent the 
phosphorylation and activation of the PKR induction cascade during infection (McAllister et 
al., 2010; Toth et al., 2009). Due to the work presented here, it can be concluded that C is able 
to inhibit the induction of interferon β independently of a viral infection. This inhibition is 
dependent on its nuclear accumulation. Consequently, as production of one of the major 
cytokine is diminished, a proper response of the innate immune system as a whole can be 
weakened by MV C. Previously it was reported that C is also able to inhibit the interferon 
signalling pathway (Shaffer et al., 2003). As a mechanism it was proposed that C binds 
phosphorylated STAT1 and thus sequester it in the cytoplasm (Yokota et al., 2011a). The 
interferon induction inhibition is still visible in STAT1 knockout cells, proving, that the 
blockage of interferon signalling is not responsible for the inhibitory effect on interferon 
induction observed here, via feedback pathways. Therefore it can be concluded that MV C , 
like the V protein (Caignard et al., 2009; Caignard et al., 2007; Lu et al., 2008; Pfaller and 
Interferon induction inhibition by MV C - Discussion 
MV C is a nuclear inhibitor of innate immunity – alone and during infection 
 
 
Page 107  
  
Conzelmann, 2008; Schuhmann et al., 2011) is an inhibitor of both interferon signalling and 
interferon induction. 
Nuclear localisation of MV C was found to be critical for optimal interferon β 
inhibitory function. The nuclear localisation signal therefore defines whether a MV C protein 
is a potent inhibitor of IFN-β or not. Subcellular localisation of the C protein according to its 
NLS is observed after individual expression and in the viral context in infected cell culture. 
2.1. Nuclear localisation of C as a hallmark of wildtype strains 
Previously it was reported that wildtype strains tend to induce less interferon than 
laboratory passaged strains or vaccine strains in cell culture (Kessler et al., 2011; Shingai et 
al., 2007). Consequently, the differences regarding the NLS sequence between vaccine and 
wildtype C proteins can be speculated to be a result of the attenuation and adaption process 
during vaccine generation by passaging on interferon negative cells (Bankamp et al., 2011; 
Schwarz, 1964). Unfortunately, the sequences of the wildtype predecessors of all vaccine 
strains are not available (Rota et al., 1994), so this hypothesis cannot be proven by comparing 
the sequences. By passaging the virus on interferon negative cells it could be possible that a 
mutation in the NLS can be artificially induced. However, introduction of mutation occurs 
randomly, and only afterwards the strains are selected according to their fitness. Therefore it 
is possible, that another mutation in the NLS sequence or elsewhere in the C ORF, 
compromising its function is sufficient to induce a vaccine-like phenotype. The very same 
conditions in which the adaptation happened for the established vaccine strains therefore 
cannot be reproduced. The significance, however, that in 4 supposedly independently 
generated vaccine strains (Edmonston/Schwarz (ENDERS et al., 1962; Schwarz, 1964), Cam-
70 (Athman and Philpott, 2004), Leningrad-4 (Smorodintsev et al., 1960), Shanghai-
191(Xiang and Chen, 1983)) this very mutation is found, is striking. If these strains do not 
share a common origin it would therefore be possible to conduct in vivo attenuation 
experiments resulting in the appearance of a compromised NLS. This would indicate that the 
NLS mutation is a more general feature of attenuation in IFN competent cells, which does not 
result in a growth, or otherwise influences the fitness of the virus in cell culture. Thus, with 
the current vaccine strains and wildtype strains in comparison it can be concluded that the 
NLS of C is able to serve as a marker discriminating the established vaccine strains from the 
wildtype strains in addition to CD46 usage as a receptor. 
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2.2. Comparison of overexpression experiments and infection 
MV C intracellular localisation 
As pointed out before, the C proteins of vaccine viruses do not possess a proper 
nuclear localisation signal. In overexpression experiments it could be shown that its 
intracellular localisation is indeed more in the cytoplasm than in the nucleus. Consequently 
Cwt and the NLS mutations localise according to their NLS, with Cwt being present 
exclusively in the nucleus. During viral infection, the nuclear content of MV C correlated 
with the localisation pattern observed in overexpression experiments. In addition, fractions of 
MV C localised to cytoplasmic inclusion bodies during infection, regardless of its NLS.  This 
phenotype however, could be explained by the presence of another viral protein MV P, which 
apparently recruits C to the viral replication factories (Nakatsu et al., 2009; Nakatsu et al., 
2008). As shown here, expression of MV P was sufficient to recruit C to cytoplasmic 
granules. Weak interaction of P and C in co-immunoprecipitation could also be shown here, 
probably indirect via endogenous SHCBP1 (Ito et al., 2013). Additional expression of MV N 
resulted in a co-localisation of N, P and C in cytoplasmic inclusion bodies similar to those 
observed during C and P co-expression. The viral perinuclear replication factories, however, 
looked slightly different during infection, being broader and less dot-like. It can be speculated 
that the viral RNA and the assembly of RNPs during the progress of the infection additionally 
is able to influence the shape and provide a compartimentalisation for efficient viral 
replication. Additionally, in polarised cells, the RNPs were observed to be transported along 
the microtubule network, this mechanism was totally dispensable in non-polarised cells 
(Jones, 1999). 
Interferon induction 
The induction of interferon β caused by infection with recombinant MV viruses 
harbouring intact or compromised NLS sequences was found to be in agreement with the 
results obtained using overexpression systems. The difference between a virus expressing C 
with an intact NLS and the rMV vac2, however, was not as pronounced as in the experiments 
with transfected plasmids. This can be partially attributed to the contribution of other MV 
encoded proteins, which are additionally able to inhibit the interferon response. V was found 
to inhibit interferon induction as well, by blocking NF-κB signalling and MDA-5 binding 
(Caignard et al., 2009), and it could be speculated that V expressed from the virus can 
compensate the lack of a robust C inhibition in cell culture during infection. In addition to that 
it was suggested, that MV N can additionally block activation of IRF3. During plasmid 
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transfection experiments, defined stimuli were used such as SeV DIs or overexpression of 
stimulatory proteins such as TBK1. These stimuli always represent only a subset of pathways 
the cell uses to induce interferon β after pathogen infection. The difference between CwtNLS 
and Cs therefore could be more visible using the specific stimuli assayed in this thesis than 
induction caused by MV, which triggers a variety of cellular signalling pathways upon 
infection. Generally, the IFN-β induction caused by MV infection is relatively weak, thus the 
innate immune response impact on the growth of MV in cell culture can also be regarded as 
low. This would explain the relatively small differences in growth between rMV 
vac2CwtNLS and rMV vac2. Whether the lower interferon β induction caused by MV strains 
with wildtype C NLS can modulate the viral growth in vivo more drastically can only be 
speculated to date. 
2.3. Infections in vivo vs cell culture 
In vivo studies using measles virus are unfortunately very difficult to do, as no 
established animal model exists apart from macaques (Auwaerter et al., 1999; de Swart, 
2009). These animals, however, also react differently to a measles challenge than the human 
organism. Therefore, in vivo studies can either relate on insights gained by inadequate animal 
models or observations made with patients infected with wildtype measles. 
In general, during all animal and human infections, the impact of a fully functional 
immune system in vivo on the growth and clearance of the virus is higher than in cell culture 
models in vitro. Both innate and adaptive immune system stimulate each other, and blockage 
of the Type I interferon response is thought to greatly modulate the adaptive response induced 
as well (Le Bon and Tough, 2002). Cell culture experiments are very limited in this respect, 
providing no adaptive immune system and no interplay between different cell types within an 
organism. In many cultured cell lines even the innate immune system and other important 
cellular pathways are compromised as a result of the immortalization and transformation of 
the cells. 
The few studies done in macaques suggest that MV is influenced greatly by the immune 
system, and the reaction induced by mutants. It was seen for MV Cko viruses that they are 
rapidly cleared from the organism (Devaux et al., 2008), although in cell culture the virus is 
more attenuated than parenteral strains, growing only up to 2 logs lower titres. This leads to 
the speculation that the higher induction of innate immune system in combination with the 
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growth defect exhibited by MV Cko causes immediate activation of protective immune 
responses and subsequent clearance of the virus from the organism. 
Regarding the NLS defect of vaccine strains, it can be speculated that these strains might 
still exhibit a high interferon induction within an animal. In contrast to Cko strains however, 
they lack the growth defect caused by the complete lack of C. Thus, the strains with a 
compromised NLS might lead to an immune reaction within the organism, which facilitates 
the easy clearance of this attenuated virus. The infection however, would last long enough to 
induce a robust innate and adaptive immune response resulting in the establishment of 
memory B-cells and lifelong immunity. Thus it can be speculated that NLS compromised MV 
virus can serve as a vaccine, being attenuated enough to be rapidly and complication-free 
cleared from a healthy organism, but on the other hand are replicative enough to induce life- 
long immunity. 
2.4. Comparison to related C proteins  
The C proteins of related viruses are also involved in the regulation of the innate immune 
system. Notably, Rinderpest virus C protein for example is also located in the nucleus and 
responsible for interferon inhibition there (Boxer et al., 2009).  
A more distantly related paramyxovirus, Sendai virus, possess 4 different C proteins, a 
nested set with 4 different start codons in the P gene. They were found to be responsible for 
inhibition of innate immunity pathways as well (Strahle et al., 2007). In addition to that, these 
C proteins are also able to inhibit the induction of the antiviral state by recombinant interferon 
(Garcin et al., 1999). 
Nipah and Hendra virus C protein was found to inhibit the interferon induction in 
reporter-gene assays as well, although the targets and mechanisms remain unknown to date 
(Basler, 2012; Shaw et al., 2005). Additionally, the W protein expressed by Hendra and Nipah 
virus is also able to inhibit interferon induction and its nuclear localisation of seemed to be of 
importance. In that respect W acts similar to the C protein of MV. 
In summary, the observed interferon inhibition caused by the measles virus C protein fits 
well, comparing the functions of related proteins. Unfortunately, in most cases little to 
nothing is known about the mechanism those proteins employ. As shown in the alignments, 
RPV C is the closest C protein of all paramyxoviruses, suggesting a probable common 
mechanism. Interestingly, the sequence of the NLS of RPV C, CDV C and MV C, however, is 
conserved, hinting that the localisation but not the exact sequence is of importance and 
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conserved. Taken together, previously published results for MV C related proteins clearly 
support the role of MV C as an innate immune modulator.  
2.5. The attenuation of Cko viruses 
As shown many times before, recombinant C knockout MVs are heavily attenuated in 
cell culture, but viable. C is therefore not essential for viral propagation and growth, although 
it contributes significantly. Strikingly, the interferon induction caused by rMV vac2Cko 
infection is multiple times higher than that caused by rMV vac2 infection in vitro and in vivo. 
This would also explain the severe attenuation found in vivo for Cko strains (Devaux et al., 
2008) which are quickly cleared from the host. There are two options regarding the reason for 
the high interferon β induction. Either C inhibits the natural stimulation caused by MV 
infection, or C ensures a proper transcription and replication, and therefore a Cko virus just 
generates more PAMPs. Most probably, both hypotheses could apply and the resulting 
interferon induction is a combination of higher induction and lower inhibition. Interestingly it 
is suggested, that C modulates the viral polymerase complex (Ito et al., 2013; Nakatsu et al., 
2008). Aberrant RNA produced by a defective viral polymerase complex could lead to an 
increase in the stimulation of innate immunity pathways. Notably, influenza virus NS1 
protein, which is known for its dsRNA binding ability, was reported to complement the 
growth defect of rMV Cko (Nakatsu et al., 2006). Previously it was reported, that Cko viruses 
lead to an activation of PKR, suggesting formation of dsRNA in the cytoplasm (McAllister et 
al., 2010; Toth et al., 2009). It was also shown for the human parainfluenza virus 1 C protein, 
that it is able to prevent dsRNA accumulation in the cytoplasm and therefore also prevent 
activation of PKR (Boonyaratanakornkit et al., 2011). For the Sendai virus C proteins it is 
known, that they prevent the formation of defective interfering particles as well as dsRNA 
formation during viral replication (Strahle et al., 2007; Takeuchi et al., 2008). Both, the 
defective particles and the dsRNA are good stimulants of pattern recognition receptors. A 
similar defective interfering particle accumulation was reported to be caused by a 
recombinant PIV5 lacking V protein expression. Notably, the V protein of PIV5 is located in 
the nucleus. As PIV5 generally lacks the expression of a C protein it can be speculated that 
the nuclear PIV5 V therefore takes over the functions of a nuclear C protein. 
For studies involving recombinant Cko the effects of C on the replication and transcription 
of MV have to be taken into account. However, with state of the art technology employed 
(Deep Sequencing, Par-CLIPs.) aberrant RNA PAMPs generated by Cko MV can be more 
easily identified and characterised as in vivo ligands of RLRs. 
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2.6. Mechanistic proposals 
In this thesis, C was shown to interfere with transcriptional induction of interferon β. 
In addition to that, the activation of a crucial transcription factor – IRF3 – was found to be 
unaltered. Several molecular mechanisms explaining the observations can be considered. The 
most likely case is the interaction of MV C with RNA, DNA or cellular proteins. These 
interactions then can cause an inhibition of pathways leading to the induction of interferon. 
However, it has to be considered as well, that the miRNA content of the cell can be altered as 
a consequence of an interaction as well. Additionally epigenetic regulation might be induced 
be nuclear C or its interaction partners and cause a decrease in transcription from the 
interferon β gene. It could also be possible that MV C performs an enzymatic function such as 
a dephosphorylation, but no putative catalytic domains could be predicted. 
RNA interaction 
RNA binding to MV C was speculated to be a possible mechanism of interference 
(Nakatsu et al., 2006; Nakatsu et al., 2008). These studies suggested that C might be able to 
bind dsRNA generated by the viral polymerase complex. The sequestration of stimulating 
RNAs, which could serve as PAMPs, as the proposed mechanism can be excluded in the work 
presented here, since inhibition of interferon induction by overexpression of more 
downstream stimulatory proteins was still observed. A sequestration or degradation of 
interferon β mRNA specifically seems highly unlikely as an RNA binding motif within C was 
neither predicted nor experimentally identified until now.  Therefore it can only be speculated, 
that C might employ a yet unknown motif, to specifically target the interferon β mRNA, this 
has to be studied in further detail however. 
DNA interaction and modification 
Due to its nuclear localisation it is also possible, that MV C interacts with the cellular 
DNA. No DNA binding motifs were experimentally found so far or could be predicted. 
Nevertheless, a disturbance of a proper interferon expression enhanceosome at the promoter 
level would be an efficient mechanism to inhibit transcription of interferon β. Additionally, 
epigenetic modifications of the genomic DNA would possibly be induced by C to inhibit 
interferon induction. DNA binding and modification has to be addressed in further detail in 
the future. 
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Protein interaction 
The most likely mechanism is the interaction of C with nuclear cellular protein, 
thereby modulating its functions. Potential targets include the master regulators of 
transcription CBP and p300, which were tested in IP experiments. No interaction between C 
and CBP or p300 could be shown yet.  
Previously, a few interaction partners of MV C were also published: IRGM, SHCBP1 
and phosphorylated STAT1. Immunity-associated GTPase family M (IRGM) was reported to 
be a common target of a variety of proteins encoded by negative strand RNA viruses, among 
them also MV. The binding of MV C to IRGM was shown to increase the rate of autophagy in 
transfected cells (Gregoire et al., 2011). The reported co-localisation of MV C and IRGM in 
the cytoplasm could be confirmed in the work presented here. Moreover the association of 
IRGM and MV C in co-immunoprecipitation experiments could also be reproduced. Yet 
another protein found to interact with MV C is SHCBP1 (Ito et al., 2013). Interestingly, the 
interaction of C and SHCBP1 is the strongest in the presence of another viral protein MV P 
and they both co-localise with SHCBP1 as shown in the literature (Ito et al., 2013). The 
interaction with SHCBP1 was suggested to modulate the activity of the viral polymerase 
complex, though the mechanism remains unknown. Notably P is responsible for the re-
localisation of C to cytosolic inclusion bodies as shown here. Additionally, the cellular 
functions of the protein SHCBP1 are not known, except that it contains a putative SHC 
binding domain and was therefore named SHC binding protein 1. However, all these so far 
described protein-MV C interactions cannot explain the inhibition of interferon induction. The 
only reported interaction partner that could be involved in the interferon induction pathways 
by feedback loops was phosphorylated STAT1 (Yokota et al., 2011a). The inhibition of 
interferon β mRNA transcription caused by MV C was found to occur still in STAT1 
knockout cells, excluding the involvement of STAT1. In addition to that, the interaction of 
pSTAT1 and MV C could not be reproduced in this study here. Notably, none of the three 
published interaction partners (IRGM, SHCBP1 and STAT1) could be confirmed using mass 
spectrometry detection of the protein content of the MV Cwt pulldowns, this can be explained 
however due to their overall low abundance in 293T cells as well as the need for a stimulus 
for the induction of pSTAT1. In addition to that it can be speculated, that the detection of all 
peptides using mass spectrometry is not similar and consequently some proteins will not be 
identified during the peptide detection. 
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During this study a few more promising interaction partners could be identified by 
different methods. The results are summarized in Table 1D. 
Table 1D: Summary of the interaction partners of MV C and their interaction in three 
different assays (yes or no). Co-immunoprecipitation (Co-IP), Co-localisation 
Immunofluorescence (Co-Loc IF) and Massspectrometry analysis of co-purified proteins (MS 
analysis) 
protein Co-IP Co-Loc IF MS analysis 
Map1B no no yes 
PSMC3 yes yes yes 
IPS-1 yes no no 
DDB1 yes no yes 
IPO8 no n.d. yes 
IRGM yes yes no 
 
The most likely interaction partners for inhibitors of interferon induction can be found 
in the signalling pathway itself. Such proteins (RIG-I, IPS-1, TBK1, IRF3) were therefore 
tested by directed immunoprecipitation experiments using overexpression. In initial 
experiments only the adaptor protein IPS-1 (interferon promoter stimulated-1) showed a 
strong binding ability to Cwt. Neither the inducing helicase (retinoic-acid inducible gene 1, 
RIG-I), a crucial kinase (Tank-binding kinase 1, TBK1) nor the respective transcription factor 
(interferon regulatory factor 3, IRF3) could bind to MV C in this assay. 
Furthermore, to establish a general picture of the mechanism of the Cwt protein, a 
different method was used to analyse the lysates of the pulldowns performed. This more 
unbiased approach used the endogenous proteins of a cell line as binding partners, which were 
subsequently identified by mass spectrometry. In this approach, it could be shown that a few 
strong cellular MV C association partners are indeed present in those cells.  
Among the previously identified interaction partners, IPS-1 could not be detected 
using this method, although it was found to strongly interact in immunoprecipitation 
experiments. The method used to perform these assays was the same as for the pulldowns 
with immunodetection, in the latter case IPS-1 was overexpressed. This artificially increased 
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expression is expected to lead to activation of the cells and an increased abundance of IPS-1 
or its modifications which could explain binding to Cwt, while endogenous IPS-1 is too 
weakly expressed to be detected as a major binding partner in non activated cells using mass 
spectrometry. In the confocal images however, no apparent interaction between Cwt and IPS-
1 was visible as co-localisation, although both proteins were overexpressed. A difference in 
intracellular localisation -C in the nucleus, while IPS-1 is in the cytoplasm, anchored to 
mitochondria - can be neglected during the pulldown, which is performed using whole cell 
lysates. Moreover, the binding of IPS-1 to Cwt could be still only transient or too weak than 
needed to induce a drastic change of localisation and recruit C to the cytoplasm. As C is a 
shuttling protein, a residual cytoplasmic fraction is always present, which might not be visible 
as a clear co-localisation during static confocal microscopy. Experiments at different 
timepoints for observation of localisation could solve the problem, as IPS-1 is known to 
undergo drastic rearrangements regarding its intracellular localisation upon stimulation or 
overexpression (Onoguchi et al., 2010a). In addition to that fluorescence complementation 
assays or FRET assays could show that a transient interaction exists in the cytoplasm. 
Moreover, the already published interaction partner of C, immunity-associated GTPase family 
M (IRGM), binds to IPS-1 (Gregoire et al., 2011). Whether this interaction is direct, was 
unfortunately not assayed in this publication, therefore interaction with IRGM can be indirect 
via IPS-1 or vice versa. IRGM was also not detected during the mass spectrometry 
experiments. Additionally it is localised to the cytoplasm usually as well. Interestingly, in 
contrast to IPS-1, overexpressed IRGM was able to recruit Cwt to the cytoplasm, and both 
proteins co-localised there, whereas the same effect was not observed for IPS-1 and C 
overexpression. Therefore it is possible that the co-purification of IPS-1 with C is mediated by 
endogenous IRGM. The major interferon inhibition however, occurs in the nucleus, so this 
interaction might play a role during a different cytoplasmic pathway. As implicated for IRGM 
already, autophagy could be the target cellular system in that case.  
However, numerous protein-protein interactions not apparently related to the IFN 
induction system could be detected in the mass spectrometry approach. Amongst them, most 
importantly, were components of the proteasome (PSMD2, PSMC3 and others) as well as an 
ATPase (ATP1A1) and a microtubule rearrangement protein MAP1B, linking C to autophagy. 
Interestingly, MAP1B was found to be required for in the interferon inhibitory functions of 
RSV non-structural proteins, being essential for STAT2 and TBK1 degradation (Swedan et 
al., 2011). Additionally, MAP1B is responsible for microtubule rearrangements, which can be 
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essential for trafficking of viral particles and proteins. Furthermore MAP1B is involved in 
autophagy being in a complex with ATG proteins and DDB1. The protein itself is processed 
in the cell into a heavy and a light chain. The heavy chain is able to bind light chains of other 
MAP1 proteins, like MAPLC3, a protein known to be a marker of autophagosomes (Behrends 
et al., 2010). The interaction between C and MAP1B could so far not be confirmed in co-
immunoprecipitation and immunofluorescence experiments. This, however, might be due to a 
specific complex formed by MAP1B in the cells, which is recognized by C. This complex 
however, might not be formed with endogenous proteins or obscured by highly overexpressed 
MAP1B. 
Among the weaker interaction partners was DDB1, which was previously described to 
bind to PIV5 V (Precious et al., 2007). The PIV5 V/DDB1 complex was found to be 
responsible for STAT1 degradation. Co-immunoprecipitation of DDB1 with MV C suggested 
a weak association. However, the association was not strong enough to direct the C protein to 
the cytoplasm in confocal experiments. Overexpression of DDB1 and Cwt was not enough to 
induce a probable complex formation, which is then clearly visible in confocal microscopy 
experiments. Also as mentioned before, the shuttling ability of Cwt can of course obscure 
possible co-localisation, if only one timepoint is analysed. Moreover, only a transient binding 
could be sufficient to execute the pathways leading to interferon inhibition. 
Judging from protein-protein interaction network analysis however, it is also possible 
that by recruiting the proteasome components and MAP1B/ATP1A1 C is able to induce 
degradation of certain proteins. This theory is supported by the fact that published viral 
interactions with MAP1B and/or DDB1 lead to degradation of certain signalling molecules 
(Precious et al., 2005; Precious et al., 2007; Swedan et al., 2011). TBK1 degradation as 
reported for MAP1B and RSV NS (Swedan et al., 2011) proteins could not be seen for MV C 
in the Western blots of luciferase assays done in this thesis. In addition, it was not observed 
that C overexpression reduced STAT1 amounts or levels of other proteins of the interferon 
induction pathway. 
To analyse the mass spectrometry data in more detail, the overlap between the 
interactomes of the C binding partners using two databases Biogrid and InnateDB was 
calculated. Surprisingly, only a small number of proteins connect the putative binding 
partners directly. These proteins are usually found in complexes with each other in the cell. 
They were identified to be mainly histone de-acetylases, acting in the nucleus of the cells to 
alter transcription levels and histone modifications (Greco et al., 2011). The reason, that these 
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proteins are missing in the co-purification of C might be, that they are excluded from a 
complex or degraded via the proteasome. Notably, the fl-CwtmNLS pulldown and subsequent 
mass spectrometry analysis showed a decreased binding efficiency to both proteasomal 
components and MAP1B. A possible mechanism of nuclear C protein would therefore be the 
induced nuclear degradation of HDACs via the nuclear proteasome and adaptor molecules, 
interconnected by C. Interestingly, HDAC6 was found to be critical for IFN-β induction 
(Chattopadhyay et al., 2013). However, one major issue is the lack of any E3 ligase in the 
mass spectrometry data associated to HDACs. Classically these ubiquitin ligases are needed 
to recognize the target and transfer the polyubiquitin chains on the targets to mark them for 
proteasomal degradation. In the mass spectrometry experiments conducted here, only 
RNF219 could be co-purified, which was described as an Ubiquitin ligase for MyD88 (Wang 
et al., 2005), no other annotations exist. In addition to that, the proteasome is responsible for 
the degradation of IκB, the inhibitor of the NF-κB transcription factor (Alkalay et al., 1995). 
Any interference with the proteasomal system leading to its attenuation can also be regarded 
as an inhibitor of NF-κB induction and therefore proper interferon β response. Especially the 
early response, quickly after RLR activation seems to be crucial for resistance towards RNA 
virus replication (Wang et al., 2010). In general, the identification of the target of a 
degradation process is usually a complex issue, due to the fact that it is not present in a protein 
pulldown.  
Notably, one major point to consider is that only parts of the 19S subunit of the 
proteasome were co-purified with MV C (Fig. 30 B). Classically, the 19S subunit is involved 
in the regulation of the protein degradation caused by the 20S proteasome core complex 
(Peters et al., 1994).  Together they form the 26S particle (Fig. 30 A). Ubiquitinylated 
proteins are recognized by the ATPase-rich 19S subunit and eventually recruited into the 
cavity of the 20S subunit (Smith et al., 2005), which then performs the degradation. However, 
both the 19S and the 20S degradation unit can act independently of each other. It was implied, 
that in the nucleus of cells, the 19S subunit is more abundant than in the cytoplasm (von, 
2006), possibly explaining the interaction differences to Cwt and CwtmNLS. Within the 
nucleus it is responsible in association with the core subunits for the degradation of important 
transcription factors or alternatively for transcriptional regulation, independently of 
degradation processes (Ferdous et al., 2001). Increased degradation of the transcription factor 
IRF3 by MV C co-expression, however, was not observed in experiments in this thesis (data 
not shown). Nevertheless, transcriptional regulation by the 19S proteasomal subunit could be 
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a putative mechanism alternative for the inhibition of interferon β induction. It was reported 
that the expression of MHC-II mRNA is regulated by the 19S subunit via the co-activator 
CIITA (Koues et al., 2008). Additional the 19S subunit influences the activity of the histone 
acetylation modulator SAGA (Lee et al., 2005), globally influencing Histone 3 acetylation 
levels. 
 
Figure 30: Model of the proteasome and the Cwt interacting subunits. 
(A) Schematic model of the 26S complete proteasome, the 19S particle indicated in blue, in grey 
the 20S core subunit. (B) Protein composition of the 19S regulatory subunit, proteins found in 
the mass spectrometry experiments are coloured in orange. 
3. Model of C in the context of infection 
 
As stated above, the localisation of the C protein during infection resembles the 
localisations found for the different NLS variants in the overexpression system. In addition to 
that a fraction of all C variants, regardless of their NLS sequence, co-localised with the viral 
replication centres during infection. 24h post infection, Cwt and CswtNLS are clearly seen in 
the nucleus supporting the interferon inhibitory role in the nucleus. Although little Cs is in the 
nucleus as well, the interferon β stimulation during vac2 infection remains fairly low, as seen 
in the microarray experiments, rising up to 6-fold only 48h post infection. This indicates that 
another viral protein might compensate for the defect (V or P) or only a little amount of 
PAMPs are generated during MV infection and the induction of interferon is generally very 
low. As mentioned above, however slight differences in interferon induction between MV 
possessing a functional C NLS and MV harbouring a compromised C NLS could be observed. 
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Recently, it was reported that during paramyxovirus infection the content of defective 
interfering particles is critical for the induction of interferon and other cytokines (Killip et al., 
2011). Defective interfering particles can also be found in MV preparations (Calain and Roux, 
1988) and might even contribute to a strong innate immune activation phenotype by vaccine 
strains. It can therefore be speculated, that the induction of the immune system by a ‘perfect’ 
measles replication and propagation is very weak. This might be due to shielding of PAMPs 
and the tendency of MV to avoid production of PAMPs like dsRNA intermediates. In addition 
to self-induced interferon, a virus has to cope with IFN induced by co-infecting pathogens and 
therefore encodes interferon induction antagonists. Strikingly, the main cause of MV induced 
mortality in developing countries are co-infections with other pathogens.  
Taken all results together, the following model of C action during infection can be 
proposed. This model only regards the immunosuppression caused by measles C, not any 
implications in replicational or transcriptional processes (Fig. 31).  
MV and DIs, as well as other invading pathogens (bacteria, viruses exemplary 
depicted in Fig. 31) are able to activate the immune system. Whereas signalling by interferon 
can be efficiently blocked by V and P (and C to some extend) (Caignard et al., 2009; Caignard 
et al., 2007; Devaux et al., 2007; Ramachandran et al., 2008; Shaffer et al., 2003), the 
interferon induction can only be blocked partially by V by blocking MDA-5 signalling 
(Andrejeva et al., 2004; Childs et al., 2007; Motz et al., 2013) and inhibiting IRF3 activation 
(Lu et al., 2008), Toll-like receptor signalling (Pfaller and Conzelmann, 2008) and 
sequestration of NF-κB p65 (Schuhmann et al., 2011). MV C protein residing in the nucleus 
could additionally inhibit the cellular response particularly to these stimuli. As revealed in the 
localisation studies with recombinant MV encoding different C variants, only Cwt and 
CswtNLS are able to substantially accumulate in the nucleus during infection. Consequently, 
a lower capacity of counteracting innate immunity activation of the infected cells with vaccine 
or C NLS compromised recombinant MV would be expected. 
Stimulation in low extend caused by MV replication itself, can also be restricted 
earlier by a nuclear mechanism than a more cytoplasmic mechanism. Signalling starting from 
RLRs by incoming virus activation takes an estimated 12h to activate IRF3 and the first 
transcription of interferon β mRNA. A mechanism in the nucleus would lead to a time-
advantage for the virus, as its accessory proteins like V and C have to be synthesized first to 
inhibit the earlier steps of induction of interferon β. Therefore, the later and the more 
Interferon induction inhibition by MV C - Discussion 
Model of C in the context of infection 
 
 
Page 120  
  
downstream the inhibitory step is, the better the virus can defend itself against the first wave 
of interferon induction. This is supported by data obtained after MV infection of 12h. 
 
Figure 31: Model of C during infection with exogenous innate immunity stimuli.  
Viruses are depicted in red, bacteria in green and the human cells in blue. Intracellular 
expression of the C protein during infection is visualized by a yellow colour. The innate immune 
response including the production of interferon β is indicated by a blue arrow. Incoming DIs or 
other pathogens (exemplary bacteria and viruses) are able to activate the innate immune system. 
MV C expression in the nucleus is able to counteract this induction, causing a lower cellular 
response. 
In summary, the nuclear localisation of MV C is likely to contribute to the strong 
immunoinhibitory phenotype observed during wildtype MV infections. This striking 
phenotype seems to be absent during vaccinations the established vaccine strains, lacking the 
C NLS. 
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4. Outlook and future perspectives 
 
During this study, MV C could be identified as a major inhibitor of interferon β 
induction encoded by MV. This inhibition is dependent on the nuclear accumulation of C, 
both during overexpression experiments and during infection with recombinant MV. The 
localisation of different C variants was determined during infection and resembled the 
overexpression experiments. Additionally, several protein-protein interaction partners of C 
could be identified. The molecular mechanism of C to inhibit interferon induction could 
however not be fully revealed during this thesis. However, a lot of possibilities could be 
excluded and some are more likely now.  
The most probable mechanism involves regulation of the 19S subunit either by 
alteration of proteasomal degradation pathways or direct transcriptional regulation. Further 
experiments are needed however, to clarify whether this hypothesis holds true. Assays 
controlling the already known regulated genes could be done, as well as localisation studies 
regarding the interaction partners found in their endogenous context, meaning fully assembled 
19S particles. To test for an influence on the degradation system by C, functional assays of 
the proteasome have to be conducted and the degradation of C itself by the proteasome 
checked. 
For future studies it will be definitely be interesting to elucidate the role of C at 
mitochondria in more detail. Both IRGM and IPS-1 are mitochondrial proteins and C binds 
strongly to both. The former even causes a re-localisation of C upon co-expression. They 
implicate a role of C in the autophagy system, which was already reported before, however 
this system needs to be studied in more detail. Additionally, C interaction with IPS-1 could 
have multiple other effects on different cellular pathways as well. These pathways could be 
studied using screening approaches employing microarrays or siRNA knockdown screens. 
It has been speculated that binding of C to RNA or DNA can occur (Nakatsu et al., 
2008). There was however, no prove provided since and the question still remains to be 
answered. MV C does not contain any classical RNA or DNA binding motifs, but this does 
not rule out an actual binding. Interaction of MV C with RNA and DNA definitively has to be 
studied especially focusing on the possible interaction with the interferon β promoter in 
further detail using chromatin immunoprecipitation experiments. 
Interferon induction inhibition by MV C - Discussion 
Outlook and future perspectives 
 
 
Page 122  
  
If C is responsible for a downregulation of snoRNAs, it can be speculated that this 
mechanism might influence interferon induction of the virus as well. However this would not 
explain the interferon inhibitory effect observed in the overexpression system. Nonetheless 
downregulation of snoRNAs might be an important regulatory mechanism by either the cell or 
MV to modulate viral growth. This has to be studied further, to reveal any implications.  
Additionally it will be of interest to study viruses in more detail which lack both of its 
interferon induction inhibitory proteins. It is possible that V can at least partially compensate 
the interferon inhibition in cell culture. As Vko viruses grow perfectly well in cell culture and 
do not show an obvious interferon inhibition defect, it would be possible to combine V and C 
knockout in the P gene, and complement this virus with the different C mutants. It is likely 
that the effect of the C mutants would become even more pronounced. 
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293T       Human embryonic kidney cells 293 T 
5’-ppp      5’-triphosphate 
A        alanine 
aa       amino acid 
AP-1       activator protein 1 
APS       ammonium persulfate 
bp       base pair 
CARD     terminal caspase activation and recruitment domain 
CBP       CREB-binding protein 
cDNA      copy DNA 
CDV        Canine distemper virus 
CoIP       co-immunoprecipitation 
cRNA      copy (antigenomic) RNA 
C-terminus      Carboxy-terminus 
Cwt     MV C wildtype 
Cs     MV C Schwarz 
CwtmNLS    MV C wildtype with mutated NLS 
CswtNLS    MV C Schwarz with repaired NLS 
DAMPs     danger associated molecular patterns 
DCs       dendritic cells 
DI       defective interfering 
DMEM      Dulbecco's Modified Eagle Medium 
DNA       deoxyribonucleic acid 
ds       double-strand 
DTT       1,4-dithiothreitol 
E. coli      Escherichia coli 
EDTA      ethylene-diamin-tetraacetic acid-disodium salt 
EV       empty vector 
F       fusion protein 
FCS       fetal calf serum 
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ffu       focus forming units 
FITC       fluorescein isothiocyanate 
Fl      Flag-tag 
G       guanosine 
GAPDH     Glyceraldehyde 3-phosphate dehydrogenase 
GFP       green fluorescent protein 
H       hemagglutinin protein 
HA       hemagglutinin tag 
PO       horseradish peroxidase 
IFN        interferon 
IFN-β     interferon β 
IFNR       IFN receptor 
IKK       IκB kinase 
IL       interleukin 
IPS-1       interferon beta promoter stimulator 1 
IRAK      interleukin-1 receptor associated kinase 
IRF       interferon regulatory factor   
ISG       interferon stimulated genes 
IκB      inhibitor of κB 
JAK      Janus kinase 
K       lysine 
KO       knock out 
L       large protein 
Le       leader 
LGP2       laboratory of genetics and physiology 2 
M       matrix protein 
MAPK      mitogen-activated protein kinase 
MDA-5      melanoma differentiation-associated gene 5 
MOI       multiplicity of infection 
MV       measles virus 
MyD88      myeloid differentiation factor 88 
N       nucleocapsid protein 
NEMO      NF-κB essential modifier 
NES      nuclear export signal 
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NF-κB       nuclear factor κB 
NiV       Nipah virus 
NLS       nuclear localization signal 
N-terminus      Amino-terminus 
OAS       2’5’-oligoadenylate synthetase 
P       phosphoprotein 
p.i.       post infection 
p.tr.       post transfection 
PAGE      polyacrylamide gel electrophoresis 
PAMP      pathogen-associated molecular pattern  
PBMCs      peripheral blood mononuclear cells  
PBS       Phosphate buffered saline 
PCR       polymerase chain reaction 
pDCs       plasmacytoid dendritic cells 
PDV     phocine distemper virus 
PdPRV    Peste-de-petit ruminants virus 
PEI       polyethyleneimine 
PFA       paraformaldehyde 
PIV 5       Parainfluenza virus type 5 
PO       peroxidase 
Poly(I:C)      polyriboinosinic:polyribocytidylic acid 
PRR       pattern recognition receptor 
PVDF      polyvinylidene fluoride 
R      Arginine 
RD       regulatory domain 
RHD       Rel homology domain 
RIG-I       retinoic acid-inducible gene I 
RL       Renilla luciferase 
RLR       RIG-like receptor 
RNA       ribonucleic acid 
RNP       ribonucleoprotein 
RPV      Rinderpest Virus 
RT       reverse transcriptase 
RV        rabies virus 
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S       serine 
SDS       sodium-dodecyl sulfate 
SLAM      Signaling lymphocytic activation molecule  
ss       single-strand 
SSPE       Subacute sclerosing panencephalitis 
STAT      signal transducer and activator of transcription 
TagRFP red fluorescent protein variant from the wild-type RFP 
from sea anemone Entacmaea quadricolor 
TANK      TRAF family member-associated activator NF-κB 
TBK-1      TANK-binding kinase 1  
TEMED      tetramethylenediamine 
TIR       Toll/interleukin-1-receptor 
TLR       Toll-like receptor 
TNF       Tumor necrosis factor 
Tr       trailer 
TRADD      TNF receptor 1-associated death domain protein 
TRAF      TNF-receptor-associated factor 
TRIF       TIR domain-containing adapter inducing IFN-β 
vRdRp      viral RNA-dependent RNA polymerase 
vRNA      viral (genomic) RNA 
WB       Western blot 
WHO       world health organization 
wt       wild-type 
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Supplementary Data: 
App. 1: Consurf Settings: 
 
App. 2: I-Tasser settings: 
[Home] [Server] [Queue] [About] [Remove] [Statistics]  
I-TASSER results for job id S71451 
 
>protein 
MSKTDWNVSGLSRPSLSAHWPSRKPWQHGQKYQTTQDRTEPPARKRRQAVRVSANHASQQ 
LDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLT 
LSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKE 
GRSTSS 
 
 
 
Sequenc
e 
                  20                  40                  60                  80                 100                 120                 140 
                160                 180 
                   |                   |                   |                   |                   |                   |                   | 
                  |                   |        
MSKTDWNVSGLSRPSLSAHWPSRKPWQHGQKYQTTQDRTEPPARKRRQAVRVSANHASQQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNL
KTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS 
Predict
ion 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCHHHCCCCCCCCCCSSSSSCCHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHCCCCCCCCCCCCCCCSSCHHHHHHHHHHHHCHHHHHHHHHHHHHHCCCHHHHHHH
HHHHHHHHHHCHHHHHHHCCHHHHHHHCCCHHHHHHHHCCCCCCC 
Conf.Sc
ore 
986556556878887655777677300168877602214577667540367522427787889999999999999999999999734864334588877403401498898886510535999999999846509999999
999999998677988652002778886137788899872676689 
 
Secondary structure elements are shown as H for Alpha helix,S for Beta sheet & C for Coil 
 
 
 
Sequenc
e 
                  20                  40                  60                  80                 100                 120                 140 
                160                 180 
                   |                   |                   |                   |                   |                   |                   | 
                  |                   |        
MSKTDWNVSGLSRPSLSAHWPSRKPWQHGQKYQTTQDRTEPPARKRRQAVRVSANHASQQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNL
KTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS 
Predict
ion 
754641424414443253244244325356434445434424434444103022433344344320200131044034123303334475434734414010000002004304733200031033003113544533430
330031004112431240223103103634431330356456468 
 
Values range from 0 (buried residue) to 9 (highly exposed residue) 
 
 
 
 
Download Model 1  Download Model 2  Download Model 3
C-score=-2.60 C-score=-4.04 C-score=-
  
Estimated accuracy of Model1: 0.41±0.14 (TM-score)    11.1±4.6Å (RMSD)    (Read more about C-score of generated models) 
 
 
Ran
k 
PDB 
Hit 
Ide
n1 
Ide
n2 
Co
v. 
Nor
m. 
Z-
scor
e 
Downlo
ad 
Align.   
                  20                  40                  60                  80                 100                 120                 140     
            160                 180 
                   |                   |                   |                   |                   |                   |                   |     
              |                   |       
 
Sec.
Str 
Seq 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCHHHCCCCCCCCCCSSSSSCCHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHCCCCCCCCCCCCCCCSSCHHHHHHHHHHHHCHHHHHHHHHHHHHHCCCHHHHHHHHHHH
HHHHHHCHHHHHHHCCHHHHHHHCCCHHHHHHHHCCCCCCC 
MSKTDWNVSGLSRPSLSAHWPSRKPWQHGQKYQTTQDRTEPPARKRRQAVRVSANHASQQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAM
WILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS 
1 2qenA 0.11 0.17 
0.9
6 0.67 
Downlo
ad    
MRREDFDREEESRKLEESLENYPLTLLLGIRRVGKSSLLR-
AFLNERPGILIDCRELYAERGHTREELIKELQSTISPFQKFQSKFKISLNLKLTLEPRKLSLREVFRELNDLGEELGEFIVAFDEAQYLRFYGSRGGKELLALFAYAYDSLPNLKIILTG-------SEVGLLHDFLKIGRIAGE 
2 3o0zA 0.21 0.18 
0.6
2 0.47 
Downlo
ad    
---------QLQKQLEEAN----DLLRTESD----------TAVRLRKS-LQERNRILQILEAERRGHDSE-IGDLQARITSL-----------------------QEEVKHLKHNLEKVEGERKEAQD-
LNHSEKEKNNLEIDLNYK---------------LKSLQQRLEQEVNEHKV------ 
3 3mdd 0.13 0.18 0.9 0.74 Downlo   INGQKMWITNGGKANWRSDPDPKAPASKADTPGVQIGRKEINMGQRCEDVRVPKEIAMGTFDKTRPPVAAGAVGLAQRALDEATKYALERKTFGKLLAEHQGISFLLADMAMKVELARLSYQRAAWEIDSGRRNTYYASIAKAYA
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A 8 ad  ADIANQLATDAVQVFGGNGFN---TEYPVEKLMRDAKIYQI 
4 2of3A 0.08 0.18 
1.0
0 0.95 
Downlo
ad    
AELQLKLVKWNFQAPTDEHISQLQTLLGNQAKVSLMSQLFHKDFKQHLAALDSLVRLADTSPRSLLSNSDLLLKWCIKVLELCKVIVELIRDTETPMSQEEVSAFVPYLLLKTGRQRSECLLVIEYYITNAGISPLKSLSVEKTV
APFINVLVACFKFEGDQMWKAAGRMADKDKSVEERIKRTGV 
5 2p22A 0.07 0.16 
0.8
6 0.55 
Downlo
ad    
HEMLQNLQTVVNELYREDVDYVADKILTRQTVMQESIARFHEIIAIDKNHLRAVEQAIEQTMHSLNAQIDVLTANRAKVQQFSSTSHVDDEDVNSIAVAKTDGLNQLYNLVAQDYALTDTIECLSRMLHRLDTFVKQGRELARQQ
FLVRWHIQRITSPLS-------------------------- 
6 3kpeA 0.20 0.06 
0.2
6 0.71 
Downlo
ad    
--------------------------------------------------------------------------------------------------------HLEGEVNKIKSALL----STNKAVVSLSNGVS---
VLTSKVLDLKNYIDK-------QLLPIV------------------- 
7 1iv8A 0.15 0.20 
0.6
3 0.34 
Downlo
ad    
-----------------------------------QKRRGKI------TLNATSTHDTKFSEDVRMK--ISVLSEFPEEWKNVEEWHSIINPKVSRNDEY---RYYQVHMISVREAIN-T-SWYENRVMTFTNK-----
DFIKSFMKFESIRRI------G----MIKSLSLVALKIMSAG----- 
8 1nt2B 0.08 0.20 
1.0
0 0.45 
Downlo
ad    
LRYNLWEIKLSENFEESFLKAENPSPLPFNVSEVGAKALGKDYYRILRKTALAVSEKMVEKELRREDRYVVALVKALEEIDESINMLNEKLEDIRAVKESEITEKFEKKIRELRELRRDVEREIEEVMEKIAPNMTELVGAKVAA
KLLERALPASKIQVIGAEHGIIFLHPFIRTLPKAKRGKMAR 
9 1g73A 0.12 0.16 
0.8
3 0.46 
Downlo
ad    
----------------------AVPIAQKSEPHSLSSEA-----
LMRRAVSLVTDSTSTDLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLKMNSEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQ---- 
10 1rm1C 0.16 0.12 
0.5
9 0.57 
Downlo
ad    
----------------------------------------------------------------SNAEASRVYEIIVESVVNEVREDFENAGIDEQTLQ-----------
KKLTETKVTTFSWDNQFNDYLISEDGPDENLMLCLYDKVTRTKARWKCSLKDGVVTINRNDYTFQKAQVEAEWV-- 
(a) All the residues are colored in black; however, those residues in template which are identical to the residue in the query sequence are highlighted in color. Coloring scheme is based on the property of amino acids, where polar are brightly coloured while non-polar residues are colored in dark shade. (more about the colors used) 
(b) Rank of templates represents the top ten threading templates used by I-TASSER. 
(c) Ident1 is the percentage sequence identity of the templates in the threading aligned region with the query sequence. 
(d) Ident2 is the percentage sequence identity of the whole template chains with query sequence. 
(e) Cov. represents the coverage of the threading alignment and is equal to the number of aligned residues divided by the length of query protein. 
(f) Norm. Z-score is the normalized Z-score of the threading alignments. Alignment with a Normalized Z-score >1 mean a good alignment and vice versa. 
(g) Download Align. provides the 3D structure of the aligned regions of the threading templates. 
(h) The top 10 alignments reported above (in order of their ranking) are from the following threading programs: 
        1: MUSTER   2: HHSEARCH   3: SP3   4: PROSPECT2   5: PPA-I   6: HHSEARCH I   7: COMA   8: FUGUE   9: SPARKS   10: SAM     
 
 
 
  10 proteins in PDB which are structurally closest to the first I-TASSER model (identified by TM-align) 
 
Ran
k 
TM-
score 
RMSD
a
 
IDEN
a
 
Cov
. 
PDB 
Hit 
1 0.7958 3.02 0.10 0.96 
3mkhA 
Model
1 
  
2 0.7951 3.06 0.04 0.96 
3oibA 
Model
1 
  
3 0.7947 3.24 0.10 0.96 
1udyA 
Model
1 
  
4 0.7943 3.33 0.12 0.97 
1jqiA 
Model
1 
  
5 0.7921 3.16 0.11 0.96 
2dvlA 
Model
1 
  
6 0.7918 3.18 0.09 0.97 
2jifA 
Model
1 
  
7 0.7918 3.32 0.08 0.97 
2pg0A 
Model
1 
  
8 0.7915 3.40 0.09 0.97 
1ukwA 
Model
1 
  
9 0.7915 3.34 0.09 0.97 
1bucA 
Model
1 
  
10 0.7908 3.17 0.10 0.96 
2d29A 
Model
1 
  
 
Structural alignment using TM-align 
  
AIDFHLSASQKGTYQAARSLARNLLMPARQTYLQHPPNSPLRFQSTQPTYAAAVSAGILKGQISPAHGGTGGTLIESAILVEECYSVEPSAALTIFATGLGLTPINLAAGPQHAEFLAPFLSGEGSPLASLVFSEP-
GGVANALEKGAPGFQTTARLEGDEWVINGEKMWATNCAGWDFKG-CDLAC-VVCRDATTPLEEGQDPENKVMIILVTRADLDRNGEGSFEVLR-HVATPGHTSVSGPHVRYTNVRVPTKNV-
LCPAGQGAKVAFGAFDGSAVLVGAMGVGLMRAAFDAALKFAKEDNRGGAVPLLERQAFADLLSGVKIQTEAARALTWKAAHAMENGPGDYDARRELALAAKVFCSEAAVKACTDVINAVGISAYDL--Q-
RPFSDLLNTAVVLPIFDGGNVGIRRRHLQQLMLKPTYDAWSSTYG  
----------------------------------------------------------------------------------------------------------------------------------------MSKT---------
------------------DWNVSGL-------SRPSLSAHWPS--------------RKPWQHG----Q-----KYQTTQDRTEPPARKRRQAVR-V------------SA-----N--
HASQQLDQLKAVHLASAVRDLEKAMTTLKLWESPQE-ISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVI--AP--SQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS-------------
-----------------   
  
SIWTTAEREALRKTVRAFAEREVLPHAHEWERAGEIPRELHRKAAELGLLGAGFPEDAGGSGGDGADPVVICEEMHYAGSPGGVYASLFTCGIAVPHMIASGDQRLIDTYVRPTLRGEKIGALAITEPG-
GGSDVGHLRTRADLDGDHYVINGAKTYITSGVR-ADYVVTAARTGGPGAGGVSLIVVDKGTPGFEVTR-KLDKMGWRSSDTAELSYTDVRVPVANL-
VGSENTGFAQIAAAFVAERVGLATQAYAGAQRCLDLTVEWCRNRDTFGRPLISRQAVQNTLAGMARRIDVARVYTRHVVERQLAGETNLIAEVCFAKNTAVEAGEWVANQAVQLFGGMGY-M--
AESEVERQYRDMRILGIGGGTTEILTSLAAKTLGFQS  
---------------------------------------------------------------------------------------------------------------------------------MSKT----------------
-----DWNVSGL--SRPSLSAHWP-----S-RKPWQHG---QKYQTTQDRTEPPA-RKRRQAVRV------------SA-----N--
HASQQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVI-APSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS-----------------
---   
  
GFSFELTEQQKEFQATARKFAREEIIPVAAEYDRTGEYPVPLLKRAWELGLMNTHIPESFGGLGLGIIDSCLITEELAYGCTGVQTAIEANTLGQVPLIIGGNYQQQKKYLGRMTEEPLMCAYCVTEPGAGSDVAGIKTKAEKKGDEYI
INGQKMWITNGGK-ANWY-FLLARSDPDPKAPASKAFTGFIVEADTPGVQIGR-KEINMGQRCSDTRGIVFEDVRVPKENVLTGEGA-
GFKIAMGTFDKTRPPVAAGAVGLAQRALDEATKYALERKTFGKLLAEHQGISFLLADMAMKVELARLSYQRAAWEIDSGRRNTYYASIAKAYAADIANQLATDAVQVFGGNGF-N--
TEYPVEKLMRDAKIYQIYEGTAQIQRIIIAREHIGRYK  
-----------------------------------------------------------------------------------------------------------------------------M---SKT-----------------
----DWNVSGL--SRPSLSAHWPS------------RKPWQHG--QKYQTTQDRTEPPARKRRQAVRVS------------------ANH-AS-
QQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS---------------------
   
  
VYQSVELPETHQMLRQTCRDFAEKELVPIAAQLDKEHLFPTSQVKKMGELGLLAMDVPEELSGAGLDYLAYSIALEEISRGCASTGVIMSVNNSLYLGPILKFGSSQQKQQWITPFTNGDKIGCFALSEPGNGSDAGAASTTAREEGDS
WVLNGTKAWITNSWE-ASAT-VVFASTDRSRQNKGISAFLVPMPTPGLTLGK-
KEDKLGIRASSTANLIFEDCRIPKENLLGEPGMGFKIAMQTLDMGRIGIASQALGIAQASLDCAVKYAENRHAFGAPLTKLQNIQFKLADMALALESARLLTWRAAMLKDNKKPFTKESAMAKLAASEAATAISHQAIQILGGMGY-V-
-TEMPAERYYRDARITEIYEGTSEIQRLVIAGHLLRSYR  
-------------------------------------------------------------------------------------------------------------------------------M---SKT---------------
------DWNVSGL--SRPSLSAHWPS---------RKPWQHG--QKYQTTQDRTEPPARKRRQAVRVS------------A-----NH-AS-
QQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS---------------------
   
  
LTQEQRLVLDAVRRVAREVLYPLAPEYDRKAEYPWPQLKALAELGLLGMTTPEEWGGVGLDSVTWALALEELAAADPSVAVIVSVTSGLPQYMLLRFGSEAQKRRYLVPLARGEWIGAFCLTEPQ-
AGSDAKSLRAEARRVKGGFVLNGVKSWITSAGH-AHLYVVMARTEKGISAFLVEKGTPGLSFGR-PEEKMGLHAAHTAEVRLEEVFVPEENLLGEEGR-
GLAYALAGLDSGRVGVAAQAVGIARGAFEIAKAYAEEREQFGKKLKEHQAIAFKIADMHVKIAAARALVLEAARKKDRGERFTLEASAAKLFASAAAVEVTREAVQVLGGYGY-H--
RDYRVERYYRDAKVTEIYEGTSEIQRLVIARELYR  
-----------------------------------------------------------------------------------------------------------------------------MSKT--------------------
-DWNVSGL--SRPSLSAHWPS--RKPWQHG---QKYQTTQDRTEPPA-RKRRQAVRV------------------SAN-
HASQQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS------------------
   
  
APLQTFTDEEMMIKSSVKKFAQEQIAPLVSTMDENSKMEKSVIQGLFQQGLMGIEVDPEYGGTGASFLSTVLVIEELAKVDASVAVFCEIQNTLINTLIRKHGTEEQKATYLPQLTTEKVGSFCLSEAGAGSDSFALKTRADKEGDYYV
LNGS-KMWISSAEH-AGLFLVMANVDPTIGYKGITSFLVDRDTPGLHIGK-
PENKLGLRASSTCPLTFENVKVPEANILGQIGHGYKYAIGSLNEGRIGIAAQMLGLAQGCFDYTIPYIKERIQFGKRLFDFQGLQHQVAHVATQLEAARLLTYNAARLLEAGKPFIKEASMAKYYASEIAGQTTSKCIEWMGGVGY-T-
-KDYPVEKYFRDAKIGTIYEGASNIQLNTIAKHIDAEY  
-----------------------------------------------------------------------------------------------------------------------------------MSK---------------
----TDWNVSGL--SRPSLSAHWP------S-RKPWQHG---QKYQTTQDRTEPPARKRRQAVRVS------------A-----N--
HASQQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS------------------
--   
  
TARYLREEHHMFRAAFRKFLEKEAYPHYNDWEKRGIIPRSFWAKMGENGFLCPWVDEKYGGLNADFAYSVVINEELEKVGSSLVGIGLHNDIVTPYIASYGTEEQKQKWLPKCVTGELITAIAMTEPGAGSDLANISTTAVKDGDYYIV
NGQKTFITNGIH-ADLIVVACKTDPQAKPPHRGISLLVVERDTPGFTRGR-
KLEKVGLHAQDTAELFFQDAKVPAYNLLGEEGKGFYYLMEKLQQERLVVAIAAQTAAEVMFSLTKQYVKQRTAFGKRVSEFQTVQFRLAEMATEIALGRTFVDRVIEEHMAGKQIVTEVSMAKWWITEMAKRVAAEAMQLHGGYGY-M-
-EEYEIARRYRDIPVSAIYAGTNEMMKTIIARQLDL  
----------------------------------------------------------------------------------------------------------------------------M---SKT------------------
---DWNVSGL--SRPSLSAHWP--------S-RKPWQHG---QKYQTTQDRTEPPARKRRQAVRVS------------A-----NH-AS-
QQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS------------------   
  
IDFSLTEEQRQLQALARRFAKEVILPVAQEYDEKEEVPWPVIEKLHEVGLLNAIIPEEYGGMGLKMLDEVIVGEELAYACMGIYTIPMASDLGITPVLLAGTEEQKERFLRPLTEKPALAAFALSEPGNGSDAAALKTRAIRQGDHYVL
NGTKMWISNGGEAEWV-VVFATVNPELRHKGVVALVVERGTPGFKAIK-
IHGKMGQRASGTYELVFEDVKVPVENRLGEEGEGFKIAMQTLNKTRIPVAAGSVGVARRALDEARKYAKEREAFGEPIANFQAIQFKLVDMLIGIETARMYTYYAAWLADQGLPHAHASAIAKAYASEIAFEAANQAIQIHGGYGY-V-
-REFPVEKLLRDVKLNQIYEGTNEIQRLIIARHILAA  
----------------------------------------------------------------------------------------------------------------------------M---SKT------------------
---DWNVSGL-SRPSLSAHWPS---------RKPWQHG--QKYQTTQDRTEPPARKRRQAVRVS------------A-----NH-AS-
QQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS-------------------   
  
MDFNLTDIQQDFLKLAHDFGEKKLAPTVTERDHKGIYDKELIDELLSLGITGAYFEEKYGGSGDDGGDVLSYILAVEELAKYDAGVAITLSATVSLCANPIWQFGTEAQKEKFLVPLVEGTKLGAFGLTEPNAGTDASGQQTIATKNDD
GTYTLNGS-KIFITNGGAADIYIVFAMTDKSKGNHGITAFILEDGTPGFTYGK-
KEDKMGIHTSQTMELVFQDVKVPAENMLGEEGKGFKIAMMTLDGGRIGVAAQALGIAEAALADAVEYSKQRVQFGKPLCKFQSISFKLADMKMQIEAARNLVYKAACKKQEGKPFTVDAAIAKRVASDVAMRVTTEAVQIFGGYGY-S-
-EEYPVARHMRDAKITQIYEGTNEVQLMVTGGALLR  
--------------------------------------------------------------------------------------------------------------------------------------MSK------------
--------TDWNVSGL-SRPSLSAHWP-----S--RKPWQHG---QKYQTTQDRTEPPARKRRQAVRVS------------A-----NH-AS-
QQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS------------------   
  
GLWFEEGAEERQVLGPFREFLKAEVAPGAAERDRTGAFPWDLVRKLAEFGVFGALVPEAYGGAGLSTRLFARMVEAIAYYDGALALTVASHNSLATGHILLAGSEAQKEAFLPKLASGEALGAWGLTEPGSGSDAAALKTKAEKVEGGW
RLNGT-KQFITQGSV-AGVY-VVMARTDPPPSPERKHQGISAFAFFR-PERGLKVGR-
KEEKLGLTASDTAQLILEDLFVPEEALLGERGKGFYDVLRVLDGGRIGIAAMAVGLGQAALDYALAYAKGREAFGRPIAEFEGVSFKLAEAATELEAARLLYLKAAELKDAGRPFTLEAAQAKLFASEAAVKACDEAIQILGGYGY-V-
-KDYPVERYWRDARLTRIGEGTSEILKLVIARRLLEAV  
------------------------------------------------------------------------------------------------------------------------------------MSK--------------
-----TDWNVSGL--SRPSLSAHWPS-------------RKPWQH--GQ-KYQTTQDRTEPPARKRRQAVRVS------------A-----NH-AS-
QQLDQLKAVHLASAVRDLEKAMTTLKLWESPQEISRHQALGYSVIMFMITAVKRLRESKMLTLSWFNQALMVIAPSQEETMNLKTAMWILANLIPRDMLSLTGDLLPSLWGSGLLMLKLQKEGRSTSS--------------------   
  
 
(a) Residue pairs that are structurally aligned by TM-align program are highlighted in color. Coloring scheme is based on the property of amino acids, where polar are brightly coloured while non-polar residues are colored in dark shade.(more about the colors used) 
(b) Ranking of proteins is based on TM-score of the structural alignment between Model1 and the PDB structures in our template library. 
(c) RMSDa is the RMSD between residues that are structurally aligned by TM-align. 
(d) IDENa is the percentage sequence identity in the structurally aligned region. 
(e) Cov. represents the coverage of the alignment by TM-align and is equal to the number of structurally aligned residues divided by length of the model. 
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  Function Prediction 
 
  Predicted EC Numbers 
 
Rank TM-score RMSDa IDENa Cov. EC-Score PDB 
Hit 
EC No. 
1 0.7941 3.32 0.13 0.97 0.7323 2vigH 1.3.99.2 
  
2 0.7943 3.33 0.12 0.97 0.7003 1jqiA 1.3.99.2 
  
3 0.7949 3.13 0.10 0.96 0.6505 3mddA 1.3.99.3 
  
4 0.7909 3.18 0.10 0.97 0.6351 1bucB 1.3.99.2 
  
5 0.7915 3.34 0.09 0.97 0.6168 1bucA 1.3.99.2 
  
(a) Ranking is based on EC-score, which is a confidence score for the Enzyme Classification (EC) Number prediction. 
(b) RMSDa is the RMSD between models and the PDB structure in the structurally aligned regions by TM-align. 
(c) IDENa is percentage sequence identity in the structurally aligned region. 
(d) Cov. represents the coverage of the alignment and is equal to the number of structurally aligned residues divided by length of model. 
(e) EC-Score is defined based on the C-score of the structure prediction and similarity of the model with known enzyme structures, as identified using both global and local structural alignment programs. The global similarity score uses TM-score, IDENa,RMSDa and Cov. of the structural alignment by TM-align, while the local match 
compares the structural and chemical similarity of local spatial motifs in the model with known catalytic site of enzymes. A prediction with a EC-score >1.1 signifies a prediction with high confidence (upto 3 digit numbers of EC) and vice versa (For details, see Inferring protein function by global and local similarity of structural analogs, 
2010, submitted). 
 
 
  Predicted GO terms 
 
Rank TMscore RMSDa IDENa Cov. PDB 
Hit 
Fh-
Score 
Associated GO Terms 
1 0.7941 3.32 0.13 0.97 2vigH 0.73 GO:0000062 GO:0004085 GO:0009055 GO:0050660 GO:0050662 GO:0006631 GO:0006635 GO:0009056 GO:0009987 GO:0019395 GO:0031667 GO:0032787 GO:0042221 GO:0042594 
GO:0044248 GO:0046395 GO:0051384 GO:0055114 GO:0005622 GO:0005623 GO:0005737 GO:0005739 GO:0005759 GO:0031974 GO:0043229 GO:0044429 GO:0044444  
2 0.7942 3.33 0.12 0.97 1jqiB 0.70 GO:0004085 GO:0009055 GO:0050660 GO:0050662 GO:0006631 GO:0009987 GO:0032787 GO:0055114 GO:0005622 GO:0005623 GO:0005737 GO:0005739 GO:0005759 GO:0031974 
GO:0043229 GO:0044429 GO:0044444  
3 0.7994 3.29 0.11 0.97 2a1tD 0.67 GO:0003995 GO:0009055 GO:0050660 GO:0050662 GO:0006631 GO:0006635 GO:0009056 GO:0009987 GO:0019395 GO:0032787 GO:0044248 GO:0046395 GO:0055114 GO:0005622 
GO:0005623 GO:0005737 GO:0005739 GO:0005759 GO:0031974 GO:0043229 GO:0044429 GO:0044444  
4 0.7955 3.23 0.10 0.96 3mdeB 0.65 GO:0003995 GO:0009055 GO:0006631 GO:0006635 GO:0009056 GO:0009987 GO:0019395 GO:0032787 GO:0044248 GO:0046395 GO:0055114 GO:0005622 GO:0005623 GO:0005737 
GO:0005739 GO:0005759 GO:0031974 GO:0043229 GO:0044429 GO:0044444  
5 0.7932 3.33 0.10 0.97 2dvlB 0.65 GO:0003995 GO:0009055 GO:0050660 GO:0050662 GO:0008152  
6 0.7886 3.14 0.10 0.96 2zafD 0.65 GO:0003995 GO:0009055 GO:0050660 GO:0050662 GO:0008152  
7 0.7822 3.28 0.10 0.97 1rx0D 0.64 GO:0003995 GO:0009055 GO:0050660 GO:0050662 GO:0006139 GO:0006519 GO:0006629 GO:0006807 GO:0009056 GO:0009058 GO:0009889 GO:0009987 GO:0043283 GO:0044248 
GO:0044249 GO:0044260 GO:0050794 GO:0055114 GO:0060255 GO:0065007 GO:0005622 GO:0005623 GO:0005737 GO:0005739 GO:0043229 GO:0044444  
8 0.7909 3.18 0.10 0.97 1bucB 0.64 GO:0004085 GO:0009055 GO:0050660 GO:0050662 GO:0006631 GO:0009987 GO:0032787 GO:0055114  
9 0.7611 3.39 0.10 0.96 2fonC 0.63 GO:0003995 GO:0003997 GO:0009055 GO:0050660 GO:0050662 GO:0006631 GO:0006635 GO:0009056 GO:0009987 GO:0019395 GO:0032787 GO:0044248 GO:0046395 GO:0005622 
GO:0005623 GO:0005737 GO:0005777 GO:0043229 GO:0044444  
10 0.7888 3.17 0.10 0.96 2d29B 0.63 GO:0003995 GO:0009055 GO:0050660 GO:0050662 GO:0008152  
Consensus Prediction of Gene Ontology terms 
 
  
Molecular Function    Biological Process   Cellular Location 
GO term GO-Score    GO term GO-Score   GO term GO-Score 
GO:0009055 0.659    GO:0008152 0.659    GO:0043229 0.638 
GO:0003995 0.659    GO:0044237 0.466    GO:0005737 0.638 
GO:0050660 0.594    GO:0009987 0.466    GO:0005623 0.638 
GO:0050662 0.594    GO:0006629 0.466    GO:0005622 0.638 
GO:0004085 0.207    GO:0044238 0.466    GO:0044444 0.638 
GO:0000062 0.073    GO:0055114 0.403    GO:0005739 0.575 
GO:0008289 0.073    GO:0044255 0.402    GO:0044429 0.511 
GO:0005504 0.073    GO:0032787 0.402    GO:0005759 0.395 
GO:0016634 0.063    GO:0006631 0.402    GO:0031974 0.395 
GO:0003997 0.063    GO:0019752 0.402    GO:0070013 0.395 
 
       
(a) Ranking in the first table is based on a function prediction score (Fh-score), which is calculated based on the C-score of the structure prediction and the TM-score, IDENa, RMSDa and Cov. of the structural alignment by TM-align between the predicted model and the PDB structures (For details, see Inferring protein function by global 
and local similarity of structural analogs, 2010, submitted). 
(b) RMSDa is the RMSD between models and the PDB structure in the structurally aligned regions by TM-align. 
(c) IDENa is the percentage sequence identity in the structurally aligned region. 
(d) Cov. represents the coverage of the alignment and is equal to the number of structurally aligned residues divided by length of model. 
(e) A consensus prediction of GO terms is derived from the structural analogs that have an Fh-score of >=1.0. The GO-Score associated with each prediction is defined as the average weight of the GO term, where the weights are assigned based on the Fh-score of the template from which the GO term is derived. A prediction with a 
GO-score >0.5 signifies a prediction with high confidence and vice versa. 
 
 
  Predicted Binding Site 
 
 
Spin On/Off 
Identified stuctural analogs with similar binding site: 
  Rank PDB 
Hit 
TM-score RMSDa IDENa Cov. BS-score Lig. Name Download Complex 
Predicted binding site residues in the model 
 
1 2pg0B  0.7922 3.3200 0.0820 0.9731 1.1581 FAD Download  90,92,97,100,101,102,158,159,160,161,162,163 
 
2 3oibA  0.7951 3.0600 0.0440 0.9624 1.1076 FDA Download  90,92,97,100,102,158,159,160,161,162 
 
3 2c0uA  0.7911 3.2000 0.1050 0.9624 1.0249 POL Download  103,158,159,160,161 
 
4 2r0mA  0.7849 3.2300 0.0710 0.9677 0.8162 4NI Download  112,113,116,117,121,141,148,149 
 
5 2c12F  0.7897 3.1100 0.1050 0.9570 1.0196 FAD Download  74,76,117,142,144,145,146,148 
 
6 3eonC  0.7713 3.3500 0.0610 0.9516 0.8240 341 Download  79,80,152,156,176,179,180 
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7 1egcB  0.7973 3.2900 0.1100 0.9677 0.4348 CO8 Download  3,4,5,8,44,54,55,57,61,64,65,67,68,138,180,181,185 
 
8 2jifD  0.7908 3.1900 0.0880 0.9677 0.9876 FAD Download  90,97,100,104,158,159,160,161,164 
 
9 3d9gB  0.7900 3.1200 0.1050 0.9570 1.0250 POL Download  103,158,159,160,161 
 
10 3oibA  0.7951 3.0600 0.0440 0.9624 0.6506 FDA Download  76,79,80,81,106,107,108,112,113,114,115,143,147,150,151,153,154,156 
 
 
Click on the radio buttons to visualize predicted binding sites and residues. 
   
(a) Ranking of the predicted binding sites is based on the size of the clusters formed after local superposition of ligands of the templates onto the query structure. 
(b) BS-score is a measure of local sequence & structure similarity between template's binding site and predicted binding site in the query structure. Based on large scale benchmarking analysis, binding site predictions with BS-score>1.1 signify predictions with high confidence. 
(c) RMSDa the RMSD between residues that are structurally aligned by TM-align. 
(d) IDENa is the percentage sequence identity in the structurally aligned region. 
(e) Cov. represents the coverage of the alignment by TM-align and is equal to the number of structurally aligned residues divided by length of the model. 
(f) For details, see COFACTOR: protein-ligand binding site predictions by global structure match and local geometry refinement. (In preparation) 
 
 
 
 
 
  Please cite following articles when you use the I-TASSER server: 
1. Ambrish Roy, Alper Kucukural, Yang Zhang. I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protocols, vol 5, 725-738 (2010). 
2. Yang Zhang. Template-based modeling and free modeling by I-TASSER in CASP7. Proteins, vol 69 (Suppl 8), 108-117 (2007). 
 
App. 3: Full Clustering: 
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App. 4: Full Annotations: 
The functional annotations were done using the go.david websuite and the standard pathway 
settings. 
Genes upregulated after 24h and declining after 48h: 
Category Term Count % PValue 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini 
GOTERM_BP_FAT 
GO:0009070~serine family amino acid biosynthetic 
process 2 33.3333333 0.00162566 3 11 13528 819.878788 0.07662694 0.07662694 
GOTERM_BP_FAT GO:0009069~serine family amino acid metabolic process 2 33.3333333 0.00384033 3 26 13528 346.871795 0.17183121 0.08996221 
SP_PIR_KEYWORDS amino-acid biosynthesis 2 33.3333333 0.00498196 5 24 19235 320.583333 0.10405565 0.10405565 
KEGG_PATHWAY hsa00260:Glycine, serine and threonine metabolism 2 33.3333333 0.00609636 2 31 5085 164.032258 0.02416336 0.02416336 
GOTERM_BP_FAT GO:0008652~cellular amino acid biosynthetic process 2 33.3333333 0.00752598 3 51 13528 176.836601 0.30938158 0.11608049 
GOTERM_BP_FAT GO:0009309~amine biosynthetic process 2 33.3333333 0.01193975 3 81 13528 111.341564 0.44487865 0.13682872 
GOTERM_BP_FAT GO:0016053~organic acid biosynthetic process 2 33.3333333 0.02278499 3 155 13528 58.1849462 0.67676657 0.20218306 
GOTERM_BP_FAT GO:0046394~carboxylic acid biosynthetic process 2 33.3333333 0.02278499 3 155 13528 58.1849462 0.67676657 0.20218306 
GOTERM_BP_FAT GO:0044271~nitrogen compound biosynthetic process 2 33.3333333 0.04747306 3 325 13528 27.7497436 0.90774581 0.32780128 
 
Genes upregulated after 24h and further upregulated after 48h: 
Category Term Count % PValue 
List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment Bonferroni Benjamini 
SP_PIR_KEYWORDS Antiviral defense 19 4.41860465 3.01E-16 403 62 19235 14.626791 1.07E-13 1.07E-13 
GOTERM_BP_FAT GO:0009615~response to virus 22 5.11627907 6.04E-15 281 109 13528 9.71680434 1.01E-11 1.01E-11 
PIR_SUPERFAMILY PIRSF001934:interferon alpha 11 2.55813953 1.28E-14 142 15 7396 38.1953052 1.89E-12 1.89E-12 
INTERPRO IPR000471:Interferon alpha/beta/delta 11 2.55813953 2.24E-13 347 17 16659 31.0644177 1.38E-10 1.38E-10 
INTERPRO IPR015589:Interferon alpha 10 2.3255814 4.31E-13 347 13 16659 36.9297273 2.66E-10 1.33E-10 
KEGG_PATHWAY 
hsa04060:Cytokine-cytokine receptor 
interaction 28 6.51162791 5.05E-13 103 262 5085 5.27606907 4.95E-11 4.95E-11 
SMART SM00076:IFabd 11 2.55813953 1.43E-12 230 17 9079 25.5419437 2.34E-10 2.34E-10 
KEGG_PATHWAY hsa04622:RIG-I-like receptor signaling pathway 15 3.48837209 6.46E-11 103 71 5085 10.4300561 6.33E-09 3.17E-09 
SP_PIR_KEYWORDS antiviral 9 2.09302326 9.14E-11 403 14 19235 30.6832683 2.94E-08 1.47E-08 
KEGG_PATHWAY hsa04630:Jak-STAT signaling pathway 20 4.65116279 1.20E-10 103 155 5085 6.37018478 1.17E-08 3.91E-09 
KEGG_PATHWAY hsa04140:Regulation of autophagy 11 2.55813953 8.17E-10 103 35 5085 15.5159501 8.01E-08 2.00E-08 
INTERPRO IPR012351:Four-helical cytokine, core 12 2.79069767 1.84E-09 347 46 16659 12.5239945 1.14E-06 3.79E-07 
GOTERM_BP_FAT GO:0006952~defense response 38 8.8372093 4.80E-09 281 615 13528 2.97464919 8.13E-06 4.07E-06 
KEGG_PATHWAY 
hsa04650:Natural killer cell mediated 
cytotoxicity 17 3.95348837 5.46E-09 103 133 5085 6.31031462 5.35E-07 1.07E-07 
KEGG_PATHWAY hsa04623:Cytosolic DNA-sensing pathway 12 2.79069767 7.05E-09 103 55 5085 10.7714034 6.91E-07 1.15E-07 
SP_PIR_KEYWORDS leukocyte 8 1.86046512 9.21E-09 403 15 19235 25.4557486 2.97E-06 9.88E-07 
KEGG_PATHWAY hsa04620:Toll-like receptor signaling pathway 14 3.25581395 7.44E-08 103 101 5085 6.8432183 7.29E-06 1.04E-06 
SP_PIR_KEYWORDS cytokine 18 4.18604651 2.70E-07 403 181 19235 4.74658295 8.68E-05 2.17E-05 
KEGG_PATHWAY hsa05320:Autoimmune thyroid disease 10 2.3255814 5.57E-07 103 51 5085 9.68018275 5.46E-05 6.83E-06 
GOTERM_MF_FAT 
GO:0005132~interferon-alpha/beta receptor 
binding 6 1.39534884 6.29E-07 291 9 12983 29.7434135 2.90E-04 2.90E-04 
UP_SEQ_FEATURE compositionally biased region:Poly-Ser 29 6.74418605 9.91E-07 402 475 19113 2.9027337 0.0011335 0.0011335 
GOTERM_MF_FAT GO:0005125~cytokine activity 18 4.18604651 1.77E-06 291 195 12983 4.11831879 8.14E-04 4.07E-04 
KEGG_PATHWAY hsa04612:Antigen processing and presentation 11 2.55813953 4.87E-06 103 83 5085 6.54287051 4.77E-04 5.30E-05 
GOTERM_BP_FAT GO:0006917~induction of apoptosis 21 4.88372093 1.14E-05 281 320 13528 3.15934164 0.01917395 0.0064326 
GOTERM_BP_FAT 
GO:0012502~induction of programmed cell 
death 21 4.88372093 1.20E-05 281 321 13528 3.14949945 0.0200404 0.0050482 
GOTERM_BP_FAT 
GO:0043067~regulation of programmed cell 
death 36 8.37209302 2.99E-05 281 812 13528 2.13438985 0.0493232 0.01006523 
GOTERM_BP_FAT GO:0001775~cell activation 19 4.41860465 3.02E-05 281 287 13528 3.18712413 0.04981729 0.00848067 
GOTERM_BP_FAT GO:0010941~regulation of cell death 36 8.37209302 3.22E-05 281 815 13528 2.1265332 0.05302025 0.0077523 
GOTERM_BP_FAT 
GO:0043068~positive regulation of 
programmed cell death 24 5.58139535 3.48E-05 281 433 13528 2.66839808 0.05723971 0.00734083 
UP_SEQ_FEATURE compositionally biased region:Ser-rich 24 5.58139535 3.62E-05 402 425 19113 2.68488147 0.0406274 0.02052432 
GOTERM_BP_FAT GO:0010942~positive regulation of cell death 24 5.58139535 3.70E-05 281 435 13528 2.65612959 0.06076683 0.00694152 
GOTERM_BP_FAT GO:0042981~regulation of apoptosis 35 8.13953488 5.71E-05 281 804 13528 2.09574901 0.09220711 0.00962726 
GOTERM_BP_FAT GO:0043065~positive regulation of apoptosis 23 5.34883721 8.98E-05 281 430 13528 2.57505586 0.14107233 0.01372948 
GOTERM_CC_FAT GO:0005615~extracellular space 28 6.51162791 1.40E-04 235 685 12782 2.22330175 0.03625952 0.03625952 
GOTERM_BP_FAT GO:0045321~leukocyte activation 16 3.72093023 1.58E-04 281 242 13528 3.18296521 0.23497433 0.02207323 
GOTERM_BP_FAT GO:0006955~immune response 30 6.97674419 2.30E-04 281 690 13528 2.0931456 0.32289592 0.02954926 
GOTERM_BP_FAT 
GO:0043122~regulation of I-kappaB 
kinase/NF-kappaB cascade 10 2.3255814 3.74E-04 281 107 13528 4.49928493 0.46924831 0.04423882 
SP_PIR_KEYWORDS zinc-finger 57 13.255814 5.61E-04 403 
171
8 19235 1.58357574 0.16529645 0.03549063 
UP_SEQ_FEATURE mutagenesis site 65 15.1162791 7.19E-04 402 
204
5 19113 1.51120315 0.56114082 0.24006743 
GOTERM_BP_FAT 
GO:0043123~positive regulation of I-kappaB 
kinase/NF-kappaB cascade 9 2.09302326 8.97E-04 281 97 13528 4.46681586 0.7810111 0.09629197 
PIR_SUPERFAMILY PIRSF038749:interferon lambda 3 0.69767442 
0.001069
19 142 3 7396 52.084507 0.14642784 0.07611031 
GOTERM_BP_FAT GO:0030278~regulation of ossification 8 1.86046512 
0.001138
5 281 78 13528 4.9376768 0.85464612 0.11355527 
GOTERM_MF_FAT 
GO:0005072~transforming growth factor beta 
receptor, cytoplasmic mediator activity 4 0.93023256 
0.001593
19 291 11 12983 16.2236801 0.52051726 0.21730782 
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GOTERM_BP_FAT GO:0007243~protein kinase cascade 18 4.18604651 
0.001838
02 281 370 13528 2.34206021 0.95560543 0.16741004 
BIOCARTA h_tgfbPathway:TGF beta signaling pathway 5 1.1627907 
0.001896
21 49 17 1437 8.62545018 0.15702755 0.15702755 
GOTERM_BP_FAT GO:0012501~programmed cell death 25 5.81395349 
0.002001
48 281 611 13528 1.96981787 0.96635509 0.17174859 
GOTERM_BP_FAT GO:0008219~cell death 28 6.51162791 
0.002017
02 281 719 13528 1.87480635 0.96723071 0.16465345 
GOTERM_BP_FAT GO:0016265~death 28 6.51162791 
0.002193
23 281 724 13528 1.86185879 0.97569836 0.16961064 
SP_PIR_KEYWORDS zinc 66 15.3488372 
0.002275
45 403 
218
9 19235 1.43908126 0.51978935 0.11507738 
GOTERM_BP_FAT 
GO:0010740~positive regulation of protein 
kinase cascade 11 2.55813953 
0.002510
82 281 167 13528 3.17105291 0.98582345 0.18345607 
GOTERM_BP_FAT GO:0046649~lymphocyte activation 12 2.79069767 
0.002879
04 281 199 13528 2.90305621 0.99241243 0.19898427 
SP_PIR_KEYWORDS Proto-oncogene 13 3.02325581 
0.003407
96 403 230 19235 2.69775596 0.66687455 0.14532477 
PIR_SUPERFAMILY PIRSF028804:protein yippee-like 3 0.69767442 
0.003475
4 142 5 7396 31.2507042 0.40265183 0.15781175 
GOTERM_BP_FAT GO:0006915~apoptosis 24 5.58139535 
0.003491
01 281 602 13528 1.9192963 0.99731646 0.22695513 
INTERPRO IPR004910:Yippee-like protein 3 0.69767442 
0.004126
59 347 5 16659 28.8051873 0.92202569 0.47156949 
GOTERM_BP_FAT GO:0045449~regulation of transcription 73 16.9767442 
0.004331
42 281 
260
1 13528 1.35116934 0.99935677 0.26376723 
GOTERM_BP_FAT 
GO:0006357~regulation of transcription from 
RNA polymerase II promoter 27 6.27906977 
0.004596
27 281 727 13528 1.78795518 0.99959003 0.26800162 
GOTERM_CC_FAT GO:0044421~extracellular region part 30 6.97674419 
0.005211
78 235 960 12782 1.69973404 0.74829747 0.49830036 
GOTERM_BP_FAT 
GO:0051252~regulation of RNA metabolic 
process 54 12.5581395 
0.005402
88 281 
181
3 13528 1.43391441 0.99989608 0.29725727 
GOTERM_BP_FAT 
GO:0006355~regulation of transcription, DNA-
dependent 53 12.3255814 
0.005508
85 281 
177
3 13528 1.43911138 0.99991323 0.29275656 
GOTERM_BP_FAT 
GO:0010627~regulation of protein kinase 
cascade 13 3.02325581 
0.005772
08 281 249 13528 2.51345596 0.99994457 0.29532326 
INTERPRO 
IPR000340:Protein-tyrosine phosphatase, dual 
specificity 5 1.1627907 
0.007036
22 347 37 16659 6.4876548 0.98717932 0.58160913 
PIR_SUPERFAMILY 
PIRSF005552:guanine nucleotide-binding 
protein 1 3 0.69767442 
0.007117
49 142 7 7396 22.3219316 0.65255742 0.23224835 
GOTERM_MF_FAT GO:0046914~transition metal ion binding 81 18.8372093 
0.007314
76 291 
278
5 12983 1.29760314 0.96610527 0.57092515 
GOTERM_BP_FAT GO:0045087~innate immune response 9 2.09302326 
0.007988
28 281 138 13528 3.1397184 0.99999873 0.37388614 
GOTERM_MF_FAT GO:0008270~zinc ion binding 69 16.0465116 
0.008302
59 291 
231
1 12983 1.33208278 0.97858086 0.53638187 
INTERPRO IPR018957:Zinc finger, C3HC4 RING-type 12 2.79069767 
0.008316
43 347 228 16659 2.52677082 0.99421618 0.57632217 
INTERPRO 
IPR003191:Guanylate-binding protein, C-
terminal 3 0.69767442 
0.008430
27 347 7 16659 20.5751338 0.99461171 0.52584362 
INTERPRO 
IPR000340:Dual specificity phosphatase, 
catalytic domain 5 1.1627907 
0.008483
77 347 39 16659 6.15495456 0.99478814 0.48164882 
INTERPRO IPR019787:Zinc finger, PHD-finger 7 1.62790698 
0.008503
2 347 85 16659 3.95365316 0.99485076 0.44313592 
GOTERM_BP_FAT GO:0042742~defense response to bacterium 8 1.86046512 
0.008638
97 281 112 13528 3.4387392 0.99999958 0.38715557 
GOTERM_BP_FAT 
GO:0010629~negative regulation of gene 
expression 20 4.65116279 
0.008735
34 281 504 13528 1.91041066 0.99999965 0.38069532 
SP_PIR_KEYWORDS metal-binding 81 18.8372093 
0.009092
67 403 
297
2 19235 1.30083843 0.94719932 0.30764323 
UP_SEQ_FEATURE domain:Rhodanese 4 0.93023256 
0.009207
32 402 21 19113 9.05614783 0.99997486 0.92919345 
BIOCARTA h_il7Pathway:IL-7 Signal Transduction 4 0.93023256 
0.009830
68 49 14 1437 8.37900875 0.58899058 0.35889983 
GOTERM_BP_FAT 
GO:0006942~regulation of striated muscle 
contraction 4 0.93023256 
0.010096
1 281 22 13528 8.75315432 0.99999997 0.41541992 
GOTERM_BP_FAT 
GO:0045944~positive regulation of 
transcription from RNA polymerase II promoter 16 3.72093023 
0.010391
43 281 371 13528 2.07621989 0.99999998 0.41485824 
INTERPRO IPR019542:Enhancer of polycomb-like 3 0.69767442 
0.011086
93 347 8 16659 18.0032421 0.99897066 0.4973614 
GOTERM_BP_FAT GO:0006350~transcription 59 13.7209302 
0.011729
54 281 
210
1 13528 1.35192698 1 0.44429312 
GOTERM_BP_FAT 
GO:0045667~regulation of osteoblast 
differentiation 5 1.1627907 
0.011765
95 281 43 13528 5.59794753 1 0.43589261 
SP_PIR_KEYWORDS alternative splicing 180 41.8604651 
0.011857
76 403 
748
8 19235 1.14734444 0.97852826 0.3473927 
UP_SEQ_FEATURE repeat:TNFR-Cys 3 4 0.93023256 
0.011887
58 402 23 19113 8.26865672 0.99999887 0.93533698 
INTERPRO IPR011029:DEATH-like 6 1.39534884 
0.012680
68 347 67 16659 4.29928169 0.99961949 0.51120836 
INTERPRO IPR001763:Rhodanese-like 4 0.93023256 
0.013010
65 347 24 16659 8.00144092 0.99969041 0.49000495 
GOTERM_BP_FAT GO:0001817~regulation of cytokine production 10 2.3255814 
0.013118
95 281 181 13528 2.65979827 1 0.46261338 
GOTERM_BP_FAT 
GO:0052173~response to defenses of other 
organism during symbiotic interaction 3 0.69767442 
0.013960
5 281 9 13528 16.0474496 1 0.47443837 
GOTERM_BP_FAT GO:0052200~response to host defenses 3 0.69767442 
0.013960
5 281 9 13528 16.0474496 1 0.47443837 
GOTERM_BP_FAT GO:0075136~response to host 3 0.69767442 
0.013960
5 281 9 13528 16.0474496 1 0.47443837 
GOTERM_CC_FAT GO:0031410~cytoplasmic vesicle 21 4.88372093 
0.014267
02 235 642 12782 1.77916087 0.97748602 0.71763071 
SP_PIR_KEYWORDS Apoptosis 16 3.72093023 
0.014594
1 403 381 19235 2.00438965 0.99120813 0.37711464 
GOTERM_BP_FAT GO:0007623~circadian rhythm 5 1.1627907 
0.014828
63 281 46 13528 5.232864 1 0.4860358 
UP_SEQ_FEATURE repeat:TNFR-Cys 2 4 0.93023256 
0.014970
15 402 25 19113 7.60716418 0.99999997 0.9437755 
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UP_SEQ_FEATURE repeat:TNFR-Cys 1 4 0.93023256 
0.014970
15 402 25 19113 7.60716418 0.99999997 0.9437755 
GOTERM_BP_FAT 
GO:0016481~negative regulation of 
transcription 18 4.18604651 
0.014974
5 281 459 13528 1.88793525 1 0.48053887 
UP_SEQ_FEATURE splice variant 179 41.627907 
0.015235
19 402 
745
8 19113 1.14112563 0.99999998 0.91883092 
GOTERM_CC_FAT GO:0000323~lytic vacuole 10 2.3255814 
0.015731
82 235 211 12782 2.5777957 0.98479631 0.64885438 
GOTERM_CC_FAT GO:0005764~lysosome 10 2.3255814 
0.015731
82 235 211 12782 2.5777957 0.98479631 0.64885438 
GOTERM_BP_FAT GO:0042110~T cell activation 8 1.86046512 
0.015811
38 281 126 13528 3.05665706 1 0.49062149 
GOTERM_MF_FAT 
GO:0008138~protein tyrosine/serine/threonine 
phosphatase activity 5 1.1627907 
0.016422
68 291 44 12983 5.06990003 0.99951614 0.71980944 
KEGG_PATHWAY hsa05220:Chronic myeloid leukemia 6 1.39534884 
0.016761
52 103 75 5085 3.94951456 0.80920413 0.15266158 
KEGG_PATHWAY hsa04010:MAPK signaling pathway 12 2.79069767 
0.017257
93 103 267 5085 2.21882841 0.81841677 0.14366588 
INTERPRO IPR008343:MAP kinase phosphatase 3 0.69767442 
0.017336
41 347 10 16659 14.4025937 0.9999794 0.56396306 
GOTERM_CC_FAT GO:0005773~vacuole 11 2.55813953 
0.017758
04 235 252 12782 2.37423168 0.99117572 0.6117282 
SP_PIR_KEYWORDS transcription regulation 57 13.255814 
0.017829
29 403 
202
6 19235 1.34283471 0.99695065 0.4094026 
GOTERM_BP_FAT GO:0007242~intracellular signaling cascade 38 8.8372093 
0.017862
53 281 
125
6 13528 1.45653603 1 0.52491367 
GOTERM_MF_FAT GO:0046332~SMAD binding 5 1.1627907 
0.019072
35 291 46 12983 4.8494696 0.99986048 0.71865755 
GOTERM_BP_FAT GO:0009617~response to bacterium 10 2.3255814 
0.019152
88 281 193 13528 2.49442222 1 0.54137975 
GOTERM_BP_FAT 
GO:0010558~negative regulation of 
macromolecule biosynthetic process 20 4.65116279 
0.019183
19 281 547 13528 1.76023213 1 0.53355753 
GOTERM_CC_FAT GO:0043235~receptor complex 7 1.62790698 
0.019772
6 235 116 12782 3.28224505 0.99486802 0.58468189 
GOTERM_BP_FAT 
GO:0009967~positive regulation of signal 
transduction 13 3.02325581 
0.020105
08 281 295 13528 2.12152723 1 0.54226781 
GOTERM_BP_FAT 
GO:0045934~negative regulation of 
nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process 19 4.41860465 
0.020186
42 281 512 13528 1.78653247 1 0.53570164 
UP_SEQ_FEATURE domain:Bromo 4 0.93023256 
0.020362
64 402 28 19113 6.79211087 1 0.9473708 
UP_SEQ_FEATURE DNA-binding region:Basic motif 9 2.09302326 
0.020524
5 402 161 19113 2.65778252 1 0.92852026 
INTERPRO IPR010919:SAND-like 3 0.69767442 
0.020901
22 347 11 16659 13.093267 0.99999781 0.60580497 
INTERPRO 
IPR015894:Guanylate-binding protein, N-
terminal 3 0.69767442 
0.020901
22 347 11 16659 13.093267 0.99999781 0.60580497 
GOTERM_BP_FAT 
GO:0045893~positive regulation of 
transcription, DNA-dependent 18 4.18604651 
0.020953
28 281 477 13528 1.81669241 1 0.54130319 
GOTERM_CC_FAT GO:0031982~vesicle 21 4.88372093 
0.021559
55 235 670 12782 1.70480788 0.99682984 0.56044664 
SMART SM00450:RHOD 4 0.93023256 
0.021687
76 230 24 9079 6.57898551 0.97256482 0.83436432 
INTERPRO IPR001315:Caspase Recruitment 4 0.93023256 
0.021770
71 347 29 16659 6.62188214 0.99999874 0.59561721 
GOTERM_BP_FAT 
GO:0051254~positive regulation of RNA 
metabolic process 18 4.18604651 
0.022855
71 281 481 13528 1.80158478 1 0.56518998 
GOTERM_BP_FAT 
GO:0051172~negative regulation of nitrogen 
compound metabolic process 19 4.41860465 0.022906 281 519 13528 1.76243666 1 0.55838223 
GOTERM_BP_FAT GO:0030500~regulation of bone mineralization 4 0.93023256 
0.023584
41 281 30 13528 6.41897983 1 0.56160209 
GOTERM_BP_FAT GO:0043281~regulation of caspase activity 6 1.39534884 
0.023855
74 281 79 13528 3.65638092 1 0.55848633 
INTERPRO 
IPR004827:Basic-leucine zipper (bZIP) 
transcription factor 5 1.1627907 
0.024115
85 347 53 16659 4.5291175 0.99999971 0.60990483 
GOTERM_BP_FAT 
GO:0031327~negative regulation of cellular 
biosynthetic process 20 4.65116279 
0.024164
31 281 561 13528 1.71630477 1 0.55603579 
UP_SEQ_FEATURE zinc finger region:C3H1-type 2 4 0.93023256 
0.024474
6 402 30 19113 6.33930348 1 0.94141082 
UP_SEQ_FEATURE zinc finger region:C3H1-type 1 4 0.93023256 
0.024474
6 402 30 19113 6.33930348 1 0.94141082 
INTERPRO 
IPR016129:Peptidase C14, ICE, catalytic 
subunit p20, active site 3 0.69767442 
0.024741
49 347 12 16659 12.0021614 0.99999981 0.59718017 
INTERPRO IPR006011:Syntaxin, N-terminal 3 0.69767442 
0.024741
49 347 12 16659 12.0021614 0.99999981 0.59718017 
INTERPRO 
IPR002138:Peptidase C14, caspase non-
catalytic subunit p10 3 0.69767442 
0.024741
49 347 12 16659 12.0021614 0.99999981 0.59718017 
SP_PIR_KEYWORDS coiled coil 56 13.0232558 
0.024840
5 403 
201
9 19235 1.32385022 0.99969636 0.49082929 
INTERPRO IPR011616:bZIP transcription factor, bZIP-1 4 0.93023256 
0.025983
15 347 31 16659 6.19466394 0.99999991 0.59441305 
SP_PIR_KEYWORDS Transcription 57 13.255814 
0.026281
39 403 
207
1 19235 1.31365675 0.99981138 0.48298171 
GOTERM_MF_FAT GO:0030528~transcription regulator activity 46 10.6976744 
0.026889
68 291 
151
2 12983 1.35733832 0.99999651 0.79210699 
KEGG_PATHWAY hsa04710:Circadian rhythm 3 0.69767442 
0.026911
3 103 13 5085 11.3928305 0.93098586 0.1997147 
GOTERM_BP_FAT 
GO:0052548~regulation of endopeptidase 
activity 6 1.39534884 
0.027491
26 281 82 13528 3.52261088 1 0.59650255 
GOTERM_BP_FAT 
GO:0070167~regulation of biomineral 
formation 4 0.93023256 
0.027958
89 281 32 13528 6.01779359 1 0.59579161 
UP_SEQ_FEATURE short sequence motif:SH3-binding 5 1.1627907 
0.028124
88 402 55 19113 4.32225237 1 0.94867107 
UP_SEQ_FEATURE domain:Leucine-zipper 7 1.62790698 
0.028452
09 402 110 19113 3.02557666 1 0.93633837 
GOTERM_CC_FAT GO:0030054~cell junction 17 3.95348837 
0.028528
3 235 518 12782 1.78504888 0.99951965 0.61523543 
UP_SEQ_FEATURE compositionally biased region:Asp-rich 4 0.93023256 0.029000 402 32 19113 5.94309701 1 0.92513141 
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24 
GOTERM_BP_FAT 
GO:0009890~negative regulation of 
biosynthetic process 20 4.65116279 
0.029439
82 281 573 13528 1.68036121 1 0.60814046 
BIOCARTA 
h_dcPathway:Dendritic cells in regulating TH1 
and TH2 Development 4 0.93023256 
0.030485
6 49 21 1437 5.58600583 0.93835702 0.60497201 
INTERPRO 
IPR001368:TNFR/CD27/30/40/95 cysteine-rich 
region 4 0.93023256 
0.030600
23 347 33 16659 5.81922976 1 0.63549808 
GOTERM_CC_FAT GO:0031988~membrane-bounded vesicle 18 4.18604651 
0.032059
89 235 568 12782 1.72367396 0.99981635 0.61550659 
INTERPRO 
IPR017907:Zinc finger, RING-type, conserved 
site 12 2.79069767 
0.032804
06 347 280 16659 2.05751338 1 0.64262746 
SP_PIR_KEYWORDS kinase 23 5.34883721 
0.032831
03 403 688 19235 1.59560924 0.99997853 0.5359613 
GOTERM_BP_FAT GO:0052547~regulation of peptidase activity 6 1.39534884 
0.032860
32 281 86 13528 3.35876852 1 0.6424546 
GOTERM_MF_FAT 
GO:0017017~MAP kinase 
tyrosine/serine/threonine phosphatase activity 3 0.69767442 0.032972 291 13 12983 10.295797 0.99999981 0.82046231 
GOTERM_MF_FAT GO:0033549~MAP kinase phosphatase activity 3 0.69767442 0.032972 291 13 12983 10.295797 0.99999981 0.82046231 
INTERPRO 
IPR015917:Peptidase C14, caspase precursor 
p45, core 3 0.69767442 
0.033197
17 347 14 16659 10.2875669 1 0.62913666 
GOTERM_BP_FAT 
GO:0010628~positive regulation of gene 
expression 20 4.65116279 
0.033210
15 281 581 13528 1.65722371 1 0.63978866 
SP_PIR_KEYWORDS phosphoprotein 171 39.7674419 
0.033440
25 403 
726
3 19235 1.12374355 0.99998248 0.51815251 
UP_SEQ_FEATURE zinc finger region:RING-type 10 2.3255814 
0.033584
32 402 210 19113 2.26403696 1 0.93881786 
BIOCARTA h_ifnaPathway:IFN alpha signaling pathway 3 0.69767442 
0.033869
21 49 9 1437 9.7755102 0.95499785 0.53941656 
SMART SM00503:SynN 3 0.69767442 
0.035395
76 230 12 9079 9.86847826 0.99728817 0.86054918 
SMART SM00195:DSPc 4 0.93023256 
0.035728
91 230 29 9079 5.44467766 0.99743752 0.77500903 
SMART SM00114:CARD 4 0.93023256 
0.035728
91 230 29 9079 5.44467766 0.99743752 0.77500903 
SP_PIR_KEYWORDS lysosome 8 1.86046512 
0.037264
36 403 149 19235 2.56265925 0.99999511 0.53432878 
PIR_SUPERFAMILY 
PIRSF002288:microtubule-associated protein 
MAP1B 2 0.46511628 
0.037767
8 142 2 7396 52.084507 0.99664708 0.68004812 
PIR_SUPERFAMILY 
PIRSF011866:N-myc-interactor 
protein/interferon-induced protein IFP35 2 0.46511628 
0.037767
8 142 2 7396 52.084507 0.99664708 0.68004812 
INTERPRO IPR011600:Peptidase C14, caspase catalytic 3 0.69767442 
0.037787
99 347 15 16659 9.60172911 1 0.6605145 
INTERPRO 
IPR001079:Galectin, carbohydrate recognition 
domain 3 0.69767442 
0.037787
99 347 15 16659 9.60172911 1 0.6605145 
INTERPRO IPR017855:SMAD domain-like 3 0.69767442 
0.037787
99 347 15 16659 9.60172911 1 0.6605145 
INTERPRO 
IPR001309:Peptidase C14, ICE, catalytic 
subunit p20 3 0.69767442 
0.037787
99 347 15 16659 9.60172911 1 0.6605145 
GOTERM_BP_FAT 
GO:0002366~leukocyte activation during 
immune response 4 0.93023256 
0.037905
64 281 36 13528 5.34914986 1 0.68265233 
GOTERM_BP_FAT 
GO:0002263~cell activation during immune 
response 4 0.93023256 
0.037905
64 281 36 13528 5.34914986 1 0.68265233 
INTERPRO IPR018359:Bromodomain, conserved site 4 0.93023256 
0.038276
98 347 36 16659 5.33429395 1 0.64900725 
GOTERM_BP_FAT 
GO:0001819~positive regulation of cytokine 
production 6 1.39534884 
0.038840
66 281 90 13528 3.20948992 1 0.6853676 
SP_PIR_KEYWORDS antiport 4 0.93023256 
0.038902
66 403 36 19235 5.30328095 0.99999717 0.52837827 
GOTERM_CC_FAT GO:0005925~focal adhesion 6 1.39534884 
0.039277
45 235 102 12782 3.19949937 0.99997454 0.65279438 
INTERPRO IPR001965:Zinc finger, PHD-type 6 1.39534884 
0.039432
07 347 90 16659 3.20057637 1 0.64451106 
UP_SEQ_FEATURE compositionally biased region:Gln-rich 8 1.86046512 
0.040287
51 402 151 19113 2.51892854 1 0.95667145 
GOTERM_BP_FAT GO:0031214~biomineral formation 4 0.93023256 
0.040638
45 281 37 13528 5.20457824 1 0.69592279 
GOTERM_CC_FAT GO:0044459~plasma membrane part 52 12.0930233 
0.040771
2 235 
220
3 12782 1.28386629 0.99998312 0.63175828 
INTERPRO IPR000719:Protein kinase, core 17 3.95348837 
0.040780
64 347 476 16659 1.71459448 1 0.64212225 
SP_PIR_KEYWORDS ubl conjugation 20 4.65116279 
0.040863
01 403 588 19235 1.62345335 0.99999854 0.52590563 
GOTERM_BP_FAT GO:0042118~endothelial cell activation 2 0.46511628 
0.040968
72 281 2 13528 48.1423488 1 0.69282819 
GOTERM_MF_FAT GO:0003677~DNA binding 65 15.1162791 
0.041007
12 291 
233
1 12983 1.24409387 1 0.85489277 
INTERPRO IPR009909:Nmi/IFP 35 2 0.46511628 
0.041108
95 347 2 16659 48.0086455 1 0.63070741 
INTERPRO IPR009607:Enhancer of polycomb, C-terminal 2 0.46511628 
0.041108
95 347 2 16659 48.0086455 1 0.63070741 
INTERPRO 
IPR009938:Interferon induced 35 kDa, N-
terminal 2 0.46511628 
0.041108
95 347 2 16659 48.0086455 1 0.63070741 
GOTERM_BP_FAT 
GO:0007249~I-kappaB kinase/NF-kappaB 
cascade 5 1.1627907 
0.041320
6 281 63 13528 3.82082133 1 0.69000003 
GOTERM_BP_FAT 
GO:0010647~positive regulation of cell 
communication 13 3.02325581 
0.041404
53 281 329 13528 1.90228126 1 0.68484287 
UP_SEQ_FEATURE region of interest:Substrate binging 2 0.46511628 
0.041521
86 402 2 19113 47.5447761 1 0.95191861 
UP_SEQ_FEATURE chain:Interferon alpha-1/13 2 0.46511628 
0.041521
86 402 2 19113 47.5447761 1 0.95191861 
BIOCARTA 
h_nthiPathway:NFkB activation by 
Nontypeable Hemophilus influenzae 4 0.93023256 
0.043263
25 49 24 1437 4.8877551 0.98132241 0.54890897 
SMART SM00338:BRLZ 5 1.1627907 
0.044131
94 230 53 9079 3.72395406 0.99939009 0.77246265 
INTERPRO 
IPR019786:Zinc finger, PHD-type, conserved 
site 6 1.39534884 
0.044388
28 347 93 16659 3.09733197 1 0.64568052 
GOTERM_BP_FAT GO:0010033~response to organic substance 23 5.34883721 
0.044423
19 281 721 13528 1.5357476 1 0.70509838 
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GOTERM_CC_FAT GO:0005924~cell-substrate adherens junction 6 1.39534884 
0.045116
45 235 106 12782 3.07876355 0.99999491 0.63783285 
INTERPRO IPR001841:Zinc finger, RING-type 12 2.79069767 
0.045832
51 347 296 16659 1.94629644 1 0.64435733 
GOTERM_BP_FAT 
GO:0045941~positive regulation of 
transcription 19 4.41860465 
0.045887
6 281 564 13528 1.62181671 1 0.71136829 
GOTERM_CC_FAT 
GO:0016023~cytoplasmic membrane-bounded 
vesicle 17 3.95348837 
0.046247
83 235 550 12782 1.68119149 0.99999628 0.6177185 
GOTERM_MF_FAT 
GO:0008509~anion transmembrane transporter 
activity 8 1.86046512 0.046895 291 147 12983 2.42803376 1 0.86639964 
GOTERM_BP_FAT 
GO:0031328~positive regulation of cellular 
biosynthetic process 22 5.11627907 
0.047044
76 281 685 13528 1.54617762 1 0.71495123 
SMART SM00115:CASc 3 0.69767442 
0.047224
36 230 14 9079 8.45869565 0.99964152 0.73347109 
GOTERM_BP_FAT GO:0035195~gene silencing by miRNA 3 0.69767442 
0.047322
48 281 17 13528 8.4957086 1 0.71164272 
SP_PIR_KEYWORDS bromodomain 4 0.93023256 
0.047588
4 403 39 19235 4.89533626 0.99999985 0.5623429 
INTERPRO 
IPR006012:Syntaxin/epimorphin, conserved 
site 3 0.69767442 
0.047637
07 347 17 16659 8.47211392 1 0.64599898 
GOTERM_MF_FAT 
GO:0005247~voltage-gated chloride channel 
activity 3 0.69767442 
0.048557
01 291 16 12983 8.36533505 1 0.8522464 
GOTERM_MF_FAT GO:0008656~caspase activator activity 3 0.69767442 
0.048557
01 291 16 12983 8.36533505 1 0.8522464 
SMART SM00208:TNFR 4 0.93023256 
0.049604
41 230 33 9079 4.78471673 0.99976214 0.69637888 
SP_PIR_KEYWORDS GTPase activation 8 1.86046512 
0.049863
04 403 159 19235 2.40148571 0.99999993 0.56110761 
INTERPRO IPR001487:Bromodomain 4 0.93023256 
0.049883
34 347 40 16659 4.80086455 1 0.65090345 
INTERPRO IPR013655:PAS fold-3 3 0.69767442 
0.052873
07 347 18 16659 8.00144092 1 0.66080705 
GOTERM_BP_FAT 
GO:0007264~small GTPase mediated signal 
transduction 12 2.79069767 
0.052941
72 281 305 13528 1.8941252 1 0.74702878 
GOTERM_BP_FAT 
GO:0010557~positive regulation of 
macromolecule biosynthetic process 21 4.88372093 
0.053092
18 281 654 13528 1.54585524 1 0.74288258 
GOTERM_BP_FAT 
GO:0009891~positive regulation of biosynthetic 
process 22 5.11627907 
0.053282
57 281 695 13528 1.52393046 1 0.73906185 
SMART SM00276:GLECT 3 0.69767442 
0.053603
86 230 15 9079 7.89478261 0.99988089 0.67678186 
UP_SEQ_FEATURE compositionally biased region:Poly-Pro 15 3.48837209 
0.054143
33 402 413 19113 1.72680785 1 0.97646224 
GOTERM_MF_FAT 
GO:0005160~transforming growth factor beta 
receptor binding 3 0.69767442 
0.054238
49 291 17 12983 7.87325652 1 0.86158616 
GOTERM_BP_FAT 
GO:0051241~negative regulation of 
multicellular organismal process 8 1.86046512 
0.054397
36 281 164 13528 2.34840726 1 0.74147834 
GOTERM_CC_FAT GO:0030055~cell-substrate junction 6 1.39534884 
0.054798
77 235 112 12782 2.91382979 0.99999965 0.65449222 
GOTERM_BP_FAT 
GO:0019221~cytokine-mediated signaling 
pathway 5 1.1627907 
0.056973
96 281 70 13528 3.4387392 1 0.75310316 
SP_PIR_KEYWORDS cytoplasm 83 19.3023256 
0.059239
26 403 
333
2 19235 1.18894084 1 0.60794451 
UP_SEQ_FEATURE domain:PAS 1 3 0.69767442 
0.059366
51 402 19 19113 7.50706991 1 0.97961811 
UP_SEQ_FEATURE domain:PAS 2 3 0.69767442 
0.059366
51 402 19 19113 7.50706991 1 0.97961811 
GOTERM_CC_FAT GO:0005911~cell-cell junction 8 1.86046512 
0.060644
48 235 190 12782 2.29016797 0.99999993 0.66748756 
GOTERM_MF_FAT GO:0046983~protein dimerization activity 19 4.41860465 
0.060668
44 291 542 12983 1.56399868 1 0.87265977 
GOTERM_BP_FAT 
GO:0045343~regulation of MHC class I 
biosynthetic process 2 0.46511628 
0.060821
51 281 3 13528 32.0948992 1 0.77133339 
INTERPRO 
IPR012852:Coiled-coil transcriptional 
coactivator-like 2 0.46511628 
0.061027
09 347 3 16659 32.0057637 1 0.70302704 
INTERPRO IPR015479:Transcription factor AF4 2 0.46511628 
0.061027
09 347 3 16659 32.0057637 1 0.70302704 
INTERPRO IPR007651:Lipin, N-terminal conserved region 2 0.46511628 
0.061027
09 347 3 16659 32.0057637 1 0.70302704 
UP_SEQ_FEATURE region of interest:N-LIP 2 0.46511628 
0.061633
3 402 3 19113 31.6965174 1 0.97836859 
UP_SEQ_FEATURE 
region of interest:Intramolecular interaction 
with C- terminus 2 0.46511628 
0.061633
3 402 3 19113 31.6965174 1 0.97836859 
UP_SEQ_FEATURE 
region of interest:Intramolecular interaction 
with N- terminus 2 0.46511628 
0.061633
3 402 3 19113 31.6965174 1 0.97836859 
UP_SEQ_FEATURE short sequence motif:DXDXT motif 2 0.46511628 
0.061633
3 402 3 19113 31.6965174 1 0.97836859 
UP_SEQ_FEATURE region of interest:C-LIP 2 0.46511628 
0.061633
3 402 3 19113 31.6965174 1 0.97836859 
GOTERM_BP_FAT GO:0006937~regulation of muscle contraction 5 1.1627907 
0.061955
03 281 72 13528 3.34321866 1 0.77310907 
UP_SEQ_FEATURE active site:Proton acceptor 21 4.88372093 
0.062188
65 402 658 19113 1.51738647 1 0.97467139 
GOTERM_MF_FAT 
GO:0004715~non-membrane spanning protein 
tyrosine kinase activity 4 0.93023256 
0.063124
91 291 41 12983 4.35269466 1 0.86520183 
GOTERM_BP_FAT GO:0051607~defense response to virus 3 0.69767442 
0.063504
5 281 20 13528 7.22135231 1 0.77710698 
INTERPRO 
IPR002398:Peptidase C14, caspase precursor 
p45 3 0.69767442 0.063915 347 20 16659 7.20129683 1 0.70914082 
GOTERM_CC_FAT GO:0005768~endosome 11 2.55813953 
0.064177
45 235 315 12782 1.89938534 0.99999998 0.66527138 
GOTERM_BP_FAT 
GO:0031349~positive regulation of defense 
response 5 1.1627907 
0.064529
12 281 73 13528 3.29742115 1 0.77815142 
SP_PIR_KEYWORDS biological rhythms 3 0.69767442 
0.064631
96 403 20 19235 7.15942928 1 0.62391179 
UP_SEQ_FEATURE zinc finger region:C3H1-type 3 3 0.69767442 
0.065072
24 402 20 19113 7.13171642 1 0.97449013 
GOTERM_MF_FAT GO:0015297~antiporter activity 5 1.1627907 
0.065392
94 291 68 12983 3.28052355 1 0.85752138 
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GOTERM_CC_FAT GO:0005912~adherens junction 7 1.62790698 0.065463 235 155 12782 2.45638984 0.99999998 0.65055332 
GOTERM_CC_FAT GO:0005637~nuclear inner membrane 3 0.69767442 
0.065637
91 235 23 12782 7.09454209 0.99999998 0.63054937 
GOTERM_BP_FAT 
GO:0051240~positive regulation of 
multicellular organismal process 10 2.3255814 
0.066794
53 281 244 13528 1.97304708 1 0.78561011 
GOTERM_BP_FAT 
GO:0045892~negative regulation of 
transcription, DNA-dependent 13 3.02325581 
0.067152
15 281 356 13528 1.75800712 1 0.78311477 
KEGG_PATHWAY hsa04520:Adherens junction 5 1.1627907 
0.067957
4 103 77 5085 3.20577481 0.99898911 0.41170837 
GOTERM_MF_FAT GO:0003700~transcription factor activity 30 6.97674419 
0.069156
71 291 975 12983 1.37277293 1 0.85677927 
GOTERM_BP_FAT GO:0042752~regulation of circadian rhythm 3 0.69767442 
0.069257
31 281 21 13528 6.87747839 1 0.78940734 
GOTERM_BP_FAT GO:0030101~natural killer cell activation 3 0.69767442 
0.069257
31 281 21 13528 6.87747839 1 0.78940734 
GOTERM_BP_FAT GO:0016441~posttranscriptional gene silencing 3 0.69767442 
0.069257
31 281 21 13528 6.87747839 1 0.78940734 
GOTERM_BP_FAT 
GO:0035194~posttranscriptional gene silencing 
by RNA 3 0.69767442 
0.069257
31 281 21 13528 6.87747839 1 0.78940734 
SP_PIR_KEYWORDS chromosomal rearrangement 11 2.55813953 
0.069302
52 403 279 19235 1.88180937 1 0.63413611 
GOTERM_BP_FAT GO:0002274~myeloid leukocyte activation 4 0.93023256 
0.069458
19 281 46 13528 4.1862912 1 0.78620466 
SP_PIR_KEYWORDS Aminotransferase 3 0.69767442 
0.070476
27 403 21 19235 6.81850408 1 0.62488758 
UP_SEQ_FEATURE domain:Protein kinase 16 3.72093023 
0.070591
66 402 469 19113 1.62199663 1 0.97785395 
SP_PIR_KEYWORDS chloride 5 1.1627907 
0.071982
14 403 75 19235 3.18196857 1 0.61794526 
SP_PIR_KEYWORDS isopeptide bond 12 2.79069767 
0.072808
73 403 319 19235 1.79546816 1 0.6078928 
GOTERM_MF_FAT GO:0008047~enzyme activator activity 13 3.02325581 
0.073237
28 291 335 12983 1.73133303 1 0.85743005 
GOTERM_BP_FAT 
GO:0051253~negative regulation of RNA 
metabolic process 13 3.02325581 
0.073967
9 281 362 13528 1.72886888 1 0.80333658 
PIR_SUPERFAMILY PIRSF023976:PIRSF023976 2 0.46511628 
0.074118
92 142 4 7396 26.0422535 0.99998878 0.85036663 
INTERPRO 
IPR013320:Concanavalin A-like 
lectin/glucanase, subgroup 5 1.1627907 
0.076227
61 347 77 16659 3.11744452 1 0.76280496 
SMART SM00249:PHD 6 1.39534884 
0.076769
39 230 90 9079 2.6315942 0.99999795 0.76672153 
GOTERM_BP_FAT 
GO:0032582~negative regulation of gene-
specific transcription 4 0.93023256 
0.076838
47 281 48 13528 4.0118624 1 0.81195534 
GOTERM_BP_FAT 
GO:0042108~positive regulation of cytokine 
biosynthetic process 4 0.93023256 
0.076838
47 281 48 13528 4.0118624 1 0.81195534 
UP_SEQ_FEATURE domain:t-SNARE coiled-coil homology 3 0.69767442 
0.076998
26 402 22 19113 6.48337856 1 0.98147788 
GOTERM_BP_FAT 
GO:0051173~positive regulation of nitrogen 
compound metabolic process 20 4.65116279 
0.077053
59 281 644 13528 1.495104 1 0.8090051 
GOTERM_MF_FAT GO:0005254~chloride channel activity 5 1.1627907 
0.077221
83 291 72 12983 3.09827224 1 0.85771779 
GOTERM_CC_FAT GO:0005794~Golgi apparatus 23 5.34883721 
0.078327
41 235 872 12782 1.43463791 1 0.67803979 
GOTERM_MF_FAT GO:0008483~transaminase activity 3 0.69767442 
0.079050
41 291 21 12983 6.37358861 1 0.85015697 
GOTERM_MF_FAT GO:0005484~SNAP receptor activity 3 0.69767442 
0.079050
41 291 21 12983 6.37358861 1 0.85015697 
SMART SM00297:BROMO 4 0.93023256 
0.079163
55 230 40 9079 3.9473913 0.99999866 0.74142113 
GOTERM_BP_FAT 
GO:0045776~negative regulation of blood 
pressure 3 0.69767442 
0.081243
7 281 23 13528 6.27943679 1 0.82242761 
GOTERM_BP_FAT 
GO:0010604~positive regulation of 
macromolecule metabolic process 25 5.81395349 
0.081296
59 281 857 13528 1.4043859 1 0.81894626 
UP_SEQ_FEATURE short sequence motif:LXXIL motif 2 0.46511628 
0.081323
78 402 4 19113 23.7723881 1 0.98251994 
UP_SEQ_FEATURE short sequence motif:Nuclear localization signal 12 2.79069767 
0.082159
71 402 325 19113 1.75549943 1 0.98028785 
GOTERM_CC_FAT GO:0005770~late endosome 4 0.93023256 
0.082873
58 235 56 12782 3.88510638 1 0.68079805 
GOTERM_CC_FAT GO:0005635~nuclear envelope 8 1.86046512 
0.082993
03 235 205 12782 2.12259471 1 0.66351144 
SP_PIR_KEYWORDS glycosidase 5 1.1627907 
0.083542
39 403 79 19235 3.02085624 1 0.6466907 
GOTERM_MF_FAT 
GO:0008308~voltage-gated anion channel 
activity 3 0.69767442 
0.085715
05 291 22 12983 6.08388004 1 0.86015471 
KEGG_PATHWAY hsa05210:Colorectal cancer 5 1.1627907 
0.087333
75 103 84 5085 2.93862691 0.999871 0.4725468 
GOTERM_BP_FAT GO:0051223~regulation of protein transport 6 1.39534884 
0.087912
27 281 114 13528 2.53380783 1 0.84003559 
GOTERM_BP_FAT GO:0001503~ossification 6 1.39534884 
0.090442
4 281 115 13528 2.51177472 1 0.84528604 
PIR_SUPERFAMILY PIRSF016017:PIRSF016017 2 0.46511628 
0.091779
8 142 5 7396 20.8338028 0.99999935 0.86937041 
GOTERM_CC_FAT 
GO:0009897~external side of plasma 
membrane 7 1.62790698 
0.092359
46 235 170 12782 2.23964956 1 0.68741608 
GOTERM_MF_FAT GO:0016504~peptidase activator activity 3 0.69767442 
0.092541
91 291 23 12983 5.81936351 1 0.86930015 
INTERPRO IPR000571:Zinc finger, CCCH-type 4 0.93023256 
0.093372
36 347 52 16659 3.69297273 1 0.82236305 
GOTERM_MF_FAT GO:0031404~chloride ion binding 5 1.1627907 
0.093400
35 291 77 12983 2.89708573 1 0.85989314 
INTERPRO IPR017441:Protein kinase, ATP binding site 15 3.48837209 
0.093586
13 347 455 16659 1.5827026 1 0.81438017 
GOTERM_BP_FAT 
GO:0045669~positive regulation of osteoblast 
differentiation 3 0.69767442 
0.093811
52 281 25 13528 5.77708185 1 0.85294408 
UP_SEQ_FEATURE zinc finger region:PHD-type 4 0.93023256 
0.095577
66 402 52 19113 3.65729047 1 0.98801444 
GOTERM_CC_FAT GO:0070161~anchoring junction 7 1.62790698 0.096360 235 172 12782 2.21360713 1 0.68746288 
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48 
KEGG_PATHWAY hsa04350:TGF-beta signaling pathway 5 1.1627907 
0.096378
6 103 87 5085 2.83729494 0.9999514 0.48424295 
GOTERM_MF_FAT GO:0005253~anion channel activity 5 1.1627907 
0.096815
01 291 78 12983 2.85994361 1 0.85856908 
GOTERM_BP_FAT 
GO:0045935~positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 19 4.41860465 
0.097468
35 281 624 13528 1.4658728 1 0.86095413 
SP_PIR_KEYWORDS immune response 9 2.09302326 
0.098717
92 403 224 19235 1.91770427 1 0.69737942 
UP_SEQ_FEATURE compositionally biased region:Poly-Gln 7 1.62790698 
0.098800
19 402 151 19113 2.20406247 1 0.98786389 
GOTERM_BP_FAT 
GO:0007167~enzyme linked receptor protein 
signaling pathway 12 2.79069767 
0.099101
67 281 342 13528 1.68920522 1 0.86265232 
GOTERM_BP_FAT 
GO:0052555~positive regulation by organism 
of immune response of other organism during 
symbiotic interaction 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0052556~positive regulation by symbiont 
of host immune response 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0052305~positive regulation by organism 
of innate immunity in other organism during 
symbiotic interaction 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0052166~positive regulation by symbiont 
of host innate immunity 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0002282~microglial cell activation during 
immune response 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0052306~modulation by organism of innate 
immunity in other organism during symbiotic 
interaction 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0052552~modulation by organism of 
immune response of other organism during 
symbiotic interaction 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0052553~modulation by symbiont of host 
immune response 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0052167~modulation by symbiont of host 
innate immunity 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
GOTERM_BP_FAT 
GO:0045988~negative regulation of striated 
muscle contraction 2 0.46511628 
0.099306
9 281 5 13528 19.2569395 1 0.86018948 
INTERPRO IPR005814:Aminotransferase class-III 2 0.46511628 
0.099634
16 347 5 16659 19.2034582 1 0.82625745 
INTERPRO IPR007797:AF-4 proto-oncoprotein 2 0.46511628 
0.099634
16 347 5 16659 19.2034582 1 0.82625745 
INTERPRO IPR004865:Sp100 2 0.46511628 
0.099634
16 347 5 16659 19.2034582 1 0.82625745 
 
App. 5: Individual Massspectrometry data: 
All data is presented as 80% protein identification probability: 
Experiment1: 
# Bio View:Identified Proteins (290) Accession Number 
Molecular 
Weight 
Protein 
Grouping 
Ambiguity Mock MVCwt 
49 26S proteasome subunit p97 [Homo sapiens] gi|1060888 (+3) 100 kDa 0 11 
55 
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 
5, isoform CRA_b [Homo sapiens] gi|119610275 (+3) 28 kDa 0 9 
56 filamin-A isoform 1 [Homo sapiens] gi|116063573 (+3) 280 kDa 0 14 
59 unnamed protein product [Homo sapiens] gi|189054540 (+1) 113 kDa 0 8 
66 Chain B, Structural Basis Of The Interaction Of Rbap46RBAP48 WITH Histone H4 gi|190016327 (+6) 47 kDa true 0 3 
71 proteasome 26S ATPase subunit 2 [Homo sapiens] gi|4506209 (+1) 49 kDa 0 8 
79 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 [Homo sapiens] gi|15126760 (+8) 61 kDa 0 9 
80 26S proteasome non-ATPase regulatory subunit 6 [Homo sapiens] gi|7661914 46 kDa 0 8 
85 26S proteasome non-ATPase regulatory subunit 12 isoform 2 [Homo sapiens] gi|28872765 (+3) 51 kDa 0 7 
86 proteasome (prosome, macropain) 26S subunit, ATPase, 1, isoform CRA_b [Homo sapiens] gi|119601826 (+5) 45 kDa 0 7 
88 microtubule-associated protein 1B [Homo sapiens] gi|153945728 (+1) 271 kDa 0 26 
93 26S protease regulatory subunit 6B isoform 1 [Homo sapiens] gi|5729991 (+1) 47 kDa 0 7 
98 PREDICTED: proteasome 26S non-ATPase subunit 13 isoform 3 [Pan troglodytes] gi|114635315 (+7) 43 kDa 0 5 
101 thyroid receptor interactor [Homo sapiens] gi|695370 (+3) 46 kDa 0 7 
103 lactotransferrin [Homo sapiens] gi|119585171 (+19) 78 kDa 0 5 
112 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2, isoform CRA_a [Homo sapiens] gi|119618308 (+5) 101 kDa 0 4 
113 proteasome subunit p112 [Homo sapiens] gi|1808578 (+2) 106 kDa 0 5 
126 proteasome subunit p42 [Homo sapiens] gi|1526426 (+2) 44 kDa 0 5 
133 insulin receptor substrate 4 [Homo sapiens] gi|4504733 134 kDa 0 4 
139 unnamed protein product [Homo sapiens] gi|21754583 (+1) 48 kDa true 0 41 
140 unnamed protein product [Homo sapiens] gi|193787479 (+4) 53 kDa 0 3 
143 unnamed protein product [Homo sapiens] gi|189067539 (+4) 37 kDa 0 4 
145 unnamed protein product [Homo sapiens] gi|158257224 (+6) 47 kDa 0 3 
154 ribosomal protein S4, X-linked, isoform CRA_a [Homo sapiens] gi|119592221 (+5) 43 kDa 0 3 
155 RANBP8 [Homo sapiens] gi|2337918 (+1) 120 kDa 0 4 
175 proteasome 26S non-ATPase subunit 8 [Homo sapiens] gi|156631005 (+2) 40 kDa 0 3 
179 damage-specific DNA binding protein 1, 127kDa, isoform CRA_a [Homo sapiens] gi|119594339 (+4) 121 kDa 0 3 
182 myosin VI, isoform CRA_b [Homo sapiens] gi|119569114 (+6) 147 kDa 0 2 
183 Unknown (protein for IMAGE:2901253) [Homo sapiens] gi|13111809 (+4) 35 kDa 0 4 
195 t-complex polypeptide 1 [Homo sapiens] gi|36796 (+1) 60 kDa 0 3 
196 unnamed protein product [Homo sapiens] gi|194390656 (+3) 35 kDa 0 1 
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203 unnamed protein product [Homo sapiens] gi|194383294 (+1) 52 kDa true 0 4 
205 Phosphoglycerate mutase family member 5 [Homo sapiens] gi|14198272 (+1) 28 kDa 0 3 
210 
RecName: Full=OTU domain-containing protein 4; AltName: Full=HIV-1-induced protein 
HIN-1 gi|118572680 124 kDa 0 2 
211 
Chain A, Crystal Structure Of The Heterodimeric Complex Of Human Rgs10 And Activated 
Gi Alpha 3 gi|119390147 (+2) 37 kDa 0 3 
214 unnamed protein product [Homo sapiens] gi|34527290 53 kDa true 0 2 
215 lipocalin-1 precursor [Homo sapiens] gi|4504963 (+1) 19 kDa 0 2 
216 PREDICTED: similar to protein kinase, DNA-activated, catalytic polypeptide [Homo sapiens] gi|113430845 (+5) 465 kDa 0 8 
217 angiomotin isoform 1 [Homo sapiens] gi|166064029 118 kDa 0 2 
218 unnamed protein product [Homo sapiens] gi|158259511 (+4) 36 kDa 0 3 
219 hCG2027326 [Homo sapiens] gi|119611832 (+2) 10 kDa 0 3 
220 ribosomal protein S20 isoform 1 [Homo sapiens] gi|226246671 (+1) 16 kDa 0 3 
221 solute carrier family 16, member 1 [Homo sapiens] gi|115583685 (+2) 54 kDa true 0 3 
224 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 [Homo sapiens] gi|150439371 (+4) 22 kDa 0 2 
233 
solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3, isoform 
CRA_c [Homo sapiens] gi|119618006 (+6) 26 kDa 0 2 
235 emerin [Homo sapiens] gi|4557553 (+1) 29 kDa 0 2 
241 chromosome 13 open reading frame 7, isoform CRA_b [Homo sapiens] gi|119600993 (+1) 81 kDa 0 2 
242 clathrin, heavy polypeptide (Hc), isoform CRA_c [Homo sapiens] gi|119614803 (+5) 192 kDa 0 2 
245 unnamed protein product [Homo sapiens] gi|158260761 (+1) 28 kDa 0 3 
251 
Chain A, Structural Changes Of The Active Site Cleft And Different Saccharide Binding 
Modes In Human Lysozyme Co-Crystallized With Hexa-N-Acetyl-Chitohexaose At Ph 4.0 gi|1065033 (+130) 15 kDa 0 1 
256 
PREDICTED: similar to cleavage and polyadenylation specific factor 6, 68 kD subunit 
[Macaca mulatta] gi|109097742 (+6) 63 kDa 0 1 
257 
Chain A, Crystal Structure Of Human Cleavage And Polyadenylation Specificity Factor 5 
(Cpsf5) gi|109157347 (+6) 27 kDa 0 2 
262 transmembrane protein [Homo sapiens] gi|1160963 (+10) 84 kDa 0 1 
263 desmoglein-2 preproprotein [Homo sapiens] gi|116534898 (+1) 122 kDa 0 1 
265 ribosomal protein L18, isoform CRA_b [Homo sapiens] gi|119572744 (+4) 19 kDa 0 2 
271 coatomer protein complex, subunit beta 2 (beta prime), isoform CRA_b [Homo sapiens] gi|119599446 (+1) 99 kDa 0 1 
272 chromosome 13 open reading frame 10, isoform CRA_c [Homo sapiens] gi|119600999 (+5) 112 kDa 0 1 
275 chromosome 1 open reading frame 27, isoform CRA_b [Homo sapiens] gi|119611614 (+3) 40 kDa 0 1 
276 importin 9, isoform CRA_a [Homo sapiens] gi|119611781 (+5) 112 kDa 0 1 
277 leucine zipper protein 1, isoform CRA_a [Homo sapiens] gi|119615440 (+5) 120 kDa 0 1 
279 Chaperonin containing TCP1, subunit 3 (gamma) [Homo sapiens] gi|14124984 (+9) 60 kDa 0 1 
281 
Chain A, Phosphorylation Independent Interactions Between 14-3-3 And Exoenzyme S: 
From Structure To Pathogenesis gi|161172138 (+5) 26 kDa 0 2 
282 apoptosis-inducing factor 1, mitochondrial isoform 5 [Homo sapiens] gi|195927006 (+4) 35 kDa 0 1 
283 glyceraldehyde-3-phosphate dehydrogenase [Homo sapiens] gi|31645 (+7) 36 kDa 0 2 
285 filaggrin family member 2 [Homo sapiens] gi|62122917 248 kDa 0 2 
288 protein phosphatase 1, regulatory (inhibitor) subunit 12A, isoform CRA_a [Homo sapiens] gi|119617757 (+11) 102 kDa 0 1 
73 Chain A, Crystal Structure Of The 9-10 8 Glycine Insertion Mutant Of Ubiquitin. gi|109157803 (+26) 9 kDa 1 10 
97 beta-tubulin [Homo sapiens] gi|338695 (+1) 50 kDa true 3 28 
32 unnamed protein product [Homo sapiens] gi|158259731 (+3) 50 kDa 3 18 
90 MYL6 protein [Homo sapiens] gi|113812151 (+4) 16 kDa 1 6 
105 heat shock 60kDa protein 1 (chaperonin), isoform CRA_c [Homo sapiens] gi|119590557 (+5) 41 kDa 1 5 
118 capping protein (actin filament) muscle Z-line, beta, isoform CRA_b [Homo sapiens] gi|119615295 (+6) 30 kDa 1 5 
19 tubulin, beta 2C, isoform CRA_b [Homo sapiens] gi|119608775 (+4) 49 kDa true 7 26 
31 heat shock 70 kDa protein 1A/1B [Homo sapiens] gi|167466173 (+4) 70 kDa true 6 22 
4 WD repeat domain 77 [Homo sapiens] gi|13129110 (+2) 37 kDa 50 183 
84 spindlin-1 [Homo sapiens] gi|112293285 (+3) 30 kDa 2 7 
77 BTB/POZ domain-containing protein KCTD5 [Homo sapiens] gi|9506651 26 kDa 2 6 
116 
RecName: Full=Elongation factor Tu, mitochondrial; Short=EF-Tu; AltName: Full=P43; Flags: 
Precursor gi|1706611 (+3) 50 kDa 1 3 
134 PSMA4 protein [Homo sapiens] gi|34783332 (+1) 29 kDa 1 3 
136 ribosomal protein S16 [Homo sapiens] gi|4506691 (+2) 16 kDa 1 3 
157 DNA-binding protein B [Homo sapiens] gi|181486 (+1) 40 kDa 1 3 
159 chloride channel, nucleotide-sensitive, 1A [Homo sapiens] gi|4502891 (+1) 26 kDa 1 3 
161 guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 [Mus musculus] gi|13937391 (+1) 37 kDa 1 3 
193 ribosomal protein S14 [Homo sapiens] gi|5032051 16 kDa 1 3 
1 actin, beta [Homo sapiens] gi|14250401 41 kDa true 214 570 
69 tropomyosin alpha-3 chain isoform 4 [Homo sapiens] gi|114155144 (+2) 29 kDa true 3 7 
67 albumin, isoform CRA_h [Homo sapiens] gi|119626071 (+17) 69 kDa 4 9 
2 protein arginine N-methyltransferase 5 isoform a [Homo sapiens] gi|20070220 73 kDa 76 156 
76 myosin regulatory light chain 12B [Homo sapiens] gi|15809016 (+3) 20 kDa 3 6 
96 poly(A) binding protein, cytoplasmic 1, isoform CRA_c [Homo sapiens] gi|119612222 (+6) 47 kDa true 2 4 
121 ribosomal protein L13 [Homo sapiens] gi|15431295 (+1) 24 kDa 2 4 
129 PREDICTED: similar to ribosomal protein isoform 2 [Pan troglodytes] gi|114606879 (+2) 15 kDa 2 4 
162 nucleolar protein family A member 1 [Homo sapiens] gi|56566042 (+1) 21 kDa 1 2 
60 Unknown (protein for IMAGE:3544292) [Homo sapiens] gi|13097759 (+3) 27 kDa 4 7 
23 vimentin [Homo sapiens] gi|340219 (+3) 54 kDa true 11 19 
74 peroxiredoxin 1, isoform CRA_b [Homo sapiens] gi|119627382 (+3) 21 kDa true 3 5 
102 myosin-14 isoform 2 [Homo sapiens] gi|116284394 (+6) 228 kDa true 5 8 
72 type I keratin 16 [Homo sapiens] gi|1195531 (+1) 51 kDa true 43 68 
115 Heat shock 70kDa protein 9 (mortalin) [Homo sapiens] gi|12653415 (+5) 74 kDa 2 3 
119 ribosomal protein L3, isoform CRA_d [Homo sapiens] gi|119580717 (+5) 49 kDa 2 3 
142 ribosomal protein S8, isoform CRA_a [Homo sapiens] gi|119627428 (+2) 27 kDa 2 3 
165 peroxiredoxin-6 [Homo sapiens] gi|4758638 25 kDa 2 3 
209 unnamed protein product [Homo sapiens] gi|189053201 (+4) 13 kDa 2 3 
120 small nuclear ribonucleoprotein Sm D2 isoform 1 [Homo sapiens] gi|4759158 (+1) 14 kDa 3 4 
26 PREDICTED: keratin 6A [Pan troglodytes] gi|114644568 (+5) 60 kDa true 42 55 
14 unnamed protein product [Homo sapiens] gi|193786319 (+1) 53 kDa false 19 24 
70 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, isoform CRA_a [Homo sapiens] gi|119606803 (+8) 58 kDa true 4 5 
7 Myosin, heavy chain 10, non-muscle [Homo sapiens] gi|109734611 (+2) 229 kDa true 82 101 
12 hCG15164, isoform CRA_b [Homo sapiens] gi|119605719 (+2) 16 kDa 34 41 
39 78 kDa glucose-regulated protein precursor [Mus musculus] gi|254540166 72 kDa true 11 13 
5 myosin-9 [Homo sapiens] gi|12667788 227 kDa true 114 132 
10 heat shock cognate 71 kDa protein isoform 1 [Homo sapiens] gi|5729877 71 kDa true 31 35 
17 Keratin 14 [Homo sapiens] gi|12803709 (+1) 52 kDa true 62 66 
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24 HNRPH1 [Homo sapiens] gi|48145673 (+2) 49 kDa true 17 17 
28 kinesin-related protein [Homo sapiens] gi|1155084 (+2) 119 kDa 11 11 
75 unnamed protein product [Homo sapiens] gi|194374523 (+8) 66 kDa 4 4 
125 ribosomal protein S13 [Homo sapiens] gi|4506685 17 kDa 3 3 
141 tyrosine-protein kinase JAK1 [Homo sapiens] gi|102469034 (+1) 133 kDa 2 2 
158 RuvB-like 1 [Homo sapiens] gi|197692395 (+3) 50 kDa 2 2 
167 ribosomal protein L30 [Homo sapiens] gi|4506631 13 kDa 2 2 
188 ribosomal protein S9, isoform CRA_c [Homo sapiens] gi|119592618 (+4) 17 kDa 2 2 
190 ribosomal protein L6 [Homo sapiens] gi|16753227 (+5) 33 kDa 2 2 
191 hCG26523, isoform CRA_a [Homo sapiens] gi|119617765 (+3) 17 kDa 2 2 
207 serine/arginine repetitive matrix protein 2 [Homo sapiens] gi|118572613 (+5) 300 kDa 2 2 
6 
keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris), isoform CRA_b 
[Homo sapiens] gi|119581085 (+3) 63 kDa true 153 150 
3 keratin 1 [Homo sapiens] gi|11935049 (+1) 66 kDa true 252 234 
16 unnamed protein product [Homo sapiens] gi|16549132 (+2) 61 kDa 20 18 
47 Chain L, Crystal Structure Of Fab Fragment Complexed With Gibberellin A4 gi|24158782 24 kDa true 10 9 
8 epidermal cytokeratin 2 [Homo sapiens] gi|181402 (+1) 66 kDa true 130 112 
25 keratin, type II cytoskeletal 5 [Homo sapiens] gi|119395754 (+1) 62 kDa true 59 50 
27 RNA binding motif protein 10, isoform CRA_d [Homo sapiens] gi|119579690 (+1) 110 kDa 13 11 
9 cytokeratin 9 [Homo sapiens] gi|435476 (+2) 62 kDa true 93 71 
30 serine/threonine kinase 38 [Homo sapiens] gi|6005814 54 kDa true 12 9 
45 U4/U6 snRNP-associated 61 kDa protein [Homo sapiens] gi|18249847 (+1) 55 kDa 8 6 
104 thymopoietin zeta isoform [Homo sapiens] gi|119214988 (+7) 27 kDa 4 3 
35 histone H2A type 2-C [Homo sapiens] gi|24638446 (+1) 14 kDa true 14 10 
53 unnamed protein product [Homo sapiens] gi|31092 (+10) 50 kDa 7 5 
108 insulin-like growth factor 2 mRNA-binding protein 1 isoform 1 [Homo sapiens] gi|56237027 63 kDa 3 2 
109 drebrin 1, isoform CRA_a [Homo sapiens] gi|119605395 (+8) 76 kDa 3 2 
114 ribosomal protein, large, P0, isoform CRA_a [Homo sapiens] gi|119618576 (+6) 31 kDa 3 2 
123 unnamed protein product [Homo sapiens] gi|194378142 (+4) 82 kDa true 3 2 
135 snRNP polypeptide B [Homo sapiens] gi|190247 (+9) 30 kDa 3 2 
137 unnamed protein product [Homo sapiens] gi|158260331 (+2) 33 kDa 3 2 
144 ribosomal protein L7 [Homo sapiens] gi|307388 29 kDa 3 2 
83 histone 1, H4c [Homo sapiens] gi|119575932 (+5) 14 kDa 5 3 
91 
mitogen-activated protein kinase kinase kinase 7-interacting protein 1 isoform beta [Homo 
sapiens] gi|41281798 (+2) 50 kDa 5 3 
20 PREDICTED: heterogeneous nuclear ribonucleoprotein K isoform 8 [Callithrix jacchus] gi|296189587 ? 24 12 
99 influenza virus NS1A-binding protein [Homo sapiens] gi|24475847 (+5) 72 kDa 4 2 
106 small nuclear ribonucleoprotein Sm D1 [Homo sapiens] gi|5902102 13 kDa 4 2 
168 hCG1994130, isoform CRA_b [Homo sapiens] gi|119570641 (+5) 29 kDa 2 1 
176 60S ribosomal protein L15 [Homo sapiens] gi|12006350 (+3) 24 kDa 2 1 
186 Similar to ribophorin I [Homo sapiens] gi|14124942 (+3) 65 kDa 2 1 
194 sub2.3 [Homo sapiens] gi|444021 (+2) 32 kDa true 2 1 
222 hCG1640785, isoform CRA_a [Homo sapiens] gi|119569329 (+3) 14 kDa 2 1 
223 hCG2028724 [Homo sapiens] gi|119601423 (+7) 30 kDa 2 1 
232 PREDICTED: RuvB-like 2 isoform 2 [Pan troglodytes] gi|114678325 (+2) 47 kDa 2 1 
234 Mitogen-activated protein kinase kinase kinase 7 interacting protein 3 [Homo sapiens] gi|21619770 (+1) 79 kDa 2 1 
92 KIAA0965 protein [Homo sapiens] gi|20521714 (+1) 57 kDa true 7 3 
68 heterogeneous nuclear ribonucleoprotein A1 isoform b [Homo sapiens] gi|14043070 (+4) 39 kDa 11 4 
54 RNA binding motif protein, X-linked, isoform CRA_b [Homo sapiens] gi|119608862 (+3) 24 kDa 9 3 
89 nucleolin, isoform CRA_c [Homo sapiens] gi|119591368 (+5) 59 kDa 6 2 
160 ribosomal protein L23a, isoform CRA_a [Homo sapiens] gi|119571516 (+3) 22 kDa 3 1 
185 hCG33299, isoform CRA_a [Homo sapiens] gi|119597983 (+7) 30 kDa 3 1 
192 ribosomal protein L22, isoform CRA_c [Homo sapiens] gi|119591926 (+3) 12 kDa 3 1 
201 BAT1 protein [Homo sapiens] gi|114306812 (+5) 51 kDa 3 1 
202 calcium homeostasis endoplasmic reticulum protein [Homo sapiens] gi|119226260 (+3) 104 kDa 3 1 
204 fus-like protein [Homo sapiens] gi|1040970 (+7) 53 kDa 3 1 
206 ribosomal protein L4, isoform CRA_b [Homo sapiens] gi|119598180 (+5) 53 kDa 3 1 
11 mitochondrial import inner membrane translocase subunit TIM14 [Homo sapiens] gi|21687102 (+1) 12 kDa 90 28 
18 anti-colorectal carcinoma heavy chain [Homo sapiens] gi|425518 51 kDa 64 19 
29 growth regulated nuclear 68 protein gi|226021 (+1) 67 kDa true 19 5 
107 myotubularin-related protein 14 isoform 2 [Homo sapiens] gi|117938270 (+3) 72 kDa 4 1 
117 interleukin enhancer binding factor 3, 90kDa, isoform CRA_c [Homo sapiens] gi|119604539 (+13) 92 kDa 4 1 
138 ribosomal protein L12 [Homo sapiens] gi|4506597 18 kDa 4 1 
166 ribosomal protein [Homo sapiens] gi|337518 (+1) 22 kDa 4 1 
174 ribosomal protein L10A [Rattus norvegicus] gi|13592009 (+3) 25 kDa 4 1 
64 heterogeneous nuclear ribonucleoprotein H2 [Homo sapiens] gi|9624998 49 kDa true 23 5 
37 heterogeneous nuclear ribonucleoprotein L [Homo sapiens] gi|11527777 (+4) 64 kDa 15 3 
62 splicing factor, arginine/serine-rich 1 isoform 2 [Homo sapiens] gi|118582269 (+4) 22 kDa 10 2 
78 spliceosomal protein SAP 155 [Homo sapiens] gi|4033735 (+1) 146 kDa 5 1 
95 pre-mRNA-processing factor 19 [Homo sapiens] gi|7657381 55 kDa 5 1 
111 mitogen-activated protein kinase kinase kinase 7 isoform B [Homo sapiens] gi|21735562 (+3) 67 kDa 5 1 
122 unnamed protein product [Homo sapiens] gi|158255716 (+2) 54 kDa 5 1 
153 karyopherin (importin) beta 1, isoform CRA_b [Homo sapiens] gi|119615215 (+3) 94 kDa 5 1 
52 dermcidin preproprotein [Homo sapiens] gi|16751921 11 kDa 24 4 
15 unnamed protein product [Homo sapiens] gi|189053924 (+2) 22 kDa true 41 6 
40 ATP-dependent RNA helicase A [Homo sapiens] gi|100913206 (+1) 141 kDa 17 2 
33 heterogeneous nuclear ribonucleoprotein M, isoform CRA_c [Homo sapiens] gi|119589327 (+4) 78 kDa 20 2 
61 Lamin B1 [Homo sapiens] gi|15126742 (+1) 66 kDa 10 1 
63 histone H2B type 1-D [Homo sapiens] gi|10800138 (+11) 14 kDa 10 1 
130 probable ATP-dependent RNA helicase DDX17 isoform 3 [Homo sapiens] gi|148613856 (+6) 80 kDa true 10 1 
21 heterogeneous nuclear ribonucleoprotein U isoform b [Homo sapiens] gi|14141161 (+5) 89 kDa 32 3 
42 histone H3 [Homo sapiens] gi|1568559 (+11) 15 kDa 14 1 
51 heterogeneous nuclear ribonucleoproteins C1/C2 isoform b [Homo sapiens] gi|117190174 (+5) 32 kDa 16 1 
36 unnamed protein product [Homo sapiens] gi|158256968 (+3) 136 kDa 22 1 
13 heterogeneous nuclear ribonucleoproteins A2/B1 isoform B1 [Homo sapiens] gi|14043072 37 kDa 47 1 
22 heterogeneous nuclear ribonucleoprotein A3, isoform CRA_a [Homo sapiens] gi|119631468 (+1) 37 kDa 35 0 
34 lamin A/C, isoform CRA_c [Homo sapiens] gi|119573383 (+2) 87 kDa 23 0 
38 unnamed protein product [Homo sapiens] gi|194387670 (+1) 19 kDa 21 0 
41 rRNA 2'-O-methyltransferase fibrillarin [Homo sapiens] gi|12056465 (+2) 34 kDa 19 0 
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43 nucleophosmin isoform 1 [Homo sapiens] gi|10835063 (+7) 33 kDa 20 0 
44 PRP8 pre-mRNA processing factor 8 homolog (yeast), isoform CRA_b [Homo sapiens] gi|119610995 (+2) 274 kDa 17 0 
46 KIAA0788 protein [Homo sapiens] gi|20521660 (+2) 232 kDa 17 0 
48 NOP58 protein [Homo sapiens] gi|33872137 (+1) 59 kDa 17 0 
50 PREDICTED: U5 snRNP-specific protein, 116 kD isoform 1 [Pan troglodytes] gi|114666744 (+7) 108 kDa 15 0 
57 
splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated), 
isoform CRA_e [Homo sapiens] gi|119627830 (+3) 66 kDa 13 0 
58 NOP56 protein [Homo sapiens] gi|118142846 (+8) 50 kDa 13 0 
65 unnamed protein product [Homo sapiens] gi|10435335 (+6) 40 kDa 11 0 
81 Chain A, Crystal Structure Of Human Apo-Eif4aiii gi|114794619 (+7) 45 kDa 10 0 
82 matrin-3 [Homo sapiens] gi|21626466 (+1) 95 kDa 10 0 
87 HNRPF protein [Homo sapiens] gi|16876910 (+2) 46 kDa true 15 0 
94 heterogeneous nuclear ribonucleoprotein U-like 2 [Homo sapiens] gi|118601081 (+2) 85 kDa 9 0 
100 Chain A, Solution Structure Of The Rrm Domain Of Sr Rich Factor 9g8 gi|119389969 (+5) 11 kDa true 8 0 
110 hCG39912, isoform CRA_b [Homo sapiens] gi|119576757 (+5) 21 kDa 5 0 
124 unnamed protein product [Homo sapiens] gi|194387362 (+3) 35 kDa 6 0 
127 
splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila), isoform CRA_c 
[Homo sapiens] gi|119598613 (+6) 34 kDa 6 0 
128 PREDICTED: hypothetical protein isoform 2 [Pan troglodytes] gi|114638645 (+7) 90 kDa 9 0 
131 histone H2A type 1-B/E [Homo sapiens] gi|10645195 (+3) 14 kDa true 18 0 
132 HNRPR protein [Homo sapiens] gi|111494085 (+6) 68 kDa true 5 0 
146 
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle 
[Homo sapiens] gi|127798841 (+3) 60 kDa 5 0 
147 DEAH (Asp-Glu-Ala-His) box polypeptide 15, isoform CRA_g [Homo sapiens] gi|119613226 (+4) 81 kDa 5 0 
148 
heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 
37kDa), isoform CRA_a [Homo sapiens] gi|119626277 (+11) 41 kDa 4 0 
149 splicing factor, arginine/serine-rich 3, isoform CRA_c [Homo sapiens] gi|119624305 (+2) 15 kDa true 6 0 
150 interleukin enhancer binding factor 2 [Mus musculus] gi|13385872 (+4) 43 kDa 5 0 
151 unnamed protein product [Homo sapiens] gi|194386598 (+4) 123 kDa 5 0 
152 histone H2A.Z [Homo sapiens] gi|4504255 (+2) 14 kDa true 7 0 
156 Dyskeratosis congenita 1, dyskerin [Homo sapiens] gi|14602859 (+4) 58 kDa 5 0 
163 PREDICTED: similar to 40S ribosomal protein S2 isoform 1 [Macaca mulatta] gi|109108085 (+11) 20 kDa 4 0 
164 DNA topoisomerase 1 [Homo sapiens] gi|11225260 (+15) 91 kDa 4 0 
169 splicing factor, arginine/serine-rich 13A isoform 2 [Homo sapiens] gi|16905517 (+8) 31 kDa 4 0 
170 polypyrimidine tract binding protein 1, isoform CRA_b [Homo sapiens] gi|119581557 (+5) 57 kDa true 4 0 
171 WD40 repeat-containing protein SMU1 [Bos taurus] gi|84370185 58 kDa 4 0 
172 SYNCRIP protein [Homo sapiens] gi|116283697 (+10) 51 kDa true 4 0 
173 splicing factor, arginine/serine-rich 2, isoform CRA_d [Homo sapiens] gi|119609849 (+5) 24 kDa 4 0 
177 thyroid hormone receptor-associated protein 3 [Homo sapiens] gi|167234419 (+2) 109 kDa 4 0 
178 Chain A, Structure Of A Human Prp31-15.5k-U4 Snrna Complex gi|145580328 (+3) 14 kDa 5 0 
180 
small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen), isoform CRA_g [Homo 
sapiens] gi|119572837 (+3) 45 kDa 5 0 
181 unnamed protein product [Homo sapiens] gi|158261255 (+5) 73 kDa 5 0 
184 hCG2002711, isoform CRA_b [Homo sapiens] gi|119574041 (+5) 30 kDa 5 0 
187 putative RNA-binding protein Luc7-like 2 [Homo sapiens] gi|116812577 (+3) 47 kDa 4 0 
189 Chain A, Solution Structure Of Rrm Domain In Splicing Factor 3b gi|159163578 (+3) 11 kDa 4 0 
197 ribosomal protein SA, isoform CRA_c [Homo sapiens] gi|119584991 (+8) 20 kDa 4 0 
198 hCG27481, isoform CRA_b [Homo sapiens] gi|119599362 (+4) 115 kDa 4 0 
199 ribosomal protein L9, isoform CRA_a [Homo sapiens] gi|119613332 (+3) 15 kDa 4 0 
200 proline rich 6, isoform CRA_b [Homo sapiens] gi|119624905 (+3) 30 kDa 4 0 
208 chromobox protein homolog 3 [Homo sapiens] gi|15082258 (+1) 21 kDa 3 0 
212 PREDICTED: hypothetical protein isoform 1 [Pan troglodytes] gi|114578550 (+4) 54 kDa 4 0 
213 unnamed protein product [Homo sapiens] gi|194380928 (+2) 117 kDa 4 0 
225 U5 small nuclear ribonucleoprotein 40 kDa protein [Homo sapiens] gi|115298668 (+4) 39 kDa 3 0 
226 PRP4 pre-mRNA processing factor 4 homolog (yeast) [Homo sapiens] gi|13938549 (+5) 58 kDa 3 0 
227 Chain A, Solution Structure Of The Oxidized Microsomal Human Cytochrome B5 gi|158428699 (+7) 12 kDa 3 0 
228 unnamed protein product [Homo sapiens] gi|189067487 (+4) 60 kDa 3 0 
229 unnamed protein product [Homo sapiens] gi|194386160 (+3) 151 kDa 3 0 
230 chromosome 1 open reading frame 77, isoform CRA_e [Homo sapiens] gi|119573679 (+6) 24 kDa 3 0 
231 karyopherin alpha 3 (importin alpha 4), isoform CRA_b [Homo sapiens] gi|119629243 (+5) 56 kDa 3 0 
236 SRp55-3 [Homo sapiens] gi|1049086 (+5) 38 kDa true 3 0 
237 PREDICTED: HP1-BP74 isoform 3 [Pan troglodytes] gi|114554472 (+6) 44 kDa 3 0 
238 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46, isoform CRA_a [Homo sapiens] gi|119582642 (+6) 100 kDa 3 0 
239 TAR DNA binding protein, isoform CRA_a [Homo sapiens] gi|119592075 (+3) 39 kDa 3 0 
240 chromosome 20 open reading frame 14, isoform CRA_c [Homo sapiens] gi|119595582 (+6) 102 kDa 3 0 
243 RNA-binding protein with serine-rich domain 1 isoform 2 [Mus musculus] gi|121674799 (+5) 32 kDa 3 0 
244 Similar to ribosomal protein L23 [Homo sapiens] gi|13097600 (+2) 14 kDa 3 0 
246 
Chain A, Crystal Structure Of First Two Rrm Domains Of Fir Bound To Ssdna From A Portion 
Of Fuse gi|169404577 (+8) 23 kDa 3 0 
247 ATP synthase beta subunit [Homo sapiens] gi|179279 (+4) 57 kDa 3 0 
248 60S acidic ribosomal protein P2 [Homo sapiens] gi|4506671 12 kDa 3 0 
249 splicing factor 3 subunit 1 isoform 1 [Homo sapiens] gi|5032087 (+1) 89 kDa 3 0 
250 aldolase A, fructose-bisphosphate, isoform CRA_b [Homo sapiens] gi|119600342 (+5) 40 kDa 3 0 
252 ribosomal protein S19, isoform CRA_b [Homo sapiens] gi|119577478 (+2) 17 kDa 2 0 
253 zinc finger protein 326, isoform CRA_b [Homo sapiens] gi|119593532 (+3) 68 kDa 2 0 
254 splicing factor 3B subunit 5 [Homo sapiens] gi|13775200 10 kDa 2 0 
255 pinin [Homo sapiens] gi|11320891 (+8) 82 kDa 3 0 
258 nuclear pore complex-associated protein TPR [Homo sapiens] gi|114155142 (+4) 267 kDa 2 0 
259 PREDICTED: hypothetical protein LOC466117 isoform 6 [Pan troglodytes] gi|114631381 (+13) 15 kDa 2 0 
260 PREDICTED: similar to MGC107852 protein isoform 3 [Pan troglodytes] gi|114660748 (+10) 52 kDa 2 0 
261 
Chain A, Crystal Structure Of Human Carboxylesterase In Complex With Cholate And 
Palmitate gi|114793717 (+17) 60 kDa 2 0 
264 RBM25 protein [Homo sapiens] gi|118196855 (+6) 100 kDa 2 0 
266 heterogeneous nuclear ribonucleoprotein U-like 1, isoform CRA_c [Homo sapiens] gi|119577432 (+9) 85 kDa 2 0 
267 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R), isoform CRA_b 
[Homo sapiens] gi|119589356 (+2) 50 kDa 2 0 
268 U2 (RNU2) small nuclear RNA auxiliary factor 2, isoform CRA_a [Homo sapiens] gi|119592808 (+5) 42 kDa 2 0 
269 ribosomal protein L5, isoform CRA_b [Homo sapiens] gi|119593494 (+5) 28 kDa 2 0 
270 ARS2 protein, isoform CRA_b [Homo sapiens] gi|119596872 (+12) 102 kDa 2 0 
273 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, gi|119604569 (+20) 144 kDa 2 0 
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member 4, isoform CRA_b [Homo sapiens] 
274 THO complex 4 [Homo sapiens] gi|119610105 (+1) 25 kDa 2 0 
278 splicing factor 3a, subunit 3, 60kDa, isoform CRA_b [Homo sapiens] gi|119627711 (+7) 59 kDa 2 0 
280 unnamed protein product [Homo sapiens] gi|158254512 (+2) 51 kDa 2 0 
284 ribosomal protein L38 [Homo sapiens] gi|4506645 8 kDa 2 0 
286 SF3A2 protein [Homo sapiens] gi|116283242 (+5) 51 kDa 2 0 
287 
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta 
polypeptide, isoform CRA_d [Homo sapiens] gi|119610102 (+8) 41 kDa 2 0 
289 regulator of chromosome condensation 1 isoform a [Homo sapiens] gi|114796644 (+8) 48 kDa 2 0 
290 nucleoporin 210kDa, isoform CRA_a [Homo sapiens] gi|119584554 (+5) 106 kDa 1 0 
Experiment 2 (Protein identification probability 50%): 
# Identified Proteins (65/121) Accession Number 
Molecular 
Weight 
Protein 
Grouping 
Ambiguity mock 
MV 
fl-Cwt 
MV 
fl-
CwtmNLS 
1 Chain A, Crystal Structure Of Apo Human Ptp1b (C215s) Mutant gi|15825777 (+5) 36 kDa 108 68 71 
2 putative [Homo sapiens] gi|553734 2 kDa 52 28 26 
3 heat shock cognate 71 kDa protein isoform 2 [Homo sapiens] gi|24234686 (+2) 54 kDa true 1 13 13 
4 tubulin, alpha 1c [Homo sapiens] gi|14389309 (+12) 50 kDa 0 7 3 
5 Chain A, Crystal Structure Of The Human Hsp70 Atpase Domain In The Apo Form gi|166007012 (+10) 43 kDa true 0 5 9 
6 Tubulin, beta 2C [Homo sapiens] gi|20809886 (+3) 50 kDa true 0 14 8 
7 small nuclear ribonucleoprotein Sm D1 [Homo sapiens] gi|5902102 13 kDa 0 5 4 
8 heterogeneous nuclear ribonucleoprotein U isoform b [Homo sapiens] gi|14141161 (+4) 89 kDa 0 4 4 
9 tropomyosin alpha-3 chain isoform 4 [Homo sapiens] gi|114155144 (+4) 29 kDa 0 0 6 
10 78 kDa glucose-regulated protein [Homo sapiens] gi|16507237 (+3) 72 kDa true 0 4 3 
11 heat shock 60kDa protein 1 (chaperonin), isoform CRA_c [Homo sapiens] gi|119590557 (+5) 41 kDa 0 2 3 
12 PREDICTED: hypothetical protein isoform 19 [Pan troglodytes] gi|114625192 (+11) 51 kDa 0 1 4 
13 heterogeneous nuclear ribonucleoprotein A1, isoform CRA_g [Homo sapiens] gi|119617173 (+9) 33 kDa 0 2 2 
14 Na+,K+ ATPase [Homo sapiens] gi|1359715 (+11) 112 kDa 0 2 2 
15 hCG19195 [Homo sapiens] gi|119597218 (+6) 9 kDa 0 2 1 
16 proteasome (prosome, macropain) 26S subunit, ATPase, 2, isoform CRA_a [Homo sapiens] gi|119603737 (+2) 32 kDa 0 2 1 
17 OTUD4 protein [Homo sapiens] gi|118142854 (+8) 36 kDa 0 2 1 
18 chromosome 17 open reading frame 79, isoform CRA_a [Homo sapiens] gi|119600666 (+2) 19 kDa 0 2 1 
19 PREDICTED: similar to P26s4 isoform 1 [Pan troglodytes] gi|114654363 (+6) 41 kDa 0 1 1 
20 nucleophosmin isoform 1 [Homo sapiens] gi|10835063 (+12) 33 kDa 0 1 0 
21 small nuclear ribonucleoprotein Sm D2 isoform 2 [Homo sapiens] gi|237649049 (+1) 12 kDa 0 1 2 
22 26S proteasome subunit p97 [Homo sapiens] gi|1060888 (+7) 100 kDa 0 3 0 
23 PSMD1 protein [Homo sapiens] gi|116283467 (+9) 95 kDa 0 1 1 
24 Chain A, Structure Of Tab1 gi|116668415 (+5) 44 kDa 0 1 1 
25 thymopoietin zeta isoform [Homo sapiens] gi|119214988 (+10) 27 kDa 0 1 1 
26 DnaJ (Hsp40) homolog, subfamily A, member 1, isoform CRA_d [Homo sapiens] gi|119578931 (+4) 42 kDa 0 1 1 
27 tropomodulin 1, isoform CRA_a [Homo sapiens] gi|119579249 (+4) 44 kDa 0 1 1 
28 Unknown (protein for IMAGE:3544292) [Homo sapiens] gi|13097759 (+5) 27 kDa 0 1 1 
29 mitogen-activated protein kinase kinase kinase 7-interacting protein 2 [Homo sapiens] gi|14149669 (+4) 76 kDa 0 1 1 
30 unnamed protein product [Homo sapiens] gi|193787479 (+4) 53 kDa 0 1 1 
31 myosin VI [Homo sapiens] gi|56204015 145 kDa 0 1 1 
32 actin-like protein [Homo sapiens] gi|62421170 12 kDa true 0 4 7 
33 apoptosis-inducing factor 1, mitochondrial isoform 5 [Homo sapiens] gi|195927006 (+3) 35 kDa 0 1 1 
34 
RecName: Full=Monocarboxylate transporter 1; Short=MCT 1; AltName: Full=Solute carrier family 
16 member 1 gi|13432183 (+1) 54 kDa 0 1 0 
35 Plasminogen [Homo sapiens] gi|38051823 91 kDa 0 1 0 
36 unnamed protein product [Homo sapiens] gi|158257224 (+6) 47 kDa 0 3 0 
37 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 [Homo sapiens] gi|150439371 (+5) 22 kDa 0 0 1 
38 hCG23783, isoform CRA_a [Homo sapiens] gi|119621875 (+5) 23 kDa 0 2 0 
39 microtubule-associated protein 1B, isoform CRA_a [Homo sapiens] gi|119616102 (+2) 257 kDa 0 3 0 
40 DOK6 protein [Homo sapiens] gi|114325404 (+6) 29 kDa 0 0 1 
41 PREDICTED: similar to mSUG1 protein isoform 7 [Pan troglodytes] gi|114669878 (+5) 43 kDa 0 0 1 
42 PREDICTED: heterogeneous nuclear ribonucleoprotein M isoform 7 [Pan troglodytes] gi|114675132 (+11) 61 kDa 0 0 1 
43 hCG1640785, isoform CRA_a [Homo sapiens] gi|119569329 (+3) 14 kDa 0 0 1 
44 chromosome 1 open reading frame 77, isoform CRA_d [Homo sapiens] gi|119573678 (+7) 17 kDa 0 0 1 
45 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, isoform CRA_a [Homo sapiens] gi|119606803 (+10) 58 kDa 0 0 1 
46 Chain A, Macrophage Migration Inhibitory Factor (Mif) Complexed With Inhibitor. gi|13399777 (+5) 13 kDa 0 0 1 
47 Unknown (protein for IMAGE:3897044) [Homo sapiens] gi|14789595 (+3) 30 kDa 0 0 1 
48 U4/U6 snRNP-associated 61 kDa protein [Homo sapiens] gi|18249847 (+3) 55 kDa 0 0 1 
49 unnamed protein product [Homo sapiens] gi|189066512 (+5) 48 kDa 0 0 1 
50 actin beta related pseudogene gi|223597 42 kDa true 0 0 3 
51 Rig homolog [human, brain, Peptide Partial, 135 aa] gi|262391 (+1) 16 kDa 0 0 1 
52 hCG2028078 [Homo sapiens] gi|119569445 (+4) 7 kDa 0 0 1 
53 tat-associated protein gi|1096067 (+7) 31 kDa 0 1 0 
54 myc-associated zinc finger protein isoform 2 [Homo sapiens] gi|110347459 (+11) 51 kDa 0 1 0 
55 GLS2 protein [Homo sapiens] gi|111185682 (+6) 28 kDa 0 1 0 
56 PREDICTED: proteasome 26S non-ATPase subunit 13 isoform 3 [Pan troglodytes] gi|114635315 (+9) 43 kDa 0 1 0 
57 chromosome 13 open reading frame 7, isoform CRA_b [Homo sapiens] gi|119600993 (+2) 81 kDa 0 1 0 
58 
solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3, isoform CRA_c 
[Homo sapiens] gi|119618006 (+6) 26 kDa 0 1 0 
59 TAK1-binding protein 3, isoform CRA_b [Homo sapiens] gi|119619464 (+6) 80 kDa 0 1 0 
60 Solute carrier family 1 (neutral amino acid transporter), member 5 [Homo sapiens] gi|12652633 (+9) 57 kDa 0 1 0 
61 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 [Homo sapiens] gi|15126760 (+9) 61 kDa 0 1 0 
62 
RecName: Full=Phosphotidylinositol phosphatase PTPRQ; AltName: Full=Receptor-type tyrosine-
protein phosphatase Q; Short=R-PTP-Q; Short=PTP-RQ; Flags: Precursor gi|158563998 261 kDa 0 1 0 
63 insulin receptor substrate 4 [Homo sapiens] gi|4504733 134 kDa 0 1 0 
64 hCG2044124 [Homo sapiens] gi|119582767 (+11) 185 kDa 0 1 0 
65 unnamed protein product [Homo sapiens] gi|158260761 (+1) 28 kDa 0 1 0 
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